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The overall aim of this thesis was to examine myostatin and components of the 
insulin-like growth factor (IGF) axis during regeneration, to determine whether these 
factors were temporally regulated during regeneration, whether the absence or 
presence of growth hormone (GH) affected their levels, and lastly, whether the 
administration of exogenous IGF-11 enhanced muscle regeneration. A histological 
approach was utilised, to determine specific effects on individual tissue types 
(regenerating muscle fibres, survivor muscle fibres, undamaged muscle fibres, and 
connective tissue) within damaged muscle. Regeneration was induced by injection of 
notexin, a myotoxin, into muscle. 
The first experiment tested the hypothesis that the IGFs and their receptors are 
regulated during muscle regeneration, and that the levels of these components are 
regulated by GH. The experimental model used was the GH-deficient dwldw rat in 
which damage and subsequent regeneration were induced by a single intramuscular 
injection of notexin, then either GH- or saline-administered during the regeneration 
period. IGF-1 and -II mRNA were assessed by in situ hybridisation, and binding 
determined by in vitro incubations with 1251-IGF competed with unlabelled 
homologous IGF (specific binding). The presence of IGF binding proteins (IGFBPs) 
was determined by comparison of the specific binding of 1251-IGF-I with the residual 
binding of 1251-IGF-I following competition with des(l-3)IGF-I (which has a greatly 
reduced affinity for IGFBPs relative to IGF-1). Results of the localisation studies 
revealed up-regulation of IGF-1 and -II specific binding in regenerating fibres at the 
time of myotube formation, and indicated the presence of IGFBPs in damaged muscle 
tissues at the same timepoint. IGF-1 and -II mRNAs were significantly up-regulated in 
regenerating muscle fibres concurrent with myotube formation and enlargement, while 
IGF-1 mRNA was also elevated in regenerating muscle fibres at the time of muscle 
precursor cell proliferation. IGF-1 mRNA was elevated in connective tissue of 
damaged, relative to undamaged, muscle during early regeneration. GH 
administration increased bodyweight, and the weights of damaged and undamaged 
muscles. GH administration did not affect the level of specific binding when 1251-IGF-
I was used as the ligand, or the level of IGFBPs as determined by competition of 1251-
IGF-I binding with unlabelled IGF-1 versus unlabelled des(l-3)1GF-I, however GH 
administration did result in increased specific binding of 1251-IGF-II to all damaged 
muscle tissues, relative to muscles from saline-treated animals. GH did not affect 
IGF-1 or -II mRNA levels in damaged muscle tissues. In summary, this trial showed 
that all components of the IGF axis examined showed temporal regulation following 
muscle damage, and that GH administration significantly increased the binding of 1251-
IGF-II to damaged, but not undamaged, muscle tissues. 
The second hypothesis tested in this thesis is that the negative regulator of muscle 
growth, myostatin, is regulated during muscle regeneration, and that its levels are 
decreased in muscles undergoing enhanced growth due to the administration of GH. 
The temporal regulation of myostatin protein was assessed by immunohistochemical 
staining of regenerating muscle sections of Sprague-Dawley rats, and of GH-deficient 
dwldw rats. The effect of GH on myostatin protein levels was determined by 
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comparing myostatin protein levels in saline- versus OH-treated dwldw rats. 
Myostatin immunostaining is present in the cytoplasm of fast muscle fibres, and is 
absent from the connective tissue of undamaged muscles, however following notexin 
injection, abundant myostatin immunostaining was observed at early timepoints in 
connective tissue, and high intensity immunostaining was observed in both fast and 
slow necrotic muscle fibres. Myostatin protein was absent from muscle precursor 
cells at the time of proliferation, and fusion to form new myotubes. Myostatin then 
gradually appeared in the muscle fibres undergoing enlargement. GH administration 
did not affect the temporal regulation, or level, or myostatin immunostaining 
observed. These findings suggest a role for myostatin in the regulation of muscle 
regeneration, including possible effects on connective tissue deposition. 
The third hypothesis tested was that administration of IGF-11 peptide during muscle 
regeneration would advance the onset of muscle precursor cell proliferation and 
differentiation. This was tested by implanting miniosmotic pumps fitted with 
catheters and filled with either IGF-11 (to deliver 3.48 ug IGF-Wday) or vehicle (equal 
volume), in the subcutaneous compartment of Sprague-Dawley rats, then inducing 
damage and regeneration adjacent to the site of peptide of release. Results of the 
immunohistochemical analysis of MyoD, myogenin and developmental myosin heavy 
chain proteins in damaged muscle sections showed that IGF-11 administration resulted 
in a delay in the onset of muscle precursor cell proliferation and differentiation, as 
compared to vehicle only controls. In vitro incubations using 1251-IGF-I as the ligand 
showed no difference in the IGF binding capacity of day 1 tissues, indicating that the 
delay in early regeneration was not caused by down-regulation of the Type 1 IGF 
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receptor in response to administered IGF-II. Cross-sectional areas of regenerating 
muscle fibres on day 7 showed that late regeneration of muscle fibres was enhanced 
relative to the control, vehicle-only group. The period in which the administration of 
IGF-11 enhanced muscle regeneration coincides with the time that IGF-11 mRNA is 
elevated in regenerating muscle fibres, as shown in the first trial, suggesting that a 
greater endogenous production of IGF-II is associated with enhanced regeneration. 
In conclusion, the results of these studies indicate that changes in myostatin and 
components of the IGF axis are associated with muscle regeneration, and that the 
levels of these components are differentially regulated depending on tissue type. 
These studies suggest that IGF-II may be an effective therapeutic agent in regenerating 
skeletal muscle, pending refinement of the administration protocol. 
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1.1 General Introduction 
Muscle tissue is responsible for most types of body movement. There are three types 
of muscle, identifiable by their structure and contractile properties: skeletal muscle, 
smooth muscle, and cardiac muscle. In this thesis, skeletal muscle will be examined. 
As the name indicates, skeletal muscle is responsible for the movement of the skeletal 
framework, as well as having a role in the maintenance of posture. 
Skeletal muscle has a great capacity for regeneration, ie. the restoration of structure 
and function, following injury. This thesis addresses the hypothesis that growth 
factors regulate the regeneration of skeletal muscle. To provide sufficient background 
for the ensuing work, the composition of intact muscle will first be described, 
followed by a review of the processes that occur when muscle is damaged and 
undergoes regeneration. Subsequently, a review of the growth factors involved in the 
regulation of muscle growth and regeneration will be given, and an explanation of the 
overall aim and experimental hypotheses of this thesis. 
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1.2 An overview of muscle 
Skeletal muscle is composed of four types of tissue- muscle fibres, connective tissue, 
nerves and blood vessels- all of which are necessary for the integrity and proper 
functioning of muscle. 
1.2.1 Muscle fibres 
The basic unit of skeletal muscle is the muscle fibre. Muscle fibres are cylindrical, 
and can extend either partially or wholly down the length of a muscle. It is the 
coordinated contraction of these fibres that generates force and movement (see 
Section 1.3). Within individual fibres are numerous myonuclei, the majority of which 
reside just inside the plasmalemma of the muscle fibre in mature muscle (Allbrook 
1973). Myonuclei are post-mitotic, rendering them unable to participate in processes 
requiring cellular replication, such as growth and regeneration. Muscle cells that are, 
however, capable of replication, termed satellite cells, reside just to the exterior of the 
fibre, between the plasmalemma of the muscle fibre and its surrounding basal lamina. 
Satellite cells normally exist in a quiescent state, however, they can be activated in 
certain conditions to undergo mitosis in order to provide the additional muscle 
precursor cells (MPC) required for the growth maintenance and regeneration of 
postnatal skeletal muscle (this will be discussed in more detail in Section 1.5). 
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J.2.2 Connective tissue 
Connective tissue plays a number of key roles in skeletal muscle: a) the provision of 
strength and structure, b) as a means of attaching muscle to bone, which is necessary 
for the generation of movement, and c) as a reservoir for growth factors, for 
connective tissue is a large component of the extracellular matrix surrounding muscle 
fibres, and d) as a medium through which metabolites are exchanged between muscle 
fibres and capillaries (Bloom & Fawcett 1975). As shown in Figure 1-1, three types 
of connective tissue are found within skeletal muscle: epimysium, perimysium and 
the endomysium. The epimysium envelopes the muscle, and is connected to the 
perimysium, which surrounds fascicles, or bundles of muscle fibres. The endomysium 
surrounds individual muscle fibres, and it is the portion that lies adjacent to the 
muscle fibre that is referred to as the basal lamina. 
Connective tissue is composed primarily of a protein- and carbohydrate-rich matrix, 
including these components: collagen, elastin, fibronectin, laminin, proteo- and 
glycosaminoglycans. Collagen is a major component of connective tissue, and there 
exist numerous collagen types that are associated with skeletal muscle. Types I and ill 
collagens are key components of the epimysium and perimysium, respectively, while 
Types IV and V are predominant in the endomysium (Bailey et al. 1979; Duance et al. 
1977; Foidart et al. 1981). 
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Figure 1-1. Connective tissue elements within skeletal muscle. 
Shown is a cross-section of muscle with the endomysium (blue) surrounding individual muscle 
fibres, the perimysium (green) surrounding muscle fibre bundles, or fascicles, and the epimysium 
(red) surrounding the entire muscle. Redrawn from Lehto (1983). 
1.2.3 Nerves 
Innervation is essential to the functioning of muscle, as it is through the 
neuromuscular junction, formed where muscle meets nerve, that chemical signals are 
sent which trigger muscular contractions. Nervous input into muscles is via a main 
nerve trunk, which then bifurcates within the muscle so that each fibre is innervated. 
The majority of muscle fibres are innervated by a single motoneuron near to the centre 
of the fibre (Sanes & Lichtman 1999). Conversely, motoneurons innervate more than 
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one fibre (Engel 1994). The grouping of the motoneuron with the muscle fibres it 
innervates is referred to as a "motor unit" (Bodine-Fowler 1994). The muscle fibres 
of a motor unit are relatively uniformly distributed throughout normal, undamaged 
muscle (Bodine-Fowler 1994). 
1.2.4 Blood vessels 
Not only does proper functioning of muscle depend on innervation, it also depends 
upon adequate vascularisation. Blood vessels supply nutrients and carry away waste 
generated by muscle fibres during both rest and contraction. The patterning of the 
vascular system within individual muscles is highly varied, as muscles can be supplied 
by either single or multiple vessels (Jerusalem 1994). A common feature in muscles, 
however, is that within the perimysial space, arteries undergo remarkable branching. 
These arteries then lead to a succession of smaller vessels (arterioles, terminal 
arterioles and capillaries) that are located within the endomysium and in close 
apposition to muscle fibres, and it is through these smaller vessels that adequate 
nutrient supply to the muscle is accomplished. 
1.3 Muscle fibre composition 
As muscle fibres are the basic unit of skeletal muscle, an overview of their 
composition is integral to an understanding of the regeneration process. In adult 
muscle, the majority (80%) of muscle fibre volume is occupied by myofibrils, which 
contain the repeating contractile units known as sarcomeres (see Figure 1-2). 
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Sarcomeres, the specific units responsible for force generation, are composed of four 
types of protein filaments: thick, thin, nebulin and titin. These filaments are attached 
to, or in register with Z-discs. The main components of the thin filaments are actin, 
troponin and tropomyosin, while the thick filaments are composed of myosin, 
myomesin, as well as C-, H- and M-proteins (Schiaffino & Reggiani 1996). Within 
the proteins that comprise the thick and thin filaments there is considerable diversity 
due to the presence of numerous isoforms, and it is this variation in isoforms that 
determines the contractile properties of muscle fibres (Schiaffino et al. 1989). 





Figure 1-2. Structure of a sarcomere. 
Redrawn from Schiaffino and Reggiani (1996). 
Z-disc 
Muscle fibres are characterised on the basis of their contractile properties, as either 
slow (Type l) or fast (Type 2) fibres, and on the basis of their metabolic properties as 
either oxidative or glycolytic. As suggested by the latter terms, oxidative fibres utilise 
oxygen in their generation of energy, while glycolytic fibres utilise an anaerobic 
pathway. As such, oxidative fibres have a greater number of surrounding capillaries 
than do glycolytic fibres (Viscor et al. 1992). At present there are 4 identified muscle 
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fibre types in rats- slow oxidative (Type 1 ), fast oxidative (Type 2A), and two fast 
glycolytic (Type 28, 2X) (Schiaffino et al. 1989). Different muscles of the body 
contain varying proportions of these fibre types, giving rise to muscles that have been 
specially adapted for different functions such as postural control, running, etc. 
Muscles with a high proportion of glycolytic fibres are especially suited for short 
bursts of intense energy, while muscles with a high proportion of oxidative fibres are 
better suited to long periods of lower intensity use. 
1.4 Muscle development 
Skeletal muscle is first formed during embryonic development. The initial stages of 
muscle development occur in specialised mesenchymal structures near the neural tube, 
called somites (see Figure 1-3). Within somites, MPC are located within a dorsal 
region referred to as the dermomyotome. These MPC embark on one of two possible 
courses: a) migration from the dorsal-medial ( epaxial) region of the dermomyotome 
into the myotome, which eventually becomes part of the back musculature, or b) 
migration from the ventrolateral (hypaxial) region of the dermomyotome into the 
trunk and developing limb areas to form the muscles of the trunk and limb, 
respectively (reviewed by Hawke & Garry 2001). These MPC proliferate to form 
additional MPC, which then either fuse with other mononucleate MPC to form 
cylindrical muscle fibres, the basic units of skeletal muscle, or supplement existing 




dorsa I aorta 




A somite consists of the sclerotome and dermomyotome. The dermomyotome in turn is composed 
of the dermatome, which goes on to become the dermis, and the underlying myotome, which gives 
rise to muscle. The medial and lateral divisions of the myotome give rise to epaxial and hypaxial 
muscles, respectively. Figure revised from Hawke and Garry (2001). 
1.5 Muscle damage and regeneration 
1.5.1 General overview 
Regeneration of skeletal muscle occurs naturally in response to a number of 
conditions, including injury such as muscle strain, crush injury or freezing. Similarly, 
muscle regeneration plays a key role in myopathies such as Duchenne's muscular 
dystrophy, a heritable condition affecting young males that leads ultimately to a 
substantial reduction m life span. In Duchenne's muscular dystrophy, a 
subsarcolemmal protein (dystrophin) is lacking, leading to repeated cycles of muscle 
fibre necrosis and regeneration (Karpati & Carpenter 1989). Damaged fibres are 
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replaced by fat and connective tissue rather than muscle (Liu et al. 1993b; McGeachie 
& Grounds 1999), thus causing loss of muscle function (Cohen et al. 1982). 
In addition to the natural causes of muscle damage listed above, skeletal muscle 
damage is commonly induced experimentally by numerous means including muscle 
grafting (Carlson & Gutmann 1975; Hansen-Smith & Carlson 1979), and exposure to 
toxins (notexin, taipoxin) (Harris et al. 2000) or local anaesthetic (bupivacaine) 
(Carlson 1976). Toxin-induced regeneration will be discussed in more detail in 
Section 3.1. Irrespective of the means of damage, successful skeletal muscle 
regeneration consists of a number of coordinated, conserved processes: cellular 
infiltration of damaged muscle and phagocytosis of muscle fibre debris, 
revascularisation, proliferation of satellite cells to give rise to MPC, fusion of MPC to 
form myotubes, enlargement and maturation of regenerating myotubes, re-innervation, 
and remodelling of connective tissue (Bodine-Fowler 1994; Grounds 1991; Hansen-
Smith & Carlson 1979; Kami et al. 1993). Section 1.5 looks at these processes in 
detail, while Section 1. 7 considers the input of specific growth factors in modulating 
these processes. 
1.5.2 Phagocytosis 
The initial events that occur following muscle damage are: a) the disruption of 
myogenic structural protein organisation and myofibril retraction away from the site of 
damage (reviewed by Tidball 1995), and b) damage to the plasmalemma (reviewed by 
Grounds 1991 ). Subsequent to this there is de-regulation of calcium homeostasis, 
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leading to the free entry of calcium into the damaged muscle fibre (Armstrong 1990). 
High intracellular calcium interferes with the normal functioning of mitochondria 
(Grounds 1991; Nakayama et al. 2001), and leads to the activation of calcium-
dependent proteases, known as calpains, which then degrade myofibrillar and other 
muscle proteins (Evans et al. 1984; Koh & Tidball 2000). In addition to these 
intracellular effects, is the activation of the lytic complement pathway, as indicated by 
the presence of complement components (Orimo et al. 1991; Sewry et al. 1987) and 
the membranolytic C5b-9 complement membrane attack complex (Engel & Biesecker 
1982) on necrotic muscle fibres in vivo. The activation of this pathway contributes to 
the removal of necrotic debris from damaged muscle fibres (Grounds 1991). 
Muscles can either be fully or partially damaged. In the case of incomplete damage of 
a muscle fibre, a new plasmalemma is synthesised at the junction of damaged and 
undamaged muscle that effectively seals off the undamaged muscle fibre from the 
damaged fibre (Carpenter & Karpati 1989; Papadimitriou et al. 1990). In most forms 
of muscle damage the basal lamina survives, where it then goes on to function as the 
scaffolding for new muscle formation (Sanes 1994). 
Subsequent to muscle damage there is a remarkable increase in inflammatory and 
phagocytic cells within the lesion (Pimorady-Esfahani et al. 1997; Tidball 1995). It is 
believed that chemotactic factors attract these cells to damaged areas, as damaged 
muscle is chemotactic for polymorphonuclear leucocytes and macrophages (Robertson 
et al. 1993a), and the generation of complement reaction products stimulates cellular 
infiltration and the phagocytosis of necrotic muscle fibre debris (Engel & Biesecker 
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1982). Polymorphonuclear leucocytes appear first at the lesion, a response that has 
been shown to occur within 30 minutes, and to peak at 12 hours, following 
bupivacaine-induced myonecrosis (Orimo et al. 1991). Macrophages subsequently 
appear within damaged muscle, and are comprised of three distinct populations 
(McLennan 1996). Of these three populations, there is variability in their time of 
appearance (from three hours to 1-2 days following freeze-lesioning), as well as in 
function, for some macrophages have a clear association with necrotic tissue whereas 
others have none (McLennan 1996), suggesting that macrophages may perform 
additional functions to phagocytosis within damaged muscle (McLennan 1996; Merly 
et al. 1999). Alternative functions for macrophages include the enhancement of MPC 
chemotaxis and/or proliferation through the production of growth factors, as 
macrophages are known to secrete platelet-derived growth factor (PDGF), leukemia 
inhibitory factor (LIF), basic fibroblast growth factor (bFGF), and transforming 
growth factor-B (TGF-B) (Robertson et al. 1993a). Indeed, PDGF (AB and BB 
isoforms), LIF, bFGF, and TGF-B are all chemotactic for MPC (Robertson et al. 
1993a), while PDGF (BB isoform) and bFGF are mitogenic for MPC, indicating that 
macrophages likely function in the stimulation of MPC chemotaxis and proliferation 
(Robertson et al. 1993a). Mouse and turkey satellite cells co-cultured with 
macrophages exhibit enhanced proliferation and delayed differentiation relative to 
control satellite cell cultures (Merly et al. 1999). 
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J.5.3 Satellite cells and muscle precursor cells (MPC) 
Satellite cells, which give rise to the MPC necessary for new fibre formation during 
muscle regeneration are, as stated in Section 1.2.1, normally located in the 
compartment between the basal lamina ( also referred to as the basement membrane) 
and the plasmalemma (also referred to as the plasma membrane) as shown in Figure 
1-4. On isolated, non-regenerating rat muscle fibres, satellite cells are present at a 
frequency of 2-3 per 100 myonuclei (Bischoff 1986a). Quiescent satellite cells 
typically have a heterochromatic nucleus, and a scant cytoplasm with few organelles 
(Hawke & Garry 2001). As is the case for the embryonic and foetal myoblasts that 
give rise to muscle during embryonic development, satellite cells are generally 
believed to derive from somites (Schultz & McCormick 1994), although recent studies 
suggest that at least some satellite cells may be derived from embryonic dorsal aorta 






Figure 1-4. Location of satellite cells. 
satellite cell basal lamina 
muscle fibre 
Satellite cells are located between the plasmalemma of the muscle fibre, and the surrounding 
basal lamina. Post-mitotic myonuclei of muscle fibres are peripherally located but within the 
plasmalemma of muscle fibres. Redrawn from Chambers and McDermott (1996). 
1.5.3.1 Activation 
Satellite cells normally exist in a quiescent state, known as the Go phase of the cell 
cycle. The cell cycle consists of the following sequential phases: gap 1 (G1), synthesis 
(S), gap 2 (G2), and mitosis (M), as shown in Figure 1-5, while Go is a state of 
quiescence. In order for satellite cells to produce additional MPC, they must first be 
activated to leave Go and enter the G 1 phase of the cell cycle (Hulleman & Boonstra 
2001; Tatsumi et al. 1998). Once in G 1, cells must pass a restriction point (R) after 
which point they are committed to the phases of DNA synthesis (S phase), G2 and 
mitosis (M phase) (Dou et al. 1993; Hulleman & Boonstra 2001; Pardee 1974). 
Satellite cell activation is often referred to as "cell cycle commitment", whereas 
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passage through the restriction point in G, is referred to as "cell cycle progression" 
(Johnson & Allen 1993). Following M phase, MPC may undergo another round of 
replication, differentiate, or become quiescent by re-entering the Go phase. 
Figure 1-5. Diagram of the cell cycle. 
Satellite cells normally exist in the quiescent state (G0), but can be activated to re-enter the cell 
cycle in order to produce the MPC necessary for growth and regeneration. Activated satellite 
cells first enter the G1 growth phase, and then must pass the growth factor-dependent point 
termed the restriction point (R) in order to progress onto the synthesis (S) phase in which DNA 
replication takes place. Cells then progress into the second growth phase (G2), and finally 
undergo mitosis (division) in M phase. Redrawn from Chambers and McDermott (1996). 
1.5.3.2 Migration 
Once activated, satellite cells migrate to the site of injury (reviewed by Bischoff 
1994 ). Activated satellite cells are able to move out of their characteristic position 
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between the basal lamina and plasmalemma (Grounds 1999). Satellite cells migrate to 
damaged areas from undamaged areas, creating a gradient in the number of satellite 
cells with distance from the site of injury (Klein-Ogus & Harris 1983; Schultz et al. 
1985a). Migration of satellite cells can occur in a number of ways: longitudinally 
along a muscle fibre, perpendicular to the fibre axis, and between muscles. Migration 
of satellite cells longitudinally along muscle fibres has been shown in fibre segments 
isolated after injury, whereby the damaged portion of muscle fibres showed a four-
fold increase in the number of satellite cells, while the region furthest from the 
damage contained one-third the number of satellite cells in control muscles (Schultz et 
al. 1985b ). The occurrence of MPC migration perpendicular to the muscle fibre axis 
has been cleverly demonstrated using a longitudinally-split autograft model in the rat, 
in which one half of the muscle was devitalised by freeze damage, while the other half 
remained vital. Results of this study showed that regenerated muscle fibres formed in 
the devitalised half, with the MPC being contributed by the live half of the autograft 
(Phillips et al. 1990). This study therefore showed that MPC can travel considerable 
distances without constraint by the endomysium or perimysium, and is in keeping with 
the observation of myoblast migration across the basal lamina during normal muscle 
development (Hughes & Blau 1990). Studies of the migration of MPC between 
nearby muscles in mice and rats has led to seemingly contradictory results, with both 
positive (Morgan et al. 1987b; Partridge & Sloper 1977; Watt 1982; Watt et al. 1987) 
and negative (Ghins et al. 1984; Schultz et al. 1986) reports of a host contribution to 
the regeneration of allografted muscle. The conflict in these reports appears to be due 
to species differences (Phillips et al. 1990), whereby there is considerable input from 
nearby host muscle in mice (Morgan et al. 1987b; Partridge & Sloper 1977; Watt 
1-15 
1982; Watt et al. 1987), but not in rats (Ghins et al. 1984; Schultz et al. 1986) under 
ordinary circumstances. The formation of a physical bridge between the epimysia of 
neighbouring muscles is sufficient to allow migration from neighbouring muscles in 
rats to occur (Schultz et al. 1986), suggesting that while MPC can apparently traverse 
the epimysium of mice, they are unable to in rats due presumably to its increased 
thickness (Phillips et al. 1990). It has also been suggested that the distances for 
satellite cells to travel within the rat, but not the mouse, are too great to allow for 
satellite cell contributions from adjacent muscle (Ghins et al. 1984; Phillips et al. 
1990). 
Because of the notable increase in MPC in regenerating muscle, some researchers 
have considered additional sources of MPC other than satellite cells. A possible 
source is myoid cells, which are located in the thymus and express MyoD and 
myogenin mRNA (Grounds et al. 1992). Myoid cell levels are decreased in the 
thymus after muscle damage, and are lower than normal during dystrophy-induced 
chronic damage (Wong et al. 1999). Bone marrow cells have recently been shown to 
contribute to regeneration, however this contribution is minimal relative to total nuclei 
within regenerated muscle, and occurs late in the regeneration process (Ferrari et al. 
1998). Therefore, although a contribution to skeletal muscle regeneration by non-
satellite cell derived MPC may occur in some instances, the absolute numbers of non-
satellite cell MPC involved in regeneration appears relatively minor at present. 
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1.5.3.3 Proliferation 
The proliferation stage of muscle regeneration consists of the division of satellite cells 
to form MPC that will then go on to form the regenerating muscle fibres. As stated in 
Section 1.5.3.1, cellular proliferation involves progression through at least one entire 
cell cycle (G1 to M), thereby creating additional MPC. These daughter MPC will then 
either progress on to terminal differentiation, or undergo additional proliferation 
(Grounds & McGeachie 1989). A more in depth examination of the cell cycle and 
regulators of the cell cycle will be undertaken in Section 1. 7, in reference to growth 
factor control of these processes. 
Not all satellite cells appear to enter into the cell cycle during regeneration, based on 
the reported observation of differentiation-associated markers prior to proliferation 
markers (Rantanen et al. 1995). This has led to the assertion that a population of 
satellite cells exists which is already committed to immediate terminal differentiation 
without preceding cell division (Rantanen et al. 1995). 
Heterogeneity in the proliferating satellite cell population has been reported for rat 
muscle cells grown in culture. Specifically, two distinct populations, separable on the 
basis of phenotype and proliferation rate were reported (Molnar et al. 1996), thus 
expanding the potential range of regeneration efficiencies by differences in the 
inherent properties of the satellite cells themselves. 
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1.5.3.4 Fusion 
Once sufficient proliferation has taken place, MPC undergo terminal differentiation, 
and so exit from the cell cycle. As such, the cell is no longer capable of re-entering the 
cell cycle and proliferating. Terminal differentiation marks the time when the 
appearance of many proteins typical of mature muscle, such as sarcomeric proteins, 
takes place, and when fusion to form myotubes occurs. Myotubes are immature 
muscle fibres. They normally form within the tube-like structure of the empty basal 
lamina, which serves as a scaffolding of sorts for the newly-formed myotubes 
(Caldwell et al. 1990). In instances where there is no basal lamina, such as after 
mincing of muscle, myotube formation can still occur, but the level of organisation at 
earlier, but not later, timepoints is rather poorer than the organisation of myotubes 
within pre-existing basal lamina tubes (Caldwell et al. 1990). The generation of 
mechanical forces along a muscle may play an important role in the orientation of 
regenerating muscle fibres and their basal lamina tubes (Caldwell et al. 1990). 
Five distinct types of fusion may take place during skeletal muscle regeneration: MPC 
to MPC, MPC to myotube, myotube to myotube, myotube to muscle fibre, and MPC 
to muscle fibre (Robertson et al. 1990; Robertson et al. 1993b ). Electron microscopic 
evidence for fusion includes the formation of small gaps in the apposed myogenic 
cells, coalescence of the cytoplasm of the adjoining cells and, in some types of fusion, 
the union of the free ends (Robertson et al. 1990). In the case of myotube to myotube 
fusion, union usually occurs at multiple sites along the lateral borders of the apposed 
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myotubes (Robertson et al. 1990), while for MPC or myotube fusion to the sealed, 
damaged ends of muscle fibres, fusion occurs at the "stump" ( end) region, and gives 
rise to sarcoplasmic extensions or "buds" (Robertson et al. 1993b ). Collagen or other 
extracellular material deposited amongst sarcoplasmic extensions could give rise to 
fibres with a "split" appearance (Robertson et al. 1993b ), a phenomenon that has been 
reported often in muscle regeneration literature (Ontell 1986). 
1.5.3.5 Maturation 
Following myoblast fusion to form myotubes, a period of muscle fibre enlargement 
and maturation commences. This period is completed when the mature muscle 
phenotype has been re-established. The primary events occurring during this period 
are re-innervation (addressed in Section 1.5.4) and cytoplasmic enlargement, 
including the synthesis of new contractile units, or sarcomeres. Considerable 
alteration in the pattern of myosin heavy chain (MHC) isoform expression occurs 
during this period, and will be addressed in Section 1.6.2. Although the fibre 
enlargement during regeneration bears resemblance to muscle fibre hypertrophy 
( defined as the enlargement of muscle fibre cytoplasm) the two processes are, strictly 
speaking, distinct from one another. 
1.5.4 Innervation 
Innervation is the connection of motoneurons to muscle fibres via the formation of 
synapses and motor endplates. The re-establishment of innervation is essential for the 
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growth and maturation of regenerating muscle fibres, as shown by studies comparing 
the regeneration of muscle in the presence or absence of innervation. The early stages 
of muscle regeneration up to the time of early myotube formation occur normally in 
the absence of innervation, but thereafter diverge so that denervated muscles are 
growth retarded, have lower isometric tension values, express alternate myosin 
isoforms, have abnormal sarcotubular morphology, and eventually undergo atrophy 
(Bodine-Fowler 1994; Sesodia & Cullen 1991; Whalen et al. 1990). 
Denervated muscle can be reinnervated by either the original neurons, or by axon 
outgrowth from neighbouring muscles. Studies of the reinnervation of grafted 
muscles have shown that the former is the predominant means of muscle 
reinnervation, and that the latter tends only to occur if there has been damage to the 
epimysium of the neighbouring muscle(s) (Klueber 1987). 
The basal lamina plays an integral role in the reinnervation of muscle. New 
neuromuscular junctions (where nerve terminals meet the basal lamina) form 
predominantly at the original synaptic sites on the basal lamina (Marshall et al. 1977). 
The basal lamina contains signals that direct reinnervation to specific sites (Sanes et 
al. 1978), and this process occurs regardless of the presence of the myofibre (Sanes et 
al. 1978). In damaged muscle, the pattern of distribution of muscle fibres innervated 
by motoneurons (referred to as "motor units") is altered relative to undamaged muscle. 
In undamaged muscle, muscle fibres served by a single motoneuron are reasonably 
uniformly distributed throughout the muscle, however following reinnervation there 
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are notable groupings of muscle fibres within a given motor unit (Bodine-Fowler 
1994). 
The normal state of the neuromuscular junction is single innervation by motoneurons. 
However, in the early stages of innervation following nerve damage, polyneuronal 
innervation occurs, whereby neuromuscular junctions are innervated by multiple 
motoneurons. In order to return the neuromuscular junctions to a "normal" state, 
synapses are eliminated through a process of gradual removal of its component parts 
(Culican et al. 1998). In mice, this process occurs within two weeks of reinnervation 
(Rich & Lichtman 1989). 
1. 5. 5 Vascularisation 
Revascularisation is a critical process for the effective regeneration of skeletal muscle, 
for without the timely re-establishment of vascularisation, excessive fibrotic tissue 
deposition and muscle cell death can result (Borisov et al. 2000). Revascularisation 
begins near to the time of the onset of necrotic debris phagocytosis (Roberts & 
McGeachie 1990). In grafted muscle undergoing regeneration, revascularisation 
begins at the periphery of the muscle, then proceeds inward towards the centre of the 
muscle (Roberts & McGeachie 1990). Revascularisation occurs rapidly, with 
functional blood vessels established within 2 days of the onset of the revascularisation 
process, although the complete re-establishment can take 14 days in a heavily 
damaged muscle, such as that resulting from the transplantation model (Roberts & 
McGeachie 1990). 
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1.5.6 Connective tissue deposition 
During muscle regeneration there are changes in the connective tissue, or extracellular 
matrix, compartment. Following contusion damage to rat muscle, the sequence of 
changes in the connective tissue compartment begins with disruption of the 
extracellular matrix (Stauber et al. 1990) and an increased widening of the interstitial 
spaces due to the deposition of extracellular matrix components (Stauber et al. 1990). 
Also associated with this early phase is fibroblast proliferation (Hurme et al. 1991; 
Stauber et al. 1990), for fibroblasts produce many of the extracellular matrix 
components, such as collagens and fibronectin (Hurme et al. 1991; McMinn 1967). 
Capillary formation within the connective tissue compartment also occurs as an early 
event (Hurme et al. 1991; Jarvinen 1975). In the next phase, while satellite cells are 
proliferating and forming new myotubes, phagocytosis of unnecessary and/or surplus 
proteins occurs (Hurme et al. 1991). During this early stage, the connective tissue 
compartment is very fragile, however after new fibre formation, the connective tissue 
becomes denser and attains a greater tensile strength (Hurme et al. 1991) and, at later 
stages of fibre maturation, the endomysial and perimysial compartments appear 
thickened relative to those of undamaged muscle (Hurme et al. 1991). The connective 
tissue strength appears to be related to the collagen isoforms expressed, with first 
Type III collagen, which is associated with plasticity, then Type I collagen, which 
provides tensile strength (Hurme et al. 1991). 
Muscle regeneration is enhanced by the presence of the basal lamina (Kami et al. 
1993; Vracko & Benditt 1972), but is hindered by excessive connective tissue 
formation. Excessive connective tissue can develop after severe trauma (Carlson 
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1968; Phillips et al. 1990), forming a dense barrier that regenerating muscle fibres 
must penetrate (McMinn 1967). 
1.6 Gene expression in skeletal muscle 
1.6.1 Myogenic regulatory factors (MRFs) 
The myogenic regulatory factors (MRFs) play an important role in the commitment of 
cells to the myogenic lineage, as well as their subsequent differentiation to form 
mature skeletal muscle (Rudnicki & Jaenisch 1995; Sabourin et al. 1999). Four 
MRFs have been identified thus far: MyoD, myf-5, myogenin and MRF4. Expression 
of each of these factors in non-muscle cells results in conversion to a myogenic 
phenotype (Braun et al. 1989b; Choi et al. 1990; Edmondson & Olson 1989; Rhodes 
& Konieczny 1989; Wright et al. 1989). Targeted gene disruption experiments in 
mice support the importance of MRFs for normal muscle development, as disruption 
of myogenin and MRF-4 leads to perinatal lethality due to major defects in skeletal 
muscle (Nabeshima et al. 1993; Patapoutian et al. 1995). In the case of gene 
disruption of either MyoD or myf-5, normal muscle develops, however simultaneous 
disruption of both MyoD and myf-5 results in perinatal lethality (Braun et al. 1992; 
Rudnicki et al. 1992; Rudnicki et al. 1993). Thus there exists some measure of 
redundancy in the MRFs, by virtue of the ability of MyoD or myf-5 to compensate for 
loss of the other MRF. 
MRFs have a coordinated and sequential pattern of expression during satellite cell 
activation, proliferation, and differentiation. In quiescent satellite cells, it was 
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previously held that there was no expression of MRFs (Smith et al. 1994), however 
activation of myf-5 gene expression within quiescent mouse satellite cells 
(Beauchamp et al. 2000), and the presence of myf-5 protein in quiescent C2 muscle 
cells (Kitzmann et al. 1998) have recently been reported. Upon satellite cell 
activation, either MyoD or myf-5 mRNA is expressed, followed by frequent co-
expression of both MyoD and myf-5, as observed at both the mRNA and protein level 
(Cornelison & Wold 1997; Kitzmann et al. 1998). Myogenin and MRF-4 mRNA 
expression occur subsequent to the expression of MyoD and myf-5 mRNAs 
(Cornelison & Wold 1997), with the expression of myogenin mRNA coincident with 
early differentiation (Smith et al. 1994; Yoshida et al. 1998). In recent years, MyoD 
expression has been routinely used in muscle regeneration studies as a marker for 
MPC proliferation, and myogenin expression as a marker for the entry of MPC into 
the differentiation pathway (Floss et al. 1997; Jin et al. 2000; Merly et al. 1999). 
MRFs exert effects on muscle cells through the formation of heterodimers with E-
proteins (reviewed by Puri & Sartorelli 2000), as shown in Figure 1-6. E-proteins are 
the gene products of E2A (E12 and E47) (Brennan & Olson 1990; Lassar et al. 1991; 
Murre et al. 1989), and HEB, a gene that is highly homologous to E2A (Hu et al. 
1992). MRF-containing heterodimers bind to a region referred to as the E-box, which 
has the consensus sequence CANNTG, and is present in the promoter and enhancer 
regions of many muscle-specific genes. The enhancement of muscle differentiation by 
MRFs is positively regulated by MEF-2 (Molkentin & Olson 1996), and negatively 
regulated by the proteins Id ("inhibitor of differentiation") (Jen et al. 1992), twist 
(Hamamori et al. 1997; Hebrok et al. 1994), 1-mf (Chen et al. 1996), Mistl 
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(Lemercier et al. 1998), MyoR (Lu et al. 1999), and ZEB (Postigo & Dean 1997). An 
additional level of control is present in that the MRFs exert positive feedback on 
themselves as well as regulate the levels of other family members (Braun et al. 1989a; 















Figure 1-6. Control of gene transcription by MRFs. 
Muscle specific 
gene promoter or 
enhancer region 
MRFs bind to E-proteins, which then recognise and bind to a sequence (CANNTG) referred to as 
an "E-box" in the promoter region of muscle specific genes. The process of MRF/E-protein 
complex formation and binding to the promoter region is positively regulated by MEF-2, and 
inhibited by Id, Twist, 1-mf, Mist, MyoR and ZEB. 
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1.6.2 Myosin heavy chains (MHCs) 
As discussed in Section 1.3, muscle fibres have distinct fibre types that are determined 
by their contractile and metabolic properties. The determination of specific MHC 
isoforms is considered the most accurate determinant of fibre type (Kelly & 
Rubenstein 1994). There exist over 10 identified MHC isoforms, many of which have 
an extremely restricted expression profile. For instance, neonatal and embryonic 
MHCs are expressed during embryonic development, but are not normally present in 
the adult (Condon et al. 1990). Adult rat muscle, like the muscle of many mammals, 
normally contains four MHC isoforms- I, Ila, lib, and Ilx -with very small but 
detectable amounts of a-cardiac MHC (Dunn & Michel 1997). 
During regeneration, newly regenerated muscle fibres re-express neonatal and 
embryonic MHCs, two isoforms that together are referred to as developmental MHC 
( dMHC) (Davis et al. 1991; Sartore et al. 1982). The dMHC in the regenerating 
fibres is then replaced by either fast and/or slow MHC isoforms (Yoshimura et al. 
1998). Fibre type, and thus MHC isoform expression, at this point is highly 
dependent on the innervation status of the regenerating muscle fibres, so that fibres 
that are regenerating in the absence of nerve ("aneural") remain as fast (type II) fibres, 
and express only fast MHC isoforms as shown in Table 1-1 (Whalen et al. 1990; 
Yoshimura et al. 1998). This is in contrast to the situation for fibres that regenerate in 
the presence of nerve ("innervated"), which can become either fast or slow muscle 
fibres (predominantly slow), as indicated by the presence of either fast or slow MHC 
isoforms (Davis et al. 1991; Whalen et al. 1990; Yoshimura et al. 1998)(see Table 
1-1 ). 
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Table 1-1. Effect of innervation on MHC expression. 
The effect of innervation status of grafted muscle on the pattern of MHC isoform expression by 
regenerating muscle fibres. Abbreviations: dMHC ("dev"), fast MHC ("fast"), slow MHC 
("slow"). Adapted from Yoshimura et al. (1998). 
Innervation status MHC expression pattern 
Innervated Dev 7 dev + fast 7 fast 
~ dev + fast + slow 7 fast + slow 7 slow 
Aneural Dev 7 dev + fast 7 fast 
1. 7 Growth factors in muscle regeneration 
Growth factors and hormones modulate the processes of skeletal muscle growth and 
regeneration. A summary of the findings for the major growth factors involved in 
muscle growth, and their effects on the key processes of muscle regeneration, are 
presented in Table 1-2. As shown (Table 1-2), individual growth factors may affect 
either single or multiple processes. Much of what is currently known about the effects 
of individual growth factors on the steps of myogenesis have been determined by in 
vitro studies, and it is largely unknown whether these same actions occur in vivo. 
While in vitro studies are useful, one must bear in mind that tissue culture conditions 
are quite different to the complex in vivo environment that exists during muscle 
regeneration (Grounds 1991 ). 
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Naturally occurring growth factors, including fibroblast growth factor (FGF), platelet-
derived growth factors (PDGFs), hepatocyte growth factor (HGF), insulin-like growth 
factors (IGFs), transforming growth factors {TGFs), leukaemia inhibitory factor (LIF), 
interleukin-6 (IL-6), epidermal growth factor (EGF), and myostatin can be produced 
locally- either within the same cell that they act upon (autocrine production) or within 
a cell from the adjacent tissue (paracrine production)- or they can be produced 
elsewhere within the body ( endocrine production). The unique patterns of growth 
factor production and localisation during muscle regeneration provide a further means 
of modulating growth factor activity. 
A key aspect of growth activity within regenerating muscle is the coordination of 
expression of multiple growth factors, for there is frequent co-expression of different 
factors. Growth factor activity can be altered by the presence of other growth factors, 
as has been clearly shown in vitro by the enhancement of IGF-I-stimulated 
proliferation by the addition of either basic(b)FGF or EGF (Doumit et al. 1993), and 
the inhibition of PDGF-BB stimulated proliferation by the addition ofTGF-P (Cook et 
al. 1993). Furthermore, it has been suggested that not only is the absence/presence of 
a growth factor important for eliciting a response, so too is the growth factor gradient 
that is established within the regenerating muscle (Bischoff 1997). 
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Table 1-2. Effects of growth factors on regeneration processes. 
The effects listed below have been determined by in vitro studies. 
Growth factor Migration Pro I if eration Differentiation 
bFGF t 
t t 



















Suzuki et al. (2000) 
Robertson et al. (1993a) 
Olwin & Rapraeger 
(1992) 
Doumit et al. (1993) 
Lim & Hauschka (1984) 
Lim & Hauschka (1984) 
Fiorini et al. (1986) 
Bischoff (1997) 
Allen et al. (1995) 
Miller et al. (2000) 
Tatsumi et al. (1998) 
Suzuki et al. (2000) 
Bischoff ( 1997) 
Fiorini et al. ( 1986) 
Ewton et al. (1994) 
Suzuki et al. (2000) 
Allen & Boxhom 
(1989) 
Fiorini et al. (1986) 
Ewton et al. ( 1994) 
Rosenthal et al. ( 1994) 
Ewton et al. (1998) 
Austin & Burgess 
(1991) 
1 when in the presence of serum or other growth factor(s), but no effect in serum-free media 
2 promotes differentiation at low concentrations, inhibits differentiation at high concentrations (biphasic 
response). 
3 inhibits at high cell density, enhances at low cell density. 
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Table 1-2. Effects of growth factors on regeneration processes (continued). 
Growth factor Migration Proliferation Differentiation Reference 
LIF t Austin & Burgess 
(1991) 
t Austin et al. (1992) 
t Robertson et al. (1993a) 
Myostatin t Thomas et al. (2000) 
t Rios et al. (2001) 
PDGF-AA Ye et al. (1996) 
~ t or 1- 3 Webb & Lee (1997) 
~ Robertson et al. (1993a) 
PDGF-AB t Ye et al. (1996) 
t t or 1- 3 Webb & Lee (1997) 
t Robertson et al. ( 1993a) 
PDGF-BB t Ye et al. (1996) 
t t or 1- 3 Webb & Lee (1997) 
t t Robertson et al. (1993a) 
TGF-a t Austin & Burgess 
(1991) 
t Austin et al. (1992) 
TGF-~ t Allen & Boxhom (1989) 
t Zentella & Massague (1992) 
t Bischoff ( 1997) 
1 when in the presence of serum or other growth factor( s ), but no effect in serum-free media. 
2 promotes differentiation at low concentrations, inhibits differentiation at high concentrations (biphasic 
response). 
3 inhibits at high cell density, enhances at low cell density. 
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1. 7.1 Insulin-like growth factors 
The role of IGFs in the regeneration of skeletal muscle was pursued in this thesis 
because of the potent stimulatory effects ofIGFs on muscle growth in vitro (see Table 
1-2) (Adams & McCue 1998) and in vivo (Bark et al. 1998; Coleman et al. 1995). 
The existence of the insulin-like growth factors was first proposed by Salmon and 
Daughaday in 1957, with the "somatomedin hypothesis," namely that GH acts through 
a second factor that is secreted into the circulation (Salmon & Daughaday 1957). This 
second factor was initially called "somatomedin", and is now known as insulin-like 
growth factor-I (IGF-1). Insulin-like growth factor-II (IGF-11), previously known as 
"multiplication stimulation activity" (MSA) (Pierson & Temin 1972) and "non-
suppressible insulin-like activity-2" (NSILA) (Rinderknecht & Humbel 1978b), was 
subsequently identified and shown to be highly homologous to IGF-1. IGFs are so 
named because they are structurally related to insulin (Blundell et al. 1983). 
1. 7.1.1 IGF-I and -II peptide synthesis 
IGF-1 
Rat IGF-1 is encoded by a single gene that contains six exons. Two of these exons (3 
and 4) encode the mature IGF-1 molecule (Butler et al. 1994). Transcription and 
differential splicing of messenger RNA yield IGF-1 transcripts with numerous 
permutations of the 5 ' - and 3 '-termini. Variations in both these regions lead to 
alterations in the signal peptide and carboxy-terminal extension peptide (E-peptide) 
sequences of the preproIGF-1 peptide that is first synthesised (Steenbergh et al. 1997). 
Variation in the signal peptide sequence is believed to affect the processing and 
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secretion of IGF-1 (Gilmour et al. 1992), while variation in the 3 '-terminal sequences 
is associated with distinct patterns of expression, and possibly function (McKoy et al. 
1999). Both the signal- and E-peptides are cleaved in order to produce mature IGF-1. 
Recent studies indicate that the cleaved E-peptide, on its own, contains mitogenic 
activity (Tian et al. 1999). 
Mature IGF-1 is comprised of 70 amino acids (MW 7,646) arranged in a single chain, 
with three disulfide bonds linking six cysteine residues (Rinderknecht & Humbel 
1978a). There are four "domains" within IGF-1, extending from amino to carboxy-
termini in the order, B-C-A-D. IGFs share 38-40% homology with insulin in the A 
and B regions, however insulin does not contain a D-region (Adams et al. 1983; 
Whitfield et al. 1984). IGF-1 peptides also share a high (>92%) degree of sequence 
homology amongst mammals (Foyt & Roberts 1991; Steenbergh et al. 1997). 
IGF-11 
The gene that encodes rat IGF-11 contains six exons (Steenbergh 1997; Dull, 1984). 
The prepro-IGF-11 molecule, from which the signal and E-terminal peptides are 
cleaved to produce the mature peptide, is encoded by exons 3-6 in rodents (Soares et 
al. 1986; Steenbergh et al. 1997). As for IGF-1, numerous transcripts are produced 
from the IGF-11 gene as a result of different promoter usage, alternative splicing of the 
5' sequences, and by alternative polyadenylation of 3' sequences. The expression of 
variant IGF-11 transcripts, which may have diverse properties of stability and/or 
translatability (Rosen et al. 1993), are differentially regulated during in vitro 
myogenesis (Rosen et al. 1993). 
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Mature IGF-II contains 67 amino acids (mol wt 7,471) (Rinderknecht & Humbel 
1978b) arranged in a single chain with three disulfide bonds, and has a similar domain 
structure to IGF-1. Human IGF-1 and -II peptides are over 60% homologous at the 
amino acid level (Whitfield et al. 1984). The IGF-II peptide sequence has been shown 
to be highly conserved, with greater than 93% homology amongst mammals (Foyt & 
Roberts 1991; Steenbergh et al. 1997; Whitfield et al. 1984). 
I. 7.1.2 IGF receptors 
Type I IGF receptor 
The actions of IGFs are both mediated and modulated by binding to receptors. IGFs 
can bind to three receptors: the Type I IGF receptor, Type II IGF receptor, and the 
insulin receptor, all of which are found in muscle cells (Beguinot et al. 1985; 
Virkamaki et al. 2001). The binding affinity of the Type I IGF receptor is greatest for 
IGF-1, less for IGF-II, and least for insulin (Fiorini et al. 1996). The Type I IGF 
receptor is a tetrameric glycoprotein, composed of two alpha and two beta chains. The 
alpha-chains are entirely extracellular in location, and are responsible for ligand 
binding. The alpha-chains are linked to the transmembrane beta-chains via disulphide 
bonds in the extracellular compartment (reviewed by Butler et al. 1998). Like the 
receptors for a number of other growth factors, the Type I IGF receptor functions as a 
ligand-activated tyrosine-specific protein kinase (Ullrich et al. 1986). Within the 
cytoplasmic compartment, the beta chains have a tyrosine kinase enzymatic domain 
that includes an ATP binding site (Werner et al. 1991 ). Ligand binding stimulates 
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autophosphorylation of the intracellular domain, and enables the receptor to 
phosphorylate protein substrates (reviewed by Butler et al. 1998). 
Insulin receptor 
The insulin receptor has a similar structure to the Type I IGF receptor, and functions 
as a ligand-activated tyrosine-specific kinase receptor. The precursor molecules for 
the insulin and Type I IGF receptors are of a nearly identical length (approximately 
1340 amino acids), are 84% homologous within the beta chains, and roughly 65% 
homologous in the regions surrounding the cysteine rich region of the alpha chains 
(Werner et al. 1991). The affinity of the insulin receptor for its ligand is: insulin>> 
IGF-11> IGF-1 (Florini et al. 1996). 
Alternative splicing of the insulin receptor mRNA gives rise to two isoforms, A and 
B, of the insulin receptor (Moller et al. 1989). As indicated above, the affinity of the 
insulin receptor for IGF-11 is normally relatively low (Fiorini et al. 1996), however it 
has recently been shown that the insulin receptor isoform A, which is present in foetal 
tissues and some cancers, binds IGF-II with an affinity close to that of insulin, and on 
a par with the binding ofIGF-II to the Type I IGF receptor (Frasca et al. 1999). 
Type II IGF receptor 
The Type II IGF receptor is a single chain polypeptide that contains an extracellular 
domain comprised of 15 cysteine-rich repeating units, a hydrophobic transmembrane 
helix and a short cytoplasmic sequence (Lobel et al. 1988). Unlike the insulin and 
Type I IGF receptors, the Type II IGF receptor does not have intrinsic tyrosine kinase 
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activity (Roth 1988). The affinity of the Type II IGF receptor for its ligand is IGF-
II>>> IGF-1, and it does not bind insulin (Ewton et al. 1987; Fiorini et al. 1996; 
Rechler & Nissley 1985; Rosenfeld et al. 1987). The Type II IGF receptor is identical 
to the cation-independent mannose-6-phosphate receptor (Braulke et al. 1988; 
Morgan et al. 1987a; Roth et al. 1987), and it binds IGF-II and proteins containing 
mannose-6-phosphate moieties through two distinct binding sites on the receptor 
(Braulke et al. 1988). Proteins containing M6P moieties, including both leukaemia 
inhibitory factor (LIF) and lysosomal enzymes, are normally internalised and degraded 
(Blanchard et al. 1999; Kornfeld 1992), but in the case of the M6P-containing latent 
TGF-P, binding to the Type II IGF receptor leads to activation of TGF-P (Ghahary et 
al. 1999a; Ghahary et al. 2000). Additionally, retinoic acid can bind to Type II IGF 
receptor sites other than those used for IGF and M6P binding, resulting in altered 
Type II IGF receptor distribution within the cell (Kang et al. 1998; Kang et al. 1997). 
The Type II IGF receptor is predominantly intracellular in localisation, with only 5-
10% of the receptor located on the cell surface (Kornfeld 1992). Binding of retinoic 
acid to the Type II IGF receptor results in enhanced binding and endocytosis of 
exogenous lysosomal enzymes (Kang et al. 1998; Kang et al. 1997), as well as 
enhanced sorting of lysosomal enzymes (Kang et al. 1997). These studies thus show 
that the Type II IGF receptor interacts with numerous ligands, however, knockout 
experiments in mice clearly show that the majority of growth-related interactions of 
the Type II IGF receptor during foetal development are with IGF-II (Ludwig et al. 
1996). This is inferred by the complete rescue of the overgrowth phenotype in Type II 
IGF receptor null mice by concomitant disruption of the IGF-II gene (Ludwig et al. 
1996). 
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A cleaved form of the Type II IGF receptor is present in the circulation (Causin et al. 
1988), and is secreted from cells in culture (Clairmont & Czech 1991; Scott et al. 
1996). This soluble form of the receptor is able to bind IGF-II with high affinity, and 
appears to inhibit IGF-II, but not IGF-I, activity (Scott & Weiss 2000). 
1. 7.1.3 IGF binding proteins 
The IGF binding proteins (IGFBPs) are a group of proteins that modulate IGF action 
and are present both in the circulation and within tissues. Amongst the functions 
ascribed to the IGFBPs are extension of the IGF half-life, localisation of IGFs to 
certain cell types, and modulation of IGF binding to cell surface receptors (MacGregor 
& Parkhouse 1996). Through these functions, IGFBPs may either potentiate or inhibit 
IGF action. Inhibition is proposed to result from the association of IGFs with IGFBPs 
in solution, thereby making the IGF unavailable for binding to the receptor. 
Potentiation is believed to result from associations of IGFBPs with extracellular 
matrix or cell surface proteins, accompanied by a decrease in binding affinity, which 
allows the IGF to be released and to partake in receptor binding (Bach et al. 1994; 
Wood 1995). 
There are six identified high-affinity IGF binding proteins (IGFBPs), named IGFBP-1 
to -6 (Bach et al. 1994). IGFBP-3 is the main binding protein in the circulation, and is 
present predominantly in a GH-dependent 150kDa complex with IGF-I or -II, and an 
acid labile 85kDa subunit. IGFBP-3 binds >95% of circulating IGF-I and -II with 
high affinity (Cohick & Clemmons 1993). In vitro studies have shown that a number 
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of IGFBPs are produced within muscle cells, with proliferating myoblasts producing 
predominantly IGFBPs-2, -4, and -6 (Ernst et al. 1992; Ewton & Florini 1995). 
Differentiated muscle cells produce IGFBPs-4, -5, and -6 (Ewton & Florini 1995; 
James et al. 1993; Rotwein et al. 1995; Silverman et al. 1995), with increasing and 
decreasing amounts of IGFBPs -3 and -2, respectively, as differentiation proceeds 
(Ernst et al. 1992; Johnson et al. 1996). 
The affinities of IGFBPs for IGF-1 and IGF-11 differs; thus IGFBPs-2 and -5, and -6 
have a greater affinity for IGF-11 relative to IGF-1 (Baxter 2000; Hossner et al. 1997), 
while IGFBPs-1, -3 and -4 bind IGF-1 and -II with equal affinity (Cohick & 
Clemmons 1993; Hossner et al. 1997). 
In addition to the high affinity IGFBPs, there are four recently identified IGFBP-
related proteins (IGFBP-rP-1 to -4) that also bind IGFs. The IGFBP-rPs are highly 
homologous to IGFBPs in the N-terminal region, however they do not contain the C-
terminal region within which the IGFBPs share homology (Baxter et al. 1998; Kim et 
al. 1997). The binding affinity of IGFBP-rPs for IGFs is reduced relative to the 
affinity oflGFBPs for IGFs (Oh et al. 1996). 
1. 7.1.4 IGF gene knockout experiments 
The important role of IGF peptides and receptors in regulating foetal growth has been 
clearly shown by knockout experiments, in which the gene of interest is disrupted. 
IGF-1 knockout mice are 60% of normal weight at birth, and exhibit a generalised 
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muscular dystrophy that is particularly evident in the diaphragm, heart and tongue (Liu 
et al. 1993a; Powell-Braxton et al. 1993). IGF-1 knockout mice have a high rate of 
perinatal mortality (over 95%), and those that do survive remain smaller in size 
postnatally (Liu et al. 1993a; Powell-Braxton et al. 1993). The mouse IGF-11 gene is 
subject to imprinting, such that the paternal allele is active while the maternal allele is 
silent in virtually all embryonic tissues (DeChiara et al. 1991 ). Inactivation of the 
paternal IGF-11 allele leads to phenotypically normal, fertile mice that are also 60% of 
normal weight at birth, with persistent low weight postnatally (DeChiara et al. 1990). 
Mice with an inactivated IGF-II gene are viable, indicating that although IGF-11 
protein has profound effects on size, it is not essential for embryonic development 
(DeChiara et al. 1990; DeChiara et al. 1991). Simultaneous knockout of both IGF-1 
and IGF-11 genes results in mice that weigh only 30% of normal weight at birth (Liu et 
al. 1993a), thus indicating that IGF-1 and IGF-11 have additive effects on growth. 
Most of the biological effects of the IGFs are thought to be mediated through binding 
to the Type I IGF receptor (Ludwig et al. 1996). 1n keeping with this, inactivation of 
the Type I IGF receptor results in mice that are 45% of normal weight at birth (Liu et 
al. 1993a; Ludwig et al. 1996). Mice with a disrupted Type I IGF receptor have 
smaller muscles due to hypoplasia (decreased tissue cell number) (Liu et al. 1993a), 
and die at birth (Ludwig et al. 1996). In mice, but not humans, the Type II IGF 
receptor is oppositely imprinted to IGF-II, so that the maternal allele is 
transcriptionally active while the paternal allele is silent (Haig & Graham 1991; 
Ogawa et al. 1993). The Type II IGF receptor in mice is proposed to act, at least in 
part, as a "sink" for IGF-II during foetal development (Haig & Graham 1991), as Type 
II IGF receptor knockout mice are subject to foetal overgrowth (approximately 130% 
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of normal weight at birth (Lau et al. 1994). Taken together, these gene knockout 
experiments indicate that the IGFs and their receptors are key determinants of foetal 
growth. 
1. 7.1.5 IGFs in skeletal muscle 
1.7.1.5.1 IGF expression 
IGF-1 and -II peptides are first expressed during early foetal development, and are 
subsequently regulated in a temporal fashion. IGF-1 mRNA levels in muscle are 
highest during foetal and early neonatal development, then decline to approximately 
25% of early neonatal levels by postnatal day 50 in the rat (Adamo et al. 1989). In 
contrast, IGF-II mRNA is expressed at a high, constant level throughout rat foetal 
development, but is undetectable in muscle and all tissues, other than brain, in the 
adult (Beck et al. 1988; Soares et al. 1985). The decrease in IGF-11 mRNA levels in 
most tissues of the rat at birth is accompanied by a decrease in circulating levels of 
IGF-II (Cohick & Clemmons 1993). The decrease in circulating levels of IGF-II is 
observed in rodents, but not humans, postnatally (Cohick & Clemmons 1993; 
Steenbergh et al. 1997). The temporal patterns of expression during development 
suggest that these peptides play a role in foetal muscle development. 
Just as IGF-1 and -II are temporally regulated in muscle tissue during development, 
they are also regulated in distinctive patterns in muscle cells during in vitro 
myogenesis. In cultured C2 muscle cells, the expression of IGF-1 mRNA is normally 
low during myoblast proliferation {Tollefsen et al. 1989a; Tollefsen et al. 1989b ), but 
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increases 6-10 fold within 48-72 hours of a switch to differentiation medium 
(Tollefsen et al. 1989a). The expression of IGF-II mRNA is also low during C2 
myoblast proliferation and increases during differentiation, with 25 times higher levels 
at 96 hours after the switch to differentiation medium (Tollefsen et al. 1989b). Both 
IGF-1 and IGF-II peptides are secreted from C2 muscle cells concurrent with the 
increase in IGF transcription during differentiation (Tollefsen et al. 1989a; Tollefsen 
et al. 1989b ). The cognate receptors for IGF-1 and -II are also regulated during 
myogenesis, with detectable levels of Type I IGF receptors in proliferating BC3H-1 
myoblasts, followed by a decrease in receptors during differentiation (Rosenthal et al. 
1991 ). The Type II IGF receptor, which is non-abundant in proliferating C2 
myoblasts, increases 6-fold during early differentiation, and remains high thereafter 
(Tollefsen et al. 1989b). IGFBPs are undetectable in proliferating myoblasts, but 
increase substantially within 16 hours of the switch to differentiation medium. The 
increase in IGFBPs during differentiation is accompanied by secretion of IGFBP from 
the muscle cells (Tollefsen et al. 1989a). 
1.7.1.5.2 IGF action 
IGFs exert pleiotropic effects on skeletal muscle cells. Studies have established a role 
for the IGFs in eliciting anabolic effects, including suppression of protein degradation 
(Janeczko & Etling er 1984 ), enhanced amino acid uptake (Merrill et al. 1977), 
induction of hypertrophy (Adams & McCue 1998; Coleman et al. 1995), and the 
stimulation of myoblast proliferation and differentiation. It is the enhancement of 
myoblast proliferation and differentiation by IGFs that is most relevant to the work 
contained within this thesis. 
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Enhancement of myoblast proliferation involves an increase in the number of 
myoblasts traversing the cell cycle. As discussed in Section 1.5.3.1, the cell cycle 
consists of the phases G1, S, G2 and M, while G0 is the state of quiescence. Growth 
factors participate in different phases of the cell cycle, and it is the G1 phase of the cell 
cycle where pivotal growth factor regulation of cellular proliferation occurs (Hulleman 
& Boonstra 2001). There are two phases of growth factor dependence in G1, first of 
which is the transition from Go to G1 (activation) (Hulleman & Boonstra 2001; 
Zumstein & Stiles 1987), while the second phase is the progression through G1 and 
the growth factor-dependent restriction (R) point, after which time cells are no longer 
dependent on growth factors for cell cycle progression (Hulleman & Boonstra 2001; 
Pardee 1974). To date, only hepatocyte growth factor (HGF), a factor found in crushed 
muscle extract, has been shown to be capable of activating satellite cells (Tatsumi et 
al. 1998). IGFs have been clearly established as progression factors, that is they are 
capable of progressing cells through the restriction point (Chakravarthy et al. 2000; 
Zhang et al. 1999) so that they are committed to completion of the cell cycle 
(Hulleman & Boonstra 2001). IGFs stimulate the proliferation of both transformed 
myoblasts and primary cultures of satellite cells in vitro (Dodson et al. 1985; Doumit 
et al. 1993; Florini et al. 1977; McFarland et al. 1993). 
IGF-1 is more potent than IGF-11 in eliciting the proliferative response in myogenic 
cells (Ballard et al. 1986; Ewton et al. 1994), and early researchers recognised that the 
order of potency in stimulating proliferation (IGF-1> IGF-11> insulin) mirrored the 
order of affinity of the ligands for the Type 1 IGF receptor (Ewton et al. 1987). In 
confirmation of this, studies in chicken satellite cells show that IGF-1 and -II are 
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bound to the Type I IGF receptor during IGF-stimulated proliferation (Duclos et al. 
1991). 
The mitogenic activity of IGF-1 on myoblasts is enhanced by the presence of a co-
factor, referred to as mitogenic competence factor, that is present in horse serum 
(McWade et al. 1997; McWade et al. 1995; Napier et al. 1999). Addition of horse 
serum to cultured L6 myoblasts that have previously undergone IGF-stimulation of 
proliferation allows the myoblasts to continue responding to the IGF with increased 
proliferation, whereas that responsiveness is lost without horse serum (Napier et al. 
1999). The identity of mitogenic competence factor is unknown, but is not believed to 
be TGF-p, PDGF-BB, FGF, or IGFBPs (McWade et al. 1997; Mc Wade et al. 1995). 
The literature to date has tended to focus on the mitogenic effects of IGF-1, and not 
those of IGF-11, however that is not to say that IGF-11 is a poor mitogen. Perhaps 
some of the most compelling evidence that this is not the case comes from recent 
oncogenic research, in which high levels of IGF-11 have been associated with the 
uncontrolled cellular proliferation typical of the malignant state (Khandwala et al. 
2000). This association has also been shown to occur in rhabdomyosarcomas, a 
skeletal muscle tumour (Minniti et al. 1994 ), and may be partially explained by the 
observation of reduced cell cycling time, through a diminished G1 checkpoint, in IGF-
11 overexpressing myoblasts (Zhang et al. 1999). Such a scenario could give rise to 
the malignant state due to the importance of cell cycle checkpoints in making certain 
that all the necessary processes have been completed before progression to the next 
stage (Zhang et al. 1999). As discussed previously, IGF-11 predominantly uses the 
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Type I IGF receptor to elicit a mitogenic effect, however IGF-II has also recently been 
shown to effectively stimulate cell cycle progression via the A isoform of the insulin 
receptor as well (Frasca et al. 1999; Scalia et al. 2001 ). The insulin receptor isoform 
A is present in foetal muscle and in some cancers (Frasca et al. 1999), however it is 
unknown whether this represents a significant mitogenic pathway in undamaged 
and/or regenerating adult muscle. Taken together, these studies indicate that not only 
IGF-1, but also IGF-II, is a potent regulator of myoblast proliferation. 
IGFs are unusual growth factors, in that they are able to stimulate both proliferation 
and differentiation, as many growth factors that stimulate proliferation inhibit 
differentiation, and vice versa (Florini et al. 1996). The stimulation of myogenesis by 
IGFs has been reported for cell lines and primary cultures of satellite cells (Allen & 
Boxhom 1989; Engert et al. 1996; Ewton et al. 1994; Greene & Allen 1991), and is 
concentration-dependent, with stimulation of myogenesis at low concentrations and 
inhibition at supraphysiological levels (Florini et al. 1986; Florini & Magri 1989). 
IGFs interact predominantly with the Type I IGF receptor to elicit a myogemc 
response (Ewton et al. 1987), although involvement of the Type II IGF receptor is also 
suggested by studies showing that an IGF-II analog with high affinity for Type II IGF 
receptors stimulates differentiation (Rosenthal et al. 1994 ). The amount of Type I IGF 
receptor impacts on the speed with which myogenesis occurs, with overexpression 
leading to an increased rate of myogenesis, and functional inactivation resulting in 
delayed differentiation in vitro (Cheng et al. 2000; Quinn & Haugk 1996; Quinn et al. 
1994). While these studies show that the Type I IGF receptor modulates 
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differentiation, in vitro studies also indicate that it is not a critical component, as 
serum-induced differentiation of cells in culture can still occur in the absence of a 
functional Type I IGF receptor (Cheng et al. 2000). 
IGF-1 and IGF-11 are not equivalent in their stimulation of differentiation (Ewton et al. 
1994; Florini et al. 1993). IGF-1 has a greater potency than IGF-11- that is lesser 
amounts of IGF-1 are required to stimulate differentiation- when administered to 
cultured myoblasts, however IGF-11 effects a greater absolute stimulation of 
differentiation (Fiorini et al. 1993). The difference between IGF-1 and -II in the 
stimulation of differentiation in vitro appears to be due at least in part to the greater 
stimulation of proliferation by IGF-1 relative to IGF-11, for when the mitogenic effects 
of IGF-1 on cultured L6A 1 myoblasts are suppressed, the stimulation of differentiation 
by IGF-1 approaches that oflGF-11 (Ewton et al. 1994). 
Proliferation and differentiation are normally considered mutually exclusive events, 
and the IGFs are unique in their ability to stimulate both processes. The mechanism 
by which IGFs achieve this involves cell cycle regulatory proteins, so a review of cell 
cycle control by regulatory proteins, and in particular the retinoblastoma gene product 
(Rb), is essential. The retinoblastoma (Rb) gene product is a primary controller of the 
cell cycle. Rb is a ubiquitously expressed protein containing 16 potential sites for 
phosphorylation, and it is the phosphorylation state of these sites that determines Rb 
activity (Driscoll et al. 1999). Rb protein plays an important role at the restriction 
point in G1, by determining whether cells can undergo DNA synthesis (reviewed by 
Hatakeyama & Weinberg 1995). The active (hypo-phosphorylated) form of Rb 
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suppresses transcription of the genes necessary for DNA synthesis through inhibition 
of E2 promoter binding factor (E2F)-containing complexes, while the inactive (hyper-
phosphorylated) form of Rb does not have growth suppressor activity (La Thangue 
1994 ). The phosphorylation state of Rb protein is mediated by cyclins (A, D 1 and E) 
and cyclin-dependent kinases (cdks), so that up-regulation of cyclins and cdks is 
associated with hyperphosphorylation of Rb, and subsequent cellular proliferation 
(Hatakeyama & Weinberg 1995; Sherr 1994). 
The state of Rb phosphorylation and cyclin/cdks also plays a part in the decision by 
cells to exit the cell cycle following mitosis. Active (hypo-phosphorylated) Rb 
promotes cell cycle exit and terminal myogenic differentiation (Gu et al. 1993), while 
high levels of cyclins and cdks inhibit this process both directly through effects on Rb 
phosphorylation state, and through a mechanism independent of Rb (Skapek et al. 
1996). So important is the effect of Rb phosphorylation on terminal myogenic 
differentiation, that expression of the phosphorylated, inactive form of Rb by 
terminally differentiated SV40T antigen-transfected C2C12 cells allows re-entry into 
the cell cycle (Gu et al. 1993). However, re-entry of non-transfected, "normal" 
terminally differentiated cells back into the cell cycle does not occur because pRB is 
refractory to rephosphorylation in response to growth factors in terminally 
differentiated cells, in agreement with the inability of muscle fibre nuclei to re-enter 
the cell cycle (Gu et al. 1993). The progression of cells from the proliferative to 
differentiated state is marked by an increased incidence of apoptosis, or programmed 
cell death, as shown for C2 muscle cells in culture (Stewart & Rotwein 1996). 
Apoptosis is a normal feature of mammalian skeletal muscle development (McArdle 
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et al. 1999). Upregulation of the cdk inhibitor, p21 WAFI/CJPJ, and dephosphorylation of 
Rb are critical regulatory events for the establishment of the apoptosis-resistant state 
(Walsh & Perlman 1997), a state that allows nuclear number to be retained during 
differentiation (Stewart & Rotwein 1996). 
Studies of the early and late effects of IGFs on muscle cells show that at early 
timepoints, IGF upregulates the expression of cyclin D 1 and cdk4, which 
consequently leads to hyperphosphorylation of Rb (Rosenthal & Cheng 1995). This 
inactive form of Rb allows proliferation, in response to IGFs, to take place. 
Concurrent with the early enhancement of Rb phosphorylation, is a down-regulation 
of myogenin expression, an event that occurs independently to the effects on cell cycle 
proteins (Rosenthal & Cheng 1995). Myogenin plays a critical role in differentiation 
by controlling the transcription of muscle specific genes (Myer et al. 1997), and in 
regulating the extracellular environment in which myoblast fusion takes place, as 
indicated by the report that wild-type myoblasts rescue the ability of myogenin -/-
myoblasts to fuse in vivo (Myer et al. 1997). Regulation of myogenin gene expression 
by IGFs is biphasic, whereby IGFs inhibit myogenin gene transcription during 
proliferation, then enhance myogenin gene transcription during later stages (Adi et al. 
2000; Rosenthal & Cheng 1995). The inhibition of myogenin gene expression during 
proliferation inhibits differentiation (Adi et al. 2000; Myer et al. 1997; Rosenthal & 
Cheng 1995), while the later increase promotes differentiation (Adi et al. 2000; 
Rosenthal & Cheng 1995). The differential effects of IGFs on myogenin transcription 
occur via two distinct regions on the myogenin gene promoter, with inhibition 
occurring via promoter sequences located in the -145 to -9 region of the myogenin 
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gene, and enhancement occurring in the -1,565 to -375 region of the the myogenin 
gene (Adi et al. 2000). Effects of IGF on myogenin gene transcription via two distinct 
sites in the promoter region thus explain how IGFs can both stimulate and inhibit 
myogenin gene transcription (Adi et al. 2000). The coordinated control of cell cycle 
and muscle cell regulatory factors describes a refined mechanism by which the IGFs 
control both proliferation and differentiation processes. 
In addition to the above-mentioned effects on muscle cell proliferation and 
differentiation, both IGFs act as survival factors during muscle cell differentiation in 
culture, by preventing apoptosis (Stewart & Rotwein 1996). In cultured IGF-11 
antisense C2 cells, the switch to differentiation medium is associated with markers of 
apoptosis in over 90% of the cells, however administration of either exogenous IGF-1 
or IGF-11 is able to prevent this through interaction with the Type I IGF receptor 
(Stewart & Rotwein 1996). IGF-11 similarly prevents apoptosis in vivo, as 
demonstrated by the reduction in programmed cell death in the muscle of mdx mice 
after crossing with IGF-11 overexpressing transgenic mice (Smith et al. 2000). 
1. 7.1.6 IGFs in regenerating skeletal muscle 
The levels of IGFs and their receptors are differentially regulated during the 
regeneration process. In homogenised regenerating muscle of young rats following 
bupivacaine-induced damage, IGF-1 mRNA levels are elevated 6-fold relative to 
undamaged control muscle on days 5 and 10 of regeneration, then decline to 
approximately the same level as control muscle by day 15 post-injection (Marsh et al. 
1-47 
1997). Results of the same study showed that IGF-II mRNA levels are elevated 60-
and approximately 30-fold on days 5 and 10, respectively, and that IGF-II mRNA 
levels approach control values by day 15 (Marsh et al. 1997). In contrast, Type I IGF 
receptor mRNA levels are elevated approximately 2- and 6-fold on days 5 and 10 of 
regeneration, respectively, then decline to control muscle levels by day 15 (Marsh et 
al. 1997). The Type II IGF receptor mRNA was not measured in the same study, but 
in a separate study of regenerating muscle following notexin-injection, Type II IGF 
receptor mRNA was detected but its levels were not significantly different to that of 
the contralateral control muscle (Levinovitz et al. 1992). Thus, IGF-1 and -II, and 
their cognate receptors, are regulated differentially throughout regeneration, 
presumably as a reflection of their differing functions within regenerating muscle. 
During regeneration, the tissue type specific pattern of IGF-1 expression is altered. 
Undamaged muscle fibres do not show specific localisation of IGF-1 protein, however 
after damage, IGF-1 protein is observed in satellite cells, intramuscular nerves and 
blood vessels (Jennische & Hansson 1987; Jennische et al. 1987; Keller et al. 1999). 
Macrophages in damaged heart muscle following myocardial infarct express IGF-1 
(Matthews et al. 1999), however macrophages in regenerating skeletal muscle were 
not found to contain IGF-1 protein (Keller et al. 1999). 
The pattern of expression by different cell/tissue types during regeneration suggests 
that IGF-1 may be performing a number of different functions within regenerating 
muscle. IGF-1 stimulates the chemotaxis in vitro of skeletal myoblasts (Suzuki et al. 
2000), vascular smooth muscle cells (Bornfeldt et al. 1994), and nerve cells 
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(Puglianello et al. 2000). However, studies of murine muscle following denervation 
and devascularisation indicate that in regenerating muscle, IGF-I has varying effects 
(Lefaucheur et al. 1996). In these studies, immune neutralisation of IGF-I during 
regeneration resulted in a two-fold increase in the number of capillaries, indicating an 
enhancement of muscle revascularisation, and a 50% increase in the number of 
macrophages in the damaged area (Lefaucheur et al. 1996). Immune neutralisation of 
IGF-I during muscle regeneration also resulted in 80% and 30% decreases in 
regenerating fibre number and diameter, respectively, by day 11 of regeneration 
(Lefaucheur & Sebille 1995c ). Thus, by inference, the studies of Lefaucheur and 
colleagues show that in regenerating muscle, IGF-I may have a net negative effect on 
revascularisation and phagocytic processes (Lefaucheur et al. 1996), as well as a 
positive effect at later timepoints (Lefaucheur & Sebille 1995b ), likely through effects 
on proliferation and differentiation. Similarly, IGF-I administration during laceration-
induced regeneration resulted in a 3.5-fold increase in the number of regenerated 
myofibres, increased regenerated myofibre diameter, and increased muscle strength 
(Menetrey et al. 2000). The inferred inhibition of vascularisation reported by 
Lefaucheur and Sebille (1996) is in contrast to the marked enhancement of smooth 
muscle cell proliferation and migration following intraarterial injury in vivo, in smooth 
muscle cells that have been engineered to overexpress IGF-I (Zhu et al. 2001). The 
reason for these inconsistencies is unknown but may in part be due to the impact of 
other regeneration processes on vascularisation, or the fact that anti-IGF-I antibody 
rather than supplemental IGF-I was used for the studies by Lefaucheur and colleagues. 
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IGF-II, which is low or absent from rat muscle fibres postnatally (Levinovitz et al. 
1992), is temporally regulated after damage in regenerating muscle cells (Levinovitz 
et al. 1992), and in areas enriched with neuromuscular juctions (Pu et al. 1999b ). 
Vascular tissues contain IGF-II protein during regeneration, but strictly at constitutive 
levels (Keller et al. 1999), suggesting that IGF-II is not specifically regulated by 
vascular tissues during regeneration. As was the case for IGF-1, macrophages in 
regenerating skeletal muscle have not been shown to contain IGF-II, although IGF-11 
is present within macrophages in multiple sclerotic lesions (Gveric et al. 1999). Thus 
it is apparent from the patterns for IGF-1 and -II expression that there are both 
similarities and differences in the expression patterns of the two peptides during 
skeletal muscle regeneration. To date, there have been no studies to test the effect of 
administered IGF-11 on skeletal muscle regeneration, so it is not known if the effect of 
altered IGF-11 levels during muscle regeneration is similar to that of altered IGF-1. 
As mentioned above, both IGF-1 and -II are specifically expressed in nervous tissue 
during muscle regeneration. IGF-II is often referred to a neurotrophic factor for two 
reasons: a) IGF-11 expression is restricted to the brain in normal postnatal rats (Beck et 
al. 1988), and b) IGF-11 markedly enhances nerve regeneration (Glazner et al. 1993; 
Near et al. 1992). IGF-1 has also been shown to promote nerve regeneration (Zhuang 
et al. 1996). A consideration of the roles of IGFs in nerve regeneration is pertinent, in 
that the innervation status affects the state of the regenerating muscle fibres, in 
particular after the first 5-7 days of regeneration (Whalen et al. 1990). 
1-50 
The IGF axis in connective tissue of regenerating skeletal muscle has not been well 
characterised to date. IGF-1 mRNA is up-regulated in fibroblasts of damaged heart 
following myocardial infarct (Matthews et al. 1999), and in the hypertrophic scar 
tissue that develops following thermal injury (Ghahary et al. 1995). Treatment of 
dermal fibroblasts with IGF-1 results in increased collagen synthesis (Ghahary et al. 
1995), which suggests that increased IGF-1 levels in damaged tissues may be 
associated with increased connective tissue. Recently, the mechanism by which IGF-1 
modulates the extracellular matrix has been shown to involve IGF-1 induction of latent 
TGF-P (Ghahary et al. 2000). Latent TGF-P is then activated through binding to the 
Type II IGF receptor, and it is the activated TGF-P that then causes fibroblasts to 
increase matrix deposition (Ghahary et al. 1999b ). 
1. 7.1. 7 Regulation of IGFs 
1.7.1.7.1 Growth hormone 
Growth hormone (GH), a protein produced by the anterior lobe of the pituitary gland, 
has a dramatic effect on growth. Resistance to GH, or lack of sufficient pituitary GH 
concentrations, are associated with the dwarf phenotype in rodents and humans 
(Charlton et al. 1988; Hull & Harvey 1999). Administration of exogenous GH 
promotes also muscle growth in rodents and farm animals (Beach & Kostyo 1968; 
Beerman et al. 1990; Pell & Bates 1987). The activity of GH is greatly influenced by 
nutritional status, for a low-plane of nutrition is associated with increased circulating 
levels of GH (Breier et al. 1988a), and decreased hepatic binding of GH in steers 
(Breier et al. 1988b ). 
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The pattern of GH secretion 1s controlled by two hypothalamic peptides, the 
stimulatory factor, GH-releasing hormone (GHRH), and the inhibitory peptide, 
somatostatin (SRIF) (Wagner et al. 1998). The pattern of GH secretion differs 
between males and females, with dissimilarities in the nadir value and length, and GH 
pulse length and frequency (Jansson et al. 1985). The masculine pattern of GH 
secretion in rats is typified by narrow GH pulses at a frequency of one every 3-4 
hours, and extended periods with low to undetectable nadir values (Jansson et al. 
1985). The feminine pattern of GH secretion in rats has prolonged GH pulses, an 
irregular pattern of pulsatility, and higher nadir values than male rats (Jansson et al. 
1985). The response to GH is sexually dimorphic, with differences in hepatic gene 
expression, including the cytochrome p450 (Sundseth et al. 1992) and major urinary 
protein (MUP) families (McIntosh & Bishop 1989) and in somatic growth responses 
(Jansson et al. 1985). These differential growth and gene expression patterns are the 
result of the different patterns of GH secretion between males and females (Jansson et 
al. 1985), with the length of the nadir being a key determinant of the dimorphic effect 
(Waxman et al. 1991 ). GH receptor signalling involves the Janus kinase/signal 
transducer and activation of transcription (JAK-STAT) pathway (Carter-Su et al. 
1994; Gouilleux et al. 1995), and recent studies have shown that the STAT5b protein 
is a major determinant of the sexually dimorphic response of liver and growth rate to 
GH pulsatility (Udy et al. 1997). The pattern of GH pulsatility is regulated at least in 
part by testosterone, as exposure to testosterone can alter the pattern of pulsatility 
from a feminine to a masculine pattern (Painson et al. 2000). 
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The potent effects of GH on anabolic growth and nitrogen retention (Ambler et al. 
1993) have led to studies regarding its use to enhance wound healing (Belcher & Ellis 
1990; Kowalewski & Yong 1968) and muscle regeneration (Ullman et al. 1990). The 
latter aspect, the enhancement of muscle regeneration by GH, will be addressed in 
CHAPTER 4. 
The "somatomedin hypothesis", of 1957 (Salmon & Daughaday), postulated that the 
effects of growth hormone (GH) were mediated by a factor that was secreted into the 
circulation, a factor that is now known as IGF-I. Liver is a major contributor to 
circulating levels of IGF-1 in response to GH (Yakar et al. 1999), giving rise to 
approximately 75% of circulating IGF-1 levels in mice (Sjogren et al. 1999). Until 
recently, the dogma has been that circulating IGF-1 is the principle mediator of GH 
effects on postnatal growth and development, however recent studies using the Cre/lox 
recombination system to specifically delete the igfl gene in liver clearly show that 
normal postnatal growth occurs even when there is a substantial reduction in 
circulating levels of IGF-1 (Sjogren et al. 1999; Yakar et al. 1999). Furthermore, 
normal growth occured despite a reported compensatory increase in circulating GH, 
due presumably to the lack of negative feedback by circulating levels of IGF-1 
(Sjogren et al. 1999; Yakar et al. 1999). These reports thus suggest that 
autocrine/paracrine production of IGF-1 is likely to be critical for normal postnatal 
growth and development (Sjogren et al. 1999; Ueki et al. 2000; Yakar et al. 1999). 
IGF-1 mRNA is increased in a number of tissues in response to supraphysiological 
levels of exogenous GH, including skeletal muscle (Isgaard et al. 1989), adipose 
tissue (Vikman et al. 1991 ), and bone growth plate (Isgaard et al. 1988). Furthermore, 
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GH receptor levels in skeletal muscle change coordinately with IGF-1 mRNA levels 
during mouse development, suggesting that GH may interact directly with skeletal 
muscle to direct autocrine/paracrine synthesis of IGF-1 (Shoba et al. 1999). In 
cultured C2C12 muscle cells, direct regulation of IGF-1 levels by GH has recently 
been shown (Sadowski et al. 2001), thus providing unequivocal evidence of a direct 
effect of GH on IGF-1 production in non-hepatic cells. Not only does this study 
provide evidence of GH regulation ofIGF-1 in muscle, it also suggests an effect ofGH 
on the Type I IGF receptor, via the suppressor of cytokine signalling-2 (SOCS-2) 
protein (Sadowski et al. 2001 ), which has been shown to interact directly with the 
Type I IGF receptor both in vitro and in vivo (Dey et al. 1998). It should be noted that 
although GH has been shown to directly regulate IGF-1 in cultured muscle cells 
(Sadowski et al. 2001), GH can also exert a mitogenic effect directly on cultured pro-
B Ba/F3 cells independently ofIGF-1 (Baixeras et al. 2001). 
In contrast to the effect of GH on hepatic IGF-1 expression, GH generally does not 
induce expression of hepatic IGF-11 when administered in vivo (Lewis et al. 2000; 
Turner et al. 1988). This is consistent with the observation that hepatic IGF-11 levels 
are high in the rat foetus and low postnatally (Norstedt et al. 1988; Park & Buetow 
1991 ), while the growth response to GH is absent during foetal development but is 
present postnatally (reviewed by Bass et al. 1992). 
The association of GH with stimulation oflGF-11 production in skeletal muscle is less 
clear than the association of GH with muscle IGF-1 production. Neonatal pigs 
administered GH for 7 days do not have increased skeletal muscle IGF-11 mRNA 
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(Lewis et al. 2000), however adult rats implanted with GH-secreting, pituitary-derived 
GH3 cells for 80 days show a six-fold increase in IGF-II mRNA in muscle {Turner et 
al. 1988). Further evidence that GH may not control skeletal muscle IGF-11 
production 1s seen in the greater induction of IGF-II mRNA in the muscles of 
hypophysectomised (GH-deficient) rats relative to normal (GH-replete) rats m 
response to work-induced hypertrophy (DeVol et al. 1990). Therefore, GH regulates 
IGF-1 in the liver and also to some extent in other tissues, however it does not appear 
to regulate IGF-II in the same manner. 
1.7.1.7.2 IGF receptor downregulation by IGFs 
The first suggestions of a link between IGFs and Type I IGF receptor levels were the 
observations that a) in many tissues the Type I IGF receptor levels decrease during the 
time that IGF-1 levels increase during postnatal development in the rat (Werner et al. 
1989), and b) IGF-II mRNA levels increase while Type I IGF receptor levels decrease 
during muscle cell differentiation (Rosenthal et al. 1991 ). It has since been shown 
that both IGF-1 and -II induce down-regulation of the Type I IGF receptor (Rosenthal 
& Brown 1994 ), an effect that occurs via interaction with the Type I, but not the Type 
II, IGF receptor (Rosenthal & Brown 1994; Rosenthal et al. 1994). IGF-1 and -II 
down-regulate Type I IGF receptor levels by decreased receptor gene transcription, 
while IGF-11 has also been shown to increase degradation of the Type I IGF receptor 
protein (Hernandez-Sanchez et al. 1997; Rosenthal & Brown 1994). 
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1. 7. 2 Myostatin 
Myostatin, also known as growth and differentiation factor-8 (GDF-8), is a member of 
the transforming growth factor-beta (TGF-13) superfamily. The TGF-13 family consists 
broadly of TGF-j3s, activins, inhibins, bone morphogenetic proteins (BMPs), and 
Mullerian-inhibiting substance. TGF-13 family members are associated with wide 
ranging effects on numerous cell types, including the regulation of cell growth, cell 
differentiation, and matrix deposition. Myostatin, identified in 1997 by McPherron 
and colleagues (McPherron et al. 1997), is a potent negative regulator of skeletal 
muscle mass. Myostatin has been proposed to act as a "chalone" (Lee & McPherron 
1999), a concept that was originally proposed by Bullough (Bullough 1965). 
Chalones are molecules that are produced by a specific tissue that inhibit its growth, 
so that local and/or systemic concentrations of the chalone reflect the mass of the 
tissue where it was produced (Bullough 1965; Lee & McPherron 1999). 
1. 7.2.1 Peptide synthesis 
The myostatin gene is located on chromosome 1 in mice (Szabo et al. 1998), and on 
chromosome 2 in humans and cattle (Gonzalez-Cadavid et al. 1998; Kambadur et al. 
1997; Smith et al. 1997), and is composed of 3 exons and 2 introns ( Gonzalez-
Cadavid et al. 1998; J eanplong et al. 1999; McPherron et al. 1997). Myostatin 
nucleotide and amino acid sequence is highly conserved across species, with 93% 
homology between bovine and murine amino acid sequences (Kambadur et al. 1997). 
Full-length myostatin protein, which in mice consists of 376-amino acid residues, 
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shares many common structural features with other TGF-P family members, 
including: a carboxy(C)-terminal region containing a conserved pattern of cysteine 
residues, a signal sequence for secretion, and a proteolytic processing site (McPherron 
et al. 1997). As suggested by the latter two features, myostatin is further processed 
before it is capable of exerting biological effects. This begins with the dimerisation of 
full-length TGF-P polypeptides, via disulfide bonds, soon after translation (Gleizes et 
al. 1997). Precursor TGF-P molecules are then proteolytically cleaved in the Golgi 
apparatus to yield the N-terminal latency-associated protein (LAP) portion, and the C-
terminal mature peptide (Gleizes et al. 1997; Okada et al. 1989). The LAP and mature 
TGF-P homodimers associate with each other in a non-covalent manner, and it is this 
complex that is secreted from cells. A similar situation occurs for myostatin (Thies et 
al. 2001 ), however in the case of myostatin the processed, mature form of myostatin 
(ie, not associated with LAP) is also found within the circulation of humans 
(Gonzalez-Cadavid et al. 1998), indicating that in at least some cases myostatin is 
released from the latent complex prior to secretion. Association of myostatin with the 
LAP protein renders it inactive (Thies et al. 2001), and it is only upon dissociation 
from the LAP protein that myostatin is rendered active, and able to interact with its 
receptor (Thies et al. 2001). The LAP portion of TGF-P has been shown to be 
important not only for receptor binding capability, but also to function in the folding 
and secretion of TGF-P, and perhaps in the trafficking of TGF-P to target cells 
(Gleizes et al. 1997; Gray & Mason 1990; Lee & McPherron 2001; Thies et al. 2001). 
These aspects of the LAP portion of myostatin have not been investigated as yet, 
however the importance of the LAP for myostatin function has been clearly 
demonstrated by two studies, even though the results are apparently conflicting. The 
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first report concerns transgenic mice produced with a myostatin pro domain construct, 
which had 22-44% greater carcass weight and larger fast fibre diameters, as compared 
to control mice (Yang et al. 2001). This study clearly suggests an inhibition of 
myostatin action by the LAP protein. In the second study, the Cmpt mouse is reported 
to carry a deletion in the LAP portion of the myostatin gene, and to exhibit a 
hypermuscularity directly linked to the myostatin gene (Szabo et al. 1998). Therefore, 
if one presumes that the deletion in the LAP portion inhibits LAP function rather than 
enhances it, this report infers that the LAP portion of the myostatin gene acts to 
enhance myostatin function. The apparently conflicting findings of these two studies 
may reflect different functions of the LAP protein, whereby the mutation in the Cmpt 
mouse affects a different function of the LAP protein, such as myostatin protein 
folding, to the function that is affected by LAP overexpression. Clearly further studies 
are required in this area, particularly in identifying the specific effect of the deletion in 
the Cmpt mouse, in order to resolve this discrepancy. 
1. 7.2.2 Receptors 
TGF-P family members bind to receptors containing a cysteine-rich extracellular 
region, and an intracellular kinase domain with predicted serine/threonine specificity 
(Heldin et al. 1997). This group of receptors consists of Type I and Type II receptors, 
both of which contain kinase activity (Heldin et al. 1997). TGF-P family members 
bind to characteristic combinations of TGF-P, activin, and BMP Type I and II 
receptors, and binding to both Type I and II receptors is prerequisite for signal 
generation (Heldin et al. 1997). In the case of myostatin, substantial biological effects 
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are exerted both in vivo and in vitro through binding to the activin Type II receptor B 
(Act RIIB) (Lee & McPherron 2001). Activin Type II receptor A (Act RIIA) similarly 
binds dimerised mature myostatin, but at a much lower level than Act RIIB (Lee & 
McPherron 2001). The role of Act RIIB as the primary receptor regulating myostatin 
activity is indicated by the presence of increased muscle mass similar to that of the 
myostatin knockout mice, in transgenic mice expressing a dominant-negative form of 
Act RIIB (Lee & McPherron 2001). 
The signalling mechanisms that take place downstream of receptor activation have not 
been elucidated for myostatin, however a family of proteins called Smads are known 
to function in the intracellular signalling pathways for other TGF-P family members. 
It is believed that Smads undergo conformational changes after activation by 
receptors, form complexes with other Smads, then translocate to the nucleus to 
modulate the transcription of target genes (Heldin et al. 1997). 
1. 7.2.3 Myostatin in muscle 
1.7.2.3.1 Myostatin expression 
Myostatin expression occurs early in development, and this time of onset appears to 
be well-conserved across diverse species. In mice, the first observation of myostatin 
mRNA in the myotome compartment of developing somites is on day 9.5 post-coitum 
(p.c.), with widespread expression in nearly all somites by day 10.5 p.c. (McPherron et 
al. 1997). Similarly, bovine and porcine embryos begin to express myostatin mRNA 
on days 29 and 21, respectively (Ji et al. 1998; Kambadur et al. 1997). Piscine species 
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first express myostatin in post-hatch larvae, at the time of early myogenesis (Rodgers 
et al. 2001). Myostatin expression continues to be associated with the development of 
skeletal muscle at later gestational stages (Ji et al. 1998; McPherron et al. 1997; 
Oldham et al. 2001), with the expression of myostatin mRNA in bovine hindlimb 
muscle increasing during early embryonic development to a peak on day 90 
(approximately 6-fold birth levels), followed by a sharp decrease and steady low 
levels thereafter through the remainder of gestation (Oldham et al. 2001). Myostatin 
levels appear to be important for prenatal development, for a positive correlation 
between low birth weight and elevated myostatin expression has been shown for pigs 
(Ji et al. 1998). 
Myostatin continues to be expressed postnatally, although at lower levels than 
prenatally (Ji et al. 1998), and with considerable variation between different muscles 
(McPherron et al. 1997). Much of the variation in myostatin expression between 
muscles has been attributed to variations in fibre type (Sakuma et al. 2000), however 
this association is not clearcut. Murine M. soleus, which is composed primarily of 
Type I fibres, does not contain myostatin mRNA; rather, Type lib MHC isoform was 
found to correlate positively with myostatin mRNA (Carlson et al. 1999). In a study 
of the association of myostatin mRNA with fibre type in different fish species, 
myostatin was found to be associated with either fast fibres only, slow fibres only, or 
with both fast and slow fibres, depending on the species (Roberts & Goetz 2001). 
These variations may have been attributable to differential locomotion between the 
fish species studied (Roberts & Goetz 2001). It is apparent that this is an area of 
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research worthy of more attention m order to determine the exact nature of the 
relationship between myostatin and muscle fibre type. 
In contrast to the situation observed during embryonic development in which 
myostatin expression is strictly limited to muscle and progenitor muscle cells, 
postnatally myostatin is expressed in a much wider range of tissues. Myostatin has 
been identified in the Purkinje fibres and cardiomyocytes of adult heart (Sharma et al. 
1999), in adipose tissue (McPherron et al. 1997), and the mammary gland (Ji et al. 
1998) of mammals. In brook trout, which express 2 isoforms of myostatin, one 
isoform is found in muscle, and in brain tissues including optic lobes, the hindbrain, 
and hypothalamus (Roberts & Goetz 2001). The second isoform is localised within 
the ovaries, and is expressed during ovulation, suggesting some sort of a reproductive 
role for myostatin in fish (Roberts & Goetz 2001). 
1. 7 .2.3.2 Myostatin action 
As stated above, myostatin is a key negative controller of skeletal muscle mass, as is 
clearly shown by the enhancement of muscle size in Piedmontese and Belgian Blue 
double-muscled cattle, animals which lack a functional myostatin protein (Grobet et 
al. 1997; Kambadur et al. 1997; McPherron & Lee 1997). In Piedmontese cattle the 
non-functional myostatin protein is due to a missense mutation causing a cysteine to 
tyrosine substitution in the coding region (Kambadur et al. 1997; McPherron & Lee 
1997), while in Belgian Blue cattle the non-functional myostatin is due to an 11-bp 
deletion in the coding sequence, resulting in a premature stop codon (Grobet et al. 
1997; Kambadur et al. 1997; McPherron & Lee 1997). The disruption of the 
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myostatin gene m mice yields muscles with 2-3 times greater mass due to both 
hypertrophy and hyperplasia (McPherron et al. 1997). The hypermuscular compact 
(Cmpt) mouse, which is the result of a selection programme for high carcass protein 
content (Varga et al. 1997), has a deletion in the myostatin gene (Szabo et al. 1998). 
These studies thus support a strong inhibitory role for myostatin in controlling muscle 
growth. 
Cell culture studies have provided valuable insight into the mechanism by which 
myostatin inhibits muscle growth. Studies in our laboratory showed that the addition 
of myostatin protein to cultured C2Cl2 myoblasts resulted in blocks at two points in 
the cell cycle: the G1 to S, and G2 to M, transitions (Thomas et al. 2000). These 
findings suggest that the enhancement of muscle mass observed in double-muscled 
cattle and myostatin knockout mice is due, at least in part, to de-regulation of the 
myoblast cell cycle in the absence of functional myostatin (Thomas et al. 2000). 
Myostatin inhibits protein synthesis which, combined with the inhibition of myoblast 
proliferation, could account for the presence of both hyperplasia and hypertrophy in 
myostatin knockout mice (McPherron et al. 1997; Taylor et al. 2001). No effect of 
myostatin on either protein degradation or apoptosis was found in the same study 
(Taylor et al. 2001). 
Considerable attention has been paid to determining the role of myostatin in muscle 
atrophy and sarcopenia, with the expectation that because myostatin is a negative 
regulator of muscle growth, that the levels of myostatin would be increased in cases of 
muscle loss. Indeed, this inverse relationship of myostatin to muscle loss has been 
1-62 
observed for chronic disuse atrophy (Reardon et al. 2001 ), muscle loss due to space 
flight (Lalani et al. 2000), and weight loss associated with AIDS (Gonzalez-Cadavid 
et al. 1998). Elevated myostatin alone, however, is not sufficient for loss of muscle 
mass as surmised by the observation that rats undergoing atrophy due to hindlimb 
unloading continued to express high levels of myostatin even following periodic bouts 
of weight bearing sufficient to prevent muscle loss (Wehling et al. 2000). Further 
studies will undoubtedly be aimed at determining the factors and/or conditions that 
modulate the levels of myostatin associated with atrophy and muscle wasting. 
1. 7.2.4 Myostatin in regenerating skeletal muscle 
The potent regulation of muscle growth observed in response to myostatin meant that 
keen interest quickly developed in determining the role of myostatin in skeletal 
muscle regeneration. Following is a summarisation of the key findings regarding the 
localisation and pattern of expression of myostatin mRNA during muscle 
regeneration. In rodents, myostatin protein is temporally-regulated during muscle 
regeneration (Mendler et al. 2000; Sakuma et al. 2000), with predominantly lower 
levels of myostatin protein beyond the necrotic stage (Mendler et al. 2000; Sakuma et 
al. 2000). The levels of myostatin mRNA and protein are strikingly different during 
the early stages of muscle regeneration, suggesting that perhaps circulating levels of 
myostatin alter the level of myostatin protein detected in muscle (Mendler et al. 
2000). An intriguing study by Yamanouchi et al (2000) reported the localisation of 
myostatin mRNA in fibroblasts within regenerating skeletal muscle, then showed that 
skeletal muscle-derived fibroblasts expressed myostatin mRNA in vitro in response to 
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the addition of crushed muscle extract. Crushed muscle extract (Bischoff 1986b) is 
known to contain growth factor activity, including HGF (Tatsumi et al. 1998). HGF 
is capable of activating quiescent MPC (Allen et al. 1995), but whether it is this 
growth factor/cytokine or another that is responsible for invoking transcription of the 
myostatin gene in fibroblasts during regeneration, is unknown. This observation 
paves the way for interesting research into the interactions of myostatin with other 
growth factors, an area that is especially important in terms of muscle regeneration 
given the intricacies of growth factor expression at this time. 
In muscular dystrophy, where continual rounds of muscle fibre degeneration and 
regeneration occur, myostatin may play a role. This has recently been investigated in 
two models of murine muscular dystrophy: a) in mdx mice, which lack dystrophin and 
bear resemblance to Duchenne's muscular dystrophy (Cavanna et al. 1988; Hoffman 
et al. 1987), but do not lose muscle strength as occurs in humans with Duchenne's 
muscular dystrophy (Tanabe et al. 1986); and b) in gsg -/- mice, which lack y-
sarcoglycan and bear likeness to limb girdle muscular dystrophy (Zhu et al. 2000). 
Analysis of three hindlimb muscles showed that myostatin mRNA is markedly 
reduced in these dystrophic strains relative to normal (wild type) mice (Zhu et al. 
2000), suggesting an association of myostatin with muscular dystrophy. 
The association of myostatin with innervation status is pertinent to a discussion of 
muscle regeneration. In rats, denervation of a fast-type muscle resulted in a slight 
increase in myostatin protein, while denervation of a slow-type muscle resulted in a 
small decrease in myostatin protein (Sakuma et al. 2000). Myostatin expression thus 
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changes slightly with denervation, and these changes are altered, or determined, by the 
fibre-type composition of muscle. The effects of myostatin on the reinnervation of 
muscle have not been explored, however based on reports of improved nerve 
regeneration with neutralisation of TGF-P 1 (Davison et al. 1999) this may be an area 
worthy of future attention. 
1. 7.2.5 Regulation of myostatin 
1.7.2.5.1 Follistatin 
Follistatin was originally isolated from ovarian follicular fluid, and as its name would 
suggest, suppresses follicle stimulating hormone (FSH) production by cultured 
pituitary cells (Robertson et al. 1987). Follistatin binds to activin (Phillips 2000), 
another TGF-P family member that binds to the Act RIIB receptor (Gray et al. 2000), 
and so inhibits activin function (deWinter et al. 1996). Similarly, follistatin has been 
shown to also bind to dimerised mature myostatin, and so inhibit the binding of 
myostatin to the Act RHB receptor (Lee & McPherron 2001). Follistatin over-
expressing transgenic mice have extreme muscling, muscling that is significantly 
greater than that seen in myostatin knockout mice (Lee & McPherron 2001). This 
supports a role for follistatin as a potent inhibitor of myostatin function, and suggests 




Analysis of the promoter region located upstream of the human myostatin gene has 
identified the presence of a binding site (E-box) for the MRF family of muscle-
specific transcription factors (reviewed in Section 1.6.1) (Ferrell et al. 1999). Because 
some MRFs, ie myf-5 and MyoD, are present during early embryogenesis, as is 
myostatin, it is conceivable that the MRFs enhance the expression of myostatin at 
these early timepoints. Such a hypothesis is supported by the observation of 
coincidental increases in MyoD and myostatin mRNAs in the hindlimb muscles of 
foetal cattle during the stages of primary and secondary fibre formation (Oldham et al. 
2001). Certainly, further studies to elucidate the relationship between MRFs and 
regulation of myostatin will be vital to understanding the mechanism of myostatin 
expression in normal and damaged muscle. 
1. 7 .2.5.3 Myostatin 
Double-muscled Belgian Blue cattle lack a functional myostatin gene product due to a 
deletion that results in a premature stop codon (Kambadur et al. 1997). When the 
expression of myostatin mRNA from double-muscled Belgian Blue cattle is compared 
to that of normal-muscled cattle, significantly greater levels are found in double-
muscled cattle (Oldham et al. 2001). This suggests that a negative feedback 
mechanism by myostatin that is normally present, is non-operational in the double-
muscled Belgian Blue cattle, thus giving rise to the higher levels of myostatin 
expression (Oldham et al. 2001). Further studies to corroborate this have not, as yet, 
been carried out. 
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1.8 Summary 
The role of the insulin-like growth factors in skeletal muscle regeneration has not been 
fully explored. In particular, there is a noticeable lack of information on changes in 
the Type II IGF receptor population alongside changes in the other components of the 
IGF axis during regeneration. Most investigations up to now have involved a non-
histological approach, where the inputs of individual tissues to overall changes in IGF 
and receptor levels are indistinguishable. Such an approach ignores the facts that a) 
growth factor responses may vary depending on distance from the injury site, and b) 
important changes in the IGF axis may occur in different compartments. For this 
reason, the work contained in this thesis utilises a histological approach, so that the 
growth factor activities of different tissues within damaged muscle can be analysed. 
Growth hormone is a potent stimulator of muscle growth, suggesting that it could 
enhance muscle regeneration, however the majority of studies thus far have 
concentrated solely on its regulation of IGF-1, rather than on all components of the 
IGF axis. Furthermore, GH effects may vary depending on tissue type within the 
damaged muscle, an aspect that has been overlooked to date. In the following studies, 
GH effects on all components of the IGF axis, within the different tissues that 
comprise damaged muscle, will be examined. 
Myostatin presented itself as a newly identified protein with a potent negative effect 
on muscle growth, however nothing was known of its role or expression during 
skeletal muscle regeneration. Thus, the localisation of myostatin in damaged and 
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regenerating muscle tissues will be examined herein, and a determination made of 
whether myostatin levels are affected in a situation of enhanced growth during muscle 
regeneration, such as that due to GH administration. 
Lastly, IGF-1 is the better studied of the two IGFs, and its effect on regeneration has 
been examined by various means. The same, however, has not been done for IGF-11, 
which shares many of the same actions, but is not identical to, IGF-1. 
1.9 The Aim of this Thesis 
The aim of this thesis is to characterise components of the IGF axis, and myostatin, 
during skeletal muscle regeneration, and to determine whether the level of these 
factors is altered by the administration of GH. Finally, the effect of IGF-11 
administration on the rate of skeletal muscle regeneration will be determined. 
1.9.1 Achieving the Aim of the Thesis 
The aim of this thesis will be achieved by testing the following individual hypotheses: 
1.9.1.1 Hypothesis 1 (Chapter 4) 
The IGFs and their receptors are regulated during muscle regeneration, and the level 
of IGF expression and binding in regenerating muscle is regulated by GH. This will 
be tested by comparing regeneration and the IGF-axis components in GH- versus 
saline-treated GR-deficient dw/dw rats. 
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1.9.1.2 Hypothesis 2 (Chapter 5) 
A negative regulator of growth, myostatin, is temporally regulated during muscle 
regeneration, and its levels are decreased in muscles undergoing enhanced growth due 
to the administration of GH. The temporal regulation of myostatin protein during 
muscle regeneration will be examined in Sprague-Dawley rats, and in the GH-
deficient dw/dw rat. The effect of GH on myostatin protein levels will be tested by 
comparing saline- versus GH-treated dw/dw rats. 
1.9.1.3 Hypothesis 3 (Chapter 6) 
Administration of IGF-11 during skeletal muscle regeneration enhances the rate of 
skeletal muscle regeneration. This will be tested by comparing regeneration in 
Sprague-Dawley rats receiving a continuous infusion ofIGF-11 over the site of muscle 
damage, to Sprague-Dawley rats receiving a continous infusion of vehicle only. 
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CHAPTER2 
GENERAL MATERIALS AND 
METHODS 
This chapter describes the main methodologies employed for the studies contained in 
Chapters 4, 5, and 6, and lists the source of materials utilised. 
2.1 Materials 
2.2 Antibodies and Detection System Reagents 
2.2.1.1 Primary antibodies 
MyoD antisera (mouse anti-recombinant mouse MyoD; PharMingen Clone MoAb 
5.8A) was purchased from BD Biosciences (Franklin Lakes, NJ, USA). 
Myogenin antisera (rabbit anti-rat, catalog number sc-576) was purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). 
2-70 
Developmental myosin heavy chain (dMHC) antisera (mouse anti-rat; NCL-MHCd) 
was purchased from Novocastra Laboratories Ltd. (Newcastle upon Tyne, UK). 
Slow myosin heavy chain (slow MHC) antisera (mouse anti-human; clone 
NOQ7.1.1A) was purchased from Chemicon International (Temecula, CA, USA). 
Fast myosin heavy chain (fast MHC) antisera (mouse anti-rabbit; clone MY-32) was 
purchased from Sigma Chemical Company (St. Louis, MO, USA). 
Myostatin antibody (rabbit anti-bovine) was produced in-house and has been fully 
characterised (Sharma et al. 1999). 
2.2.1.2 Negative controls 
The following antisera/sera were purchased from DAKO Corporation (Carpinteria, 
CA, USA) for use as negative controls: 
Normal rabbit immunoglobulin fraction (product x0903) 
Normal rabbit serum, whole (x0902) 
Normal mouse immunoglobulin fraction (product x0931) 
Alpha-lactalbumin antisera (rabbit anti-human; A0579) 
2.2.1.3 Detection system reagents 
The following immunohistochemistry detection system reagents were purchased from 
Amersham Pharmacia Biotech (Auckland, New Zealand): 
Sheep anti-mouse whole antibody, biotinylated (SAM-B; RPN1001) 
Donkey anti-rabbit whole antibody, biotinylated (DAR-B; RPNl 004) 
Streptavidin-biotin-horseradish peroxidase (SA-B-HRP; RPN 1051) 
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2.3 Radioisotopes 
(a-35S)-labelled uridine-5'-triphosphate was purchased from Amersham International 
(Amersham, UK). 
Na125Iodide was purchased from New England Nuclear (Boston, MA, USA). 
2.4 Peptides and hormones 
Purified ovine (o) IGF-11 was donated by Dr. Lloyd Moore (AgResearch, Wallaceville, 
NZ). 
Recombinant human (rh) IGF-11 was donated by Eli Lilly and Company (Indianapolis, 
IN, USA) 
Recombinant human (rh) IGF-1 was donated by Ciba-Geigy Corporation (Basel, 
Switzerland). 
Recombinant human amino terminal methionyl IGF-1 ((rh)N-Met IGF-1) was donated 
by Dr. BD Burleigh (IMC/Pitman-Moore, Terre Haute, IN, USA). 
Desamino-(1-3) IGF-1 (des(l-3)1GF-I) and desamino-(1-6) IGF-11 (des(l-6)IGF-II) 
were purchased from Gro-Pep Pty (Adelaide, Australia). 
Bovine insulin was purchased from Sigma Chemical Company (St. Louis, MO, USA). 
2. 5 Chemicals and other supplies 
BDH (Poole, Dorset, UK) 
Iso-pentane (Analar grade); eosm Y; acetic anhydride, acetic acid; aluminium 
sulphate; calcium chloride; chromium potassium sulphate; formaldehyde; Paramat 
2-72 
paraffin wax; sodium hydroxide; sodium citrate; sodium chloride; hydrogen peroxide; 
Tween-20; aluminium sulphate; ethylene glycol; glacial acetic acid; magnesium 
sulphate; magnesmm chloride; sodium di-hydrogen orthophosphate; disodium 
hydrogen orthophosphate; paraformaldehyde; D.P.X. mountant; sodium iodate; 
sodium bicarbonate; sodium thiosulphate; ethanol; ammomum acetate; 
triethanolamine 
Sigma (St. Louis, MO) 
Toluidine Blue 0, C.I. 52040; diethyl pyrocarbonate (DEPC); Trizma® 
hydrochloride; Trizma® base; bovine serum albumin (BSA); 3,3 '-diaminobenzidine 
(DAB) tablets; phenylmethylsulfonyl fluoride; Triton X-100; citric acid; Type II-S 
trypsin from porcme pancreas; aluminium potassium sulphate; thymol; 
aminopropyltriethoxysilane; proteinase K; dextran sulphate; beta-mercaptoethanol 
(BME) 
Promega Corporation (Madison, WI, USA) 
Promega transcription kit, RNase-free Dnase 
Oxoid Ltd. (Basingstoke, Hampshire, UK) 
Phosphate buffered saline (PBS) tablets 
Biolab Scientific (Auckland, NZ) 
Esco Polysine™ slides; Esco coverslips 
Life Technologies (Gaithersberg, MD, USA) 
Formamide 
International Merchants (Wellington, New Zealand) 
Home Pro 4.8 mm cork tiles 
2-73 
Andrew Industrial Ltd. (Auckland, NZ) 
Xylene 
Aiax Chemicals Ltd. (Sydney, Aust.) 
Haematoxylin (C.1. 75290) 
George T. Gurr, Ltd. (London, UK) 
Nuclear fast red (CL 60760) 
DAKO Corporation (Carpinteria, CA, USA) 
PAP pen 
Eastman Kodak (Rochester, NY, USA) 
X-OMAT-AR5 (XAR) film 
Amersham Pharmacia Biotech (Auckland, New Zealand) 
Dipping chamber for photographic emulsion; LM-1 
Miles Inc. {Elkhart, IN, USA) 
Tissue-Tek® O.C.T. Compound 
Bayer Diagnostics (Mulgrave, Victoria, AUST) 
Tissue-Tek Unicassettes 
Roche Molecular Biochemicals (Switzerland) 
Yeast tRNA; degraded herring sperm DNA 
Ethicon Inc. (Somerville, NJ, USA) 
3-0 silk suture thread, 7-0 braided silk suture 
National Veterinary Supplies, Ltd. (Christchurch, NZ) 
Rompun®(xylazine hydrochloride) 2%; ketamine hydrochloride (100 mg/ml) 
Ilford (Aust.) Pty. Ltd. (Mt. Waverley, Victoria) 
Phenisol X-ray developer 
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2.6 Animals 
The rats used for the ensuing experiments were housed in the Ruakura Small Animal 
Colony, where they were kept at constant temperature with a natural day/night cycle, 
and provided ad libitum food and water both before and during the trials. Rats were 
normally housed in groups of 3 or more within plastic cages, but were housed singly 
during the duration of the trial work. 
Following all surgical manipulations, rats were kept in a warm (28-29°C) room until 
normal movement and activity was observed. Rats were then returned to a 20-22°C 
room where they were then monitored regularly throughout the duration of the trial. 
All trial work described in this thesis was conducted in accordance with the 
AgResearch animal ethics policy. Each trial was approved by an institutional animal 
ethics committee that has representatives from the New Zealand Veterinary 
Association, the SPCA, MAF, and local authorities as mandated by New Zealand 
animal welfare legislation: the Animal Welfare Act 1999 and the Animals Protection 
Act 1960. 
2. 7 Tissue handling 
2. 7.1 Sacrifice and dissection 
Rats were sacrificed with CO2 gas followed by cervical dislocation, then the right and 
left biceps femoris muscles dissected out, weighed, and muscle samples taken for 
histological purposes. 
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2. 7.2 Tissue processing 
Cross-sectional and longitudinal samples were obtained from the most heavily 
damaged area, to be both frozen and formalin-fixed. Considerable attention was given 
to developing methods that would allow tissues to lie flat while being either fixed or 
frozen, so as to optimise for cross-sectional representations of the entire muscle. 
2. 7.2.1 Frozen samples 
Frozen samples were taken for receptor autoradiography and immunohistochemistry 
purposes. For frozen samples, the muscle pieces were adhered to small rectangles of 
cork tile by placing a few drops of Tissue-Tek® O.C.T. Compound on the cork prior 
to laying the muscles samples upon it. The piece of cork was then stabbed with a 
scalpel, allowing the cork to be held firmly in a horizontal position during the freezing 
stage, and immersed in a container of melting iso-pentane. Melting iso-pentane was 
obtained by sitting a container of iso-pentane within a larger container of liquid 
nitrogen, freezing the iso-pentane until solid, then removing the iso-pentane from the 
liquid nitrogen until a sufficient volume had melted to cover the piece of muscle and 
cork. The muscle sample was held under the melting iso-pentane until the overt 
bubbling had subsided, and the tissue had taken on a whitish appearance. The muscle 
and attached cork were then rapidly wrapped in foil, and placed on dry ice until 
transfer into a -80°C freezer for storage. 
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2. 7.2.2 Formalin-fixed samples 
2.7.2.2.1 Solutions 
Formalin fixative 3 7-40% formaldehyde solution 10 mls 
Phosphate buffered saline tablets 1 tablet 
Distilled water 90 mls 
2.7.2.2.2 Procedure 
Samples for formalin-fixation were cut as for frozen sections, then placed on pieces of 
stiff cardboard to keep them flat during fixation. The samples were submerged for 18 
hours in formalin fixative. Tissues were removed and rinsed in 0.02% diethyl 
pyrocarbonate (DEPC)-treated water that had been autoclaved, then placed in marked 
histology cassettes (Tissue-Tek Uni cassettes). The fixed tissues were processed 
overnight on the "routine overnight" programme in a Jung TP 1050 fully enclosed 
vacuum tissue processor (Leica, Cambridge Instruments GmbH, Heidelberg, West 
Germany). At the finish of the cycle, tissues were immediately transferred into a 
container of melted paraffin wax (Paramat). The tissues were then embedded in blocks 
of paraffin wax, using a Thermolyne Risto-Centre II-N embedding machine 
(Barnstead Thermolyne, Doubuque, Iowa). 
2. 7.3 Sectioning 
2. 7.3.1 Frozen tissues 
Frozen tissue blocks were sectioned on a Cryocut 1800 (Reichert-Jung, Cambridge 
Instruments GmbH, Heidelberg, West Germany), at a thickness of 8 or 10 microns, for 
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receptor autoradiography or immunohistochemistry, respectively. Orientation and 
histology were examined by staining with a 1 % aqueous stock of toluidine blue for 1 O 
seconds, dabbing off the excess, then viewing under an Olympus BH-2 microscope at 
low magnification. Experimental sections were placed on Esco Polysine™ slides, and 
left to dry at air temperature. Sections were either stored at -20°C (if they were to be 
used within a week) or-80°C (if they were to be stored longer than one week). 
2. 7.3.2 Formalin-fixed, paraffin-embedded tissues 
Formalin-fixed, paraffin-embedded tissue blocks were sectioned at 8 microns on a 
Leitz Type 1212 microtome (Ernst Leitz, GmbH, Wetzlar, Germany). Ribbons of 
tissue were floated out on a 42°C DEPC-water bath, and then the sections collected on 
Polysine™ slides. Sections were smoothed onto slides by resting slides on the side of 
the water bath (less than 5 minutes), then dried by placing slides on 60°C heating 
plates fitted with bars to provide an approximate 8 mm gap between slide and plate. 
Cut slides were stored in boxes fitted with spacers, unless they were to be used 
immediately. 
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2.8 Histological staining of tissue sections 
Histological staining using haematoxylin and eosin was carried out m order to 
distinguish nuclei and cytoplasm, respectively, in muscle sections. 
2. 8.1 Solutions 
The composition of the following solutions was sourced from a standard histology 
text (such as Lillie 1965). 
Gill's haematoxylin* 
Mayer's haematoxylin 
Nuclear fast red# 
Scott's tap water 
Eosin (1 % solution) 





Glacial acetic acid 
Haematoxylin (C.I. 75290) 
Aluminium potassium sulphate 
Distilled water 
Sodium iodate 
Aluminium sulphate, hydrated 
Distilled water 
Nuclear fast red (C.1. 60760) 
Crystal ofthymol 
Sodium bicarbonate (NaHC03) 
Magnesium sulphate (MgS04) 
Distilled water 
Crystal ofthymol 
Eosin Y (C.I. 45380) 
Distilled water 





















*Dissolve the aluminium sulphate in water with heat, then add the haernatoxylin. Leave overnight, then 
add the ethylene glycol and acetic acid. 
#Dissolve the aluminium sulphate in hot water, then sprinkle in the stain. Add thyrnol. 
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2.8.2 Procedure 
Formalin-fixed, paraffin-embedded sections were prepared as described above, then 
stained as follows: 
Procedure Time 
1. 60°C oven 10 minutes 
2. deparaffinise in xylene 2 x 10 minutes 
3. 100% ethanol 5 minutes 
3. 95% ethanol 2 minutes 
5. 70% ethanol 2 minutes 
6. rinse in distilled water 5 minutes 
7. Gill's haematoxylin (1: 1 in distilled water) 90 seconds 
8. tap water until clear 
9. Scott's tap water 2 minutes 
10. tap water 2 minutes 
11. 0.5% eosin Y ( diluted in distilled water) 1 minute 
12. tap water Until clear, plus 2 minutes 
13. 50% ethanol 3 dips 
14. 70% ethanol 3 dips 
15. 95% ethanol 30 seconds 
16. 100% ethanol 2 minutes 
17. 100% ethanol 5 minutes 
18. xylene 5 minutes 
19. xylene 3 minutes 
20. mount coverslips with DPX mountant 
2.9 Immunohistochemistry 
Immunohistochemistry is a technique that utilises the specificity of an antibody for its 
antigen in order to detect proteins at the cellular level. Immunohistochemistry 
involves use of a "primary" antibody, directed against the protein of interest, followed 
by a detection method that amplifies the signal so that the protein can be visualised at 
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the light microscope level. The detection method used in these studies is based on a 
labelled avidin-biotin (LAB) methodology (Boenisch 1989; Giorno 1984), which uses 
the high affinity of (strept)avidin for biotin to amplify the signal (Hsu et al. 1981 ). 
Thus, the "secondary" antibody is conjugated to biotin that the "tertiary" complex 
binds to because it contains avidin. The tertiary complex contains the enzyme 
horseradish peroxidase, which is then reacted with a substrate, 3,3'- diaminobenzidine 
(DAB), to yield a brown end-product. Immunostained sections are then 
counterstained with an appropriate histological stain for visualisation and/or 
quantitation purposes. 
2.9.1 Solutions 
1 % paraformaldehyde* PBS tablet 1 tablet 
Paraformaldehyde 1 g 
NaOH to pH 
Distilled water to 100 ml 
10 mM Citrate buffer, pH 10 mM sodium citrate 428 ml 
6.0 10 mM citric acid 72 ml 
0.1 % Trypsin Trypsin 0.05 g 
1 % CaClz solution 6ml 
distilled water 44ml 
5 M sodium chloride Sodium chloride 58.44 g 
Distilled water 200ml 
1 M Tris, pH 7.4 Trizma hydrochloride 132.2 g 
Trizma base 19.4 g 
Distilled water 1 litre 
Tris-buffered saline (TBS) 1 M Tris, pH 7.4 50ml 
( 1 litre) 5 M sodium chloride 20ml 
distilled water 930 ml 
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TBST + BSA {TBSTB) 
TBS 
Tween-20 
























TBSTB + 1.5% serum 
Sigma DAB/buffer tablet 1 tablet set 





Serum (NDS or NSS) 15 ul 
*Note on paraformaldehyde fixative preparation: Add paraformaldehyde to 70 mis water, then heat 
until dissolved, but do not let the temperature of the solution exceed 70°C. Add a few drops of 1 M 
NaOH as necessary to dissolve the paraformaldehyde. Chill on ice immediately after the 
paraformaldehyde has gone into solution, then add NaOH to take to the pH to 7.4, and add water to 100 
mis. 
2. 9.2 Procedure 
The basic procedure followed is that of Hsu et al. (1981), with modifications that were 
unique to the antibody employed, thus the individual procedures are given below for 
each. In brief, paraffin-embedded tissues on Polysine™ microscope slides were 
briefly heated to soften the paraffin, then deparaffinised and rehydrated. Frozen 
tissues were fixed in paraformaldehyde, acetone or formalin to preserve histology and, 
in some cases, antigenicity. A hydrophobic wax pen (PAP pen) was used to contain 
solution during immunohistochemistry by drawing a ring around each tissue section. 
A quenching step with a hydrogen peroxide containing solution was performed to 
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eliminate endogenous peroxidase activity in tissue sections, followed by washes and a 
blocking step to prevent non-specific binding of antibody to tissue components. 
Tissue sections were incubated with primary antibody, then following washing to 
remove excess antibody, incubated with secondary antibody, which was raised against 
the species that the primary antibody was produced in, then biotinylated. After further 
washing, tissue sections were incubated with a tertiary complex consisting of 
streptavidin-biotin-horseradish peroxidase (SA-B-HRP). Following washing, the 
horseradish peroxidase was incubated with its substrate, DAB, to form a brown end-
product, then the sections counterstained in either nuclear fast red or haematoxylin. 
Sections were then dehydrated and cleared, and coverslips placed over the tissue 
sections using D.P.X. mountant. Sections were visualised on a brightfield microscope 
to determine the cellular localisation of the protein of interest. 
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2.9.2.1 Developmental Myosin Heavy Chain (dMHC) 
For frozen tissue sections. A formalin fixation step following the primary antibody 
step was added to this procedure in order to improve the histology, which is 
suboptimal when acetone is used as the fixative. 









dMHC Ab diluted 1 :60 in blocking solution 
TBST 
Post-fix in 1.3% formalin at room temperature 
TBST 
SAM-B 1 :200 in TBS TB with 1.5% NSS 
TBST 















2 x 5 minutes 
10 minutes 
2 x 5 minutes 
30 minutes 
2 x 5 minutes 
30 minutes 
2 x 5 minutes 
6 minutes 
2 minutes 
1 minute 20 seconds 
Until clear, plus 2 
minutes 
2.9.2.2 MyoD 
As indicated below, it is necessary to use freshly cut frozen sections for anti-MyoD 
immunohistochemistry. The blocking step, and the addition of BSA and serum to 
diluents, was found to be detrimental to MyoD immunohistochemistry by reducing 
signal intensity and were therefore eliminated from the procedure for MyoD. 
Removal of these components results in slightly elevated, but acceptable, background 
(non-specific) signal that did not interfere with the detection of MyoD 
immunostaining in nuclei (as discussed in Section 6.3.3). 
Frozen tissue sections must be freshly cut, ie within 4 
hours (and NOT re-frozen after placing on slides) 
Encircle sections with PAP pen 




MyoD diluted 1 :80 in TBST 
TBST 
SAM-B 1:100 in TBST 
TBST 














2 x 5 minutes 
30 minutes 
2 x 5 minutes 
30 minutes 
2 x 5 minutes 
6 minutes 
2 minutes 
1 minute 20 seconds 
Until clear, plus 2 minutes 
2.9.2.3 Myogenin 
For frozen tissues. 
Bring frozen tissue sections to room temperature in a 
wrapped, closed box 
Encircle sections with PAP pen 
1.3% formalin 10 minutes 





20 minutes NOS blocking 
Myogenin antibody 
solution 
diluted I :200 m blocking I hour 
TBST 
DAR-B I :200 in TBSTB with 1.5% NOS 
TBST 






Dehydrate, clear in xylene, and mount coverslips 
with D.P.X. mountant. 
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2 x 5 minutes 
30 minutes 
2 x 5 minutes 
30 minutes 
2 x 5 minutes 
6 minutes 
2 minutes 
1 minute 20 seconds 
Until clear, plus 2 minutes 
2.9.2.4 Myostatin 
For formalin-fixed, paraffin-embedded sections. 
60°C oven 









30 minutes NDS blocking 
Myostatin antibody 
solution 
diluted 1 : 100 m blocking 30 minutes 
TBST 
DAR-B 1 :200 in TBSTB with 1.5% NDS 
TBST 




Nuclear fast red 
Tap water 
Dehydrate, clear in xylene, and mount coverslips 
with D.P.X. mountant. 
2-87 
2 x 5 minutes 
30 minutes 
2 x 5 minutes 
30 minutes 




Until clear, plus 2 minutes 
2.9.2.5 Slow myosin heavy chain (slow MHC) 
For formalin-fixed, paraffin-embedded sections. The immunostaining achieved with 
this antibody was enhanced by the addition of a microwave antigen retrieval step (Shi 
et al. 1991) to the staining procedure. In the microwave antigen retrieval procedure, 
formalin-fixed, paraffin-embedded tissues are microwaved in the presence of a metal 
solution, which can result in a more intense immunostaining signal. 
60°C oven 10 minutes 
Deparaffinise and rehydrate tissue As per Section 2.8.2, steps 2-6 
sections 
TBST 






10 min in citrate buffer on high power (1000 
Watts) 
15 minutes cooling down in the same 





Slow MHC antibody diluted 1: 100 in 30 minutes 
blocking solution 
TBST 2 x 5 minutes 
SAM-B 1 :200 in TBSTB with 1.5% 30 minutes 
NDS 
TBST 




Nuclear fast red 
Tap water 
Dehydrate, clear in xylene, and mount 
coverslips with D.P.X. mountant. 
2 x 5 minutes 
30 minutes 




Until clear, plus 2 minutes 
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2.9.2.6 Fast myosin heavy chain (fast MHC) 
For formalin-fixed, paraffin-embedded tissues. 
60°C oven 10 minutes 
Deparaffinise and rehydrate tissue sections As per Section 2.8.2, steps 1-6 
TBST 5 minutes 
Quench 10 minutes 
TBST 5 minutes 
NSS blocking 30 minutes 
Fast MHC antibody diluted 1 :500 m blocking 30 minutes 
solution 
TBST 
SAM-B 1 :200 in TBSTB with 1.5% NDS 
TBST 




Nuclear fast red 
Tap water 
Dehydrate, clear in xylene, and mount coverslips 
with D.P.X. mountant. 
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2 x 5 minutes 
30 minutes 
2 x 5 minutes 
30 minutes 




Until clear, plus 2 minutes 
2.9.3 Controls 
The specificity of staining for all antibodies was determined by immunostaining with 
a) diluent only for the primary antibody step, and b) with a matched concentration of 
normal immunoglobin or serum ( as appropriate), from the same species as the primary 
antibody. In the case of myostatin antibody, the irrelevant class-matched antibody a-
lactalbumin was run as an additional control to confirm specificity of staining. 
Staining was not observed for any of these negative controls. 
2.10 Receptor autoradiography 
2.10.1 Introduction 
Receptor autoradiography was used to determine the binding sites for IGF within 
muscle tissue sections, and was carried out in accordance with the method of Elliott et 
al. (1992). In short, the method consists of the incubation of tissue sections with 
radiolabelled IGF (total binding), and competition of the radiolabelled IGF binding 
with unlabelled homologous IGF (non-specific binding). Non-specific binding is 
subtracted from total binding to determine the specific binding. 
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IGF binding is characterised by competition with unlabelled peptides (IGF-I, IGF-II, 
des(l-3)IGF-I, des(l-6)IGF-II, and/or insulin). The binding affinities of the IGF 
receptors for these peptides are as follows: 
Type I IGF receptor IGF-I = des(l-3)IGF-I > IGF-II >> insulin 
Type II IGF receptor IGF-II = des(l-6)IGF-II >>> IGF-I (does not bind insulin) 
Des(l-3) IGF-1 and des(l-6) IGF-II, so named because they lack the first 3- and 6-
amino acid residues from the amino-terminus of the mature IGF-I sequence, 
respectively, have a very low affinity for IGFBPs (Francis et al. 1993; Szabo et al. 
1988). Because of the greatly reduced affinity for IGFBPs, these peptides can be used 
to distinguish binding to the receptor, from binding to IGFBPs. Thus, when either 
des(l-3) IGF-I or des(l-6) IGF-II is used as a competing peptide, radiolabelled IGF 
binding to receptors will be displaced, but radiolabelled IGF binding to IGFBPs will 
not be displaced. 
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2.10.2 Solutions 
Pre-incubation buffer 0.17 M Tris-HCl, pH 7.4 
Incubation buffer 0.17 M Tris-HCl, pH 7.4 
1%BSA 
5mMMgCh 
1 mM phenylmethylsulphonyl flouride 
Iodinated hormone (400,000 cpm/ml) 




0.01% Triton X-100 










Frozen muscle sections were cut at 8 micron thickness at l 6- l 8°C, thaw-mounted 
onto Polysine™ slides, then immediately placed in a -20°C freezer. Sections to be 
incubated were stored not longer than one week. At the time of incubation, sections 
were slowly brought up to room temperature in a closed slide box, and then encircled 
with a PAP pen, which leaves behind a hydrophobic line of wax. Sections were 
incubated for 10 minutes in pre-incubation buffer. Excess pre-incubation buffer was 
aspirated, and then 50 ul of incubation buffer containing iodinated hormone (prepared 
according to the iodogen method (Salacinski et al. 1981) as previously applied to IGF 
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(Hodgkinson et al. 1987)) with or without competing hormones was placed over the 
sections. Competing hormones were used at 1 µg/ml for (rh) N-Met IGF-1, oIGF-1, 
(rh) IGF-11, des(l-3) IGF-1, des (1-6) IGF-11, and bovine insulin at 10 ng/ml. Each 
slide contained one pair of sections for the determination of total binding, and one or 
more pairs that were incubated with iodinated peptide plus cold, unlabelled competing 
hormone. Sections were placed in a humidified slide chamber, and incubated for 2 
hours at room temperature. Incubation buffer was then aspirated, and the unbound 
ligand washed away in two 5-minute baths in post-incubation buffer. The sections 
were subsequently fixed in neutral buffered formalin for 10 minutes, then washed in 
distilled water and dried. 
2.10.3.2 Macroautoradiographs 
The dried slides were apposed to X-Omat-AR5 film for a period not exceeding 11 
days, to generate a macroautoradiograph. The images obtained on the developed film 
were used to determine the length of exposure of the emulsion-coated slides, and to 
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Slides were coated with liquid photographic emulsion for microautoradiographic 
purposes, by dipping the slides in a dipping chamber filled with molten emulsion. 
The reverse side of the slides were wiped with a clean tissue, then the slides 
immediately placed on an ice-cooled metal tray until the emulsion had solidified. 
Slides were then placed in slide boxes containing dessicant, and placed in a light-tight 
darkroom box for 24 hours, until the dessicant was replaced with a fresh supply. The 
slides were then wrapped with black polythene to omit all light, at which time they 
were removed to a 4°C refrigerator until development time. 
The silver halide crystals deposited in the emulsion by the 125I-labelled ligand were 
developed to form silver grains according to the manufacturers recommendations for 
LM-1 photographic emulsion. The procedure in brief is as follows. All solutions 
were first brought to 20°C, and were maintained at that temperature throughout the 
development process. Slides were placed in developer for 5 minutes, then in stop 
solution for one minute to end development. Slides were fixed for 8 minutes in fix 
solution, then washed in running tap water for 15 minutes, followed by two-fifteen 
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minute baths in distilled water. Slides were then air-dried until histological staining 
was carried out, at which time sections were rehydrated by placing in water for 5 
minutes. Haematoxylin and eosin histological staining was then performed as per 
Section 2.8.2, steps 7-20. 
2.11 Radiographic grain and nuclear quantification 
Image analysis was performed to quantitate nuclei after immunohistochemical 
experiments (CHAPTER 6), and autoradiographic signal resulting from in situ 
hybridisation (CHAPTER 4) and receptor autoradiography experiments (CHAPTER 4 
and CHAPTER 6). Three analysis and quantification systems were used during the 
course of the work contained in this thesis. The automated Visilog system was used 
for the analysis of radiographic grains resulting from in situ hybridisation with 
radioactive probes as carried out in CHAPTER 4. This system was chosen for use due 
to the high grain density in the in situ hybridisation experiments, whereas the lower 
resultant grain densities of receptor binding experiments in CHAPTER 4 were suited 
to manual grain counting using the Image system. The Scionlmage system was used 
for all quantitation in CHAPTER 6. This system was the only system of the three that 
would enable quantitation of chromogenic signals, such as those resulting from 
immunohistochemistry and histological staining. The Scionlmage system was used 
for manual counting of grains resulting from receptor autoradiography in CHAPTER 6 
as this system superseded the Image system for grain counting purposes. In all cases, 
sites for analysis were determined from random microscope stage coordinates, as 
generated from within Microsoft Excel (Microsoft Corp., Auckland, NZ). 
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2.11.1 Visilog system 
For hybridised sections, gram densities were determined for video images of 
microautoradiographs as obtained through an Olympus BX-50 light microscope with 
attached camera adaptor (CMA-D7CE, Sony Corporation, Japan) and CCD video 
camera (A VC-D7CE, Sony Corporation). Images were captured onto an IBM 
compatible 386 computer equipped with a MVP-AT machine vision processor 
(Matrox, Dorval, Quebec, Canada), Trinitron monitor (Sony Corporation) and Visilog 
DOS version 3.6 software (Noesis, Jouy-en-Josas, France). With this system, silver 
grains were detected following gray image processing to find local intensity maxima. 
Values obtained by this method correlate highly (r=0.99) with grain density values 
obtained by manual grain counting (Ord et al. 1993). 
2.11.2 Image system 
Manual grain counting of in vitro incubated slides was performed using an Olympus 
BH2 microscope fitted to a monochrome video camera unit (Cohu Inc., San Diego, 
CA). Neutral density filters were used to optimise for radiographic grain detection. 
Images for analysis were captured onto a Macintosh Ilfx computer equipped with a 
DT2255 Quick Capture frame grabber card, and the public domain NIH Image 
programme (this can be downloaded at http://rsb.info.nih.gov/nih-image/). 
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2.11.3 Scionlmage system 
For the analysis of chromogenic signals and manual grain counting, digital images 
were captured using the CMS700 image analysis system (Scion Corporation, 
Frederick, MD, USA) which is comprised of an MTI DAGE 330 CCD colour video 
camera, frame grabber card (CG-7, Scion Corporation), and 786 x494 pixel, 24-bit 
camera control unit. Digital images were relayed to a 200 MHz Pentium II computer 
equipped with Scionlmage software (which can be downloaded from the internet at 
http://www.scionco1p.com). Images were saved as TIFF files, then manually counted 
within Scionlmage. 
2.12 Image acquisition 
Photomicrographic images, as contained within this thesis, were captured using the 
Scionlmage system, as described in Section 2.11.3. Images were first saved as TIFF 
files in Scionlmage, then as JPEG files within the PhotoEditor programme of 
Microsoft Office 2000 (Microsoft Corporation). Files were converted into JPEG 




Data was analysed for overall effects of treatment and time by ANOV A using GenStat 
4.2 software. A modification of this method, REML, was used when indicated for the 
statistical analysis of unbalanced groups. Students' T-test was employed for statistical 
comparisons between individual groups, and the Tukey ("Honest") Significant 
Difference used when appropriate for multiple pairwise comparisons. Values shown 




This chapter describes two models of skeletal muscle regeneration, notexin-induced 
and muscle grafting-induced, and the results obtained using these models in the rat. 
The notexin-induced regeneration model was subsequently used for the studies in 
Chapters 4, 5, and 6. 
3.1 Notexin-induced regeneration model 
3.1.1 Introduction 
As discussed earlier in Section 1.5, there are a number of ways in which to damage 
muscle in order to initiate regeneration. Table 3-1 lists the key methods by which 
muscle has been experimentally damaged in published reports of skeletal muscle 
regeneration. Although the key events of MPC activation, proliferation and fusion 
occur regardless of the means of damage, the method used to damage muscle can 
result in extensive and/or prolonged damage to the basal lamina (Lawson-Smith & 
McGeachie 1997; Lefaucheur & Sebille 1995b; Trupin 1979), vascular (Hansen-Smith 
& Carlson 1979; Lefaucheur & Sebille 1995b) and nervous supplies (Yoshimura et al. 
1998), and may result in the appearance of excessive fibrosis (Vracko & Benditt 
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1972). Further, satellite cells are killed by some methods such as freezing (Ghins et al. 
1984; Schultz et al. 1986), and preserved by others (Harris 1989). These factors may 
alter the timing (Grounds & McGeachie 1990) and/or efficiency (Ghins et al. 1984; 
Lefaucheur & Sebille 1995b; McGeachie & Grounds 1987) of regeneration. 
Table 3-1. Methods for damaging skeletal muscle. 
INJECTED SUBSTANCES 
Snake toxins (notexin, taipoxin) 
REFERENCE 
Harris et al. (1975) 
Harris & Maltin 
(1982) 
Hansen-Smith & 
.................................................................... , Carlson (1979) 
Anderson ( 1991) 
......................................................... 
ische 1986) 
. ell et al. (1992) I 
· · · I Schultz et al. ( 1986) · · 
................................................................................................. LTrupin .. (.1979) 
For the work described in this thesis, the injection of notexin was chosen as the means 
of inducing muscle damage, although for the purposes of the final experimental 
chapter, muscle grafting was considered, and this will be discussed later in Section 
3.2. The reasons for choosing notexin for this work were: a) notexin-induced muscle 
damage and regeneration were well-characterised (Harris 1989; Harris et al. 1975) and 
notexin had been used for many regeneration studies (Davis et al. 1991; Klein-Ogus & 
Harris 1983; Preston et al. 1990), and b) it did not involve extensive surgical 
manipulations, and so was suitable for the large trials described herein, c) notexin 
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injection results in minor damage to microvascularisation (Harris 1989; Harris et al. 
197 5; Lefaucheur & Sebille 1995b) and basal lamina (Lefaucheur & Sebille 1995b ), 
and reinnervation occurs quickly (Harris et al. 2000; Whalen et al. 1990). 
Notexin, a fraction of the Australian tiger snake venom (Notechis scutatus scutatus), 
is a phospholipase A2 consisting of 119 amino acids and seven disulphide bridges 
(Halpert & Eaker 1975; Halpert et al. 1976). Notexin contains both neurotoxic and 
myotoxic activites. As a neurotoxin, notexin acts at the presynaptic level, causing the 
depletion of the neurotransmitter acetylcholine from motor nerve terminals within one 
hour of injection (Harris et al. 2000). The block of neuromuscular transmission at the 
motor nerve terminal caused by notexin becomes irreversible (Mebs 1989), and is 
followed by the degeneration of the motor nerve terminal and of the axonal 
cytoskeleton (Harris et al. 2000). The neurotoxic effect of notexin results in 
denervation of 70% of muscle fibres in rat M. soleus by 24 hours (Harris et al. 2000). 
The myotoxic effect of notexin is exerted through binding to the sarcolemma, causing 
small lesions in the membrane, loss of ion gradients, subsequent hypercontraction and 
myofibre degeneration (Dixon & Harris 1996). Notexin binds to the sarcolemma of 
both glycolytic and oxidative muscle fibres, although slow oxidative fibres are more 
susceptible to the myotoxic effects of notexin (Dixon & Harris 1996). 
In rats, a 2 µg quantity of notexin has typically been used for regeneration studies 
(Harris et al. 1975; Pluskal et al. 1978). The notexin in published studies has been 
administered variously, including subcutaneous injection (Harris et al. 1975; Pluskal 
et al. 1978), injection into the intermuscular space of the hindlimb (Harris & Johnson 
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1978), and intramuscular injection (Lefaucheur & Sebille 1995b; Sharp et al. 1993). 
Each mode of administration has been shown to effect damage sufficient for the study 
of regeneration, however intramuscular injection is recommended for animals that are 
larger than 1 OOg, due to problems with the diffusion of notexin through larger muscle 
when injected subcutaneously or into the epimysial compartment (Davis et al. 1991). 
The aim of the following trial was to determine the timing of regeneration events in 
GR-deficient dw/dw rats, and to optimise sampling times for the experiments 
described in CHAPTER 4 and CHAPTER 5. 
3.1.2 Materials and Methods 
Twenty-eight male dw/dw rats were castrated at 28 days of age. Castration was 
performed in this experiment, as this was a preliminary trial for the studies contained 
in CHAPTER 4 and CHAPTER 5. The reasons for castration in these studies will be 
addressed in more detail in CHAPTER 4. At 60 days of age and time O in the trial, 
rats were weighed, then anaesthetised with an intraperitoneal injection of 3 mg 
pentobarbitone sodium B.P.(Vet.) (Sagital, May and Baker Ltd., Dagenham, England) 
per 1 OOg bodyweight. The fur was trimmed from the area over the right M. biceps 
femoris, and a small incision made over the muscle. Using a 50µ1 syringe (Hamilton 
Co., Reno, Nevada, USA) with an attached 25G x 16mm needle, 2µg (in 10 µl) of 
notexin (Venom Supplies Pty. Ltd., Tanunda, South Aust) was injected 
intramuscularly into the right M. biceps femoris. A small dot of India ink (Stephen's, 
Dunedin, NZ) was placed on the surface of the muscle to mark the site of notexin 
injection. The wound was closed with 2 stitches using 3-0 silk (Ethicon, Somerville, 
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NJ, USA). Rats were moved to a warm recovery room, and when fully alert and 
active, moved into a standard temperature room. Rats were provided water and food 
ad libitum throughout all pre- and post-operative phases of the trial. At the time of 
sacrifice rats were weighed, then killed by CO2 gas and cervical dislocation. Right 
biceps femoris muscles were carefully dissected out and weighed, then formalin-fixed 
and paraffin-embedded (as per Section 2.7.2.2) for histological examination. The 
timepoints for sacrifice (days 1,2,3,5,10 and 15) were chosen to encompass the 
anticipated periods of MPC proliferation and fusion, and to include a later timepoint 
in which the fibres were enlarged but where regenerating fibres were still discemable 
from fibres that survived notexin treatment. 
3.1.3 Results 
A gross assessment of damaged muscles following notexin-injection showed that not 
all of the fibres in the injected M. biceps femoris underwent damage and regeneration. 
At the site of notexin injection, all fibres were destroyed (referred to in CHAPTER 6 
as the "core of damage"), however further out from this area, "regenerating fibres" 
were interspersed with "survivor fibres" (fibres that did not undergo necrosis and 
regeneration following notexin injection), as shown in Figure 3-1 C. Lastly, further 
out from this area of interdigitating regenerating and survivor fibres was a complete 
absence of damage (Figure 3-1 B). In this area, the fibres are referred to as 
"undamaged fibres". Undamaged fibres from notexin-injected muscles (Figure 3-lB) 
were indistinguishable from the undamaged fibres of the non-injected control muscle 
(Figure 3-lA). 
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Figure 3-1 provides a histological description of the regeneration events following 
notexin injection, as determined in haematoxylin and eosin stained muscle sections. 
The appearance of undamaged muscle fibres of non-injected control (Figure 3-lA) 
and notexin-injected muscles (Figure 3-1 B) was in contrast to the oedemaceous and 
fragmented appearance of damaged muscle one day after notexin-injection (Figure 
3-1 C). As shown in Figure 3-1 C, phagocytic and inflammatory cells were prevalent in 
day 1 damaged tissues, both in interstitial areas and within necrotic fibres, although 
many necrotic fibres were still non-infiltrated at this time. Day 2 tissues were more 
markedly hypercellular than were day 1 tissues, particularly within the necrotic fibres 
(Figure 3-lD), as necrotic debris was being phagocytosed and removed at this time. 
In day 3 notexin-injected muscle (Figure 3-lE), damaged areas contained a high 
density of mononucleate cells, of which a high proportion were presumed to be MPC, 
because: i) this is the appearance of regenerating muscle just prior to MPC fusion to 
form myotubes, and ii) these mononucleate cells have the generally scant cytoplasm 
typical ofMPC (Harris et al. 1975; Moss & LeBlond 1970; Ontell 1973). The density 
of nuclei in regenerating fibre areas was higher on day 3 than at any other timepoint 
during regeneration (Figure 3-1; E versus C, D, F-H). Necrotic debris was still present 
on day 3, although in considerably smaller amounts than on days 1 and 2. Day 5 
damaged muscle (Figure 3-lF) contained abundant myotubes, which are identifiable 
in cross-section by their centrally-located nucleus and small perimeter of cytoplasm 
(Figure 3-lF) and in longitudinal section as ladder-like arrangements of nuclei with 
surrounding cytoplasm. A few fibres still contained necrotic debris on day 5. The 
regenerating myotubes were increased in diameter by day 10 (Figure 3-1 G), but still 
often contained a centrally-located nucleus and were smaller than survivor fibres, thus 
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allowing easy distinction of the two types of fibres. However by day 15 (Figure 
3-1 H), it is difficult to distinguish regenerating from survivor and undamaged fibres as 
shown in (Figure 3-1 A) and (Figure 3-1 B), respectively, due to the movement of 
regenerating muscle fibre myonuclei to a peripheral location, and increased 
regenerating fibre diameter. The regeneration process, as assessed histologically, was 
consistent between animals, and minimal fibrosis occurred during regeneration. 
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Figure 3-1. Muscle regeneration in the dw/dw rat. 
(A) Non-injected, control muscle contains undamaged muscle fibres (u) and connective tissue (ct); 
(B) undamaged muscle fibres of the notexin-injected damaged muscle (injected on day 0), are 
located within the M. biceps femoris, but a long distance from the site of notexin-injection; (C) 
day 1 damaged muscle shows interspersed regenerating (r) and survivor (s) fibres, and the 
presence of oedema (arrowheads); (D) day 2 damaged muscle; (E) day 3 damaged muscle 
contains a greater number of mononucleate cells relative to day 2; (F) day 5 damaged muscle 
contains numerous myotubes (arrows indicate a fascicle that is filled with new myotubes); (G) 
day 10 damaged muscle with enlarged myotubes as indicated by the arrows; (H) day 15 damaged 
muscle shows many regenerating myotubes (arrows) which have become more difficult to discern 
from undamaged (u) and survivor fibres (s) of notexin-injected muscles as shown in (B) and (C), 
respectively, due to their large diameter. Sections have been stained with haematoxylin and 
eosin, and images captured at 25x magnification (bar=200 microns). 
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3.1.4 Discussion 
The results of this preliminary trial showed that the intramuscular injection of 2 µg of 
notexin into the M. biceps femoris of dw/dw rats resulted in muscle damage and 
subsequent regeneration. The regeneration events observed in this study are identical 
to those reported in the literature for rat muscle (Harris & Johnson 1978; Harris et al. 
1975), with a similar onset of timing of phagocytic cell infiltration (within the first 
day), a profusion ofMPC present on day 3, and myotube formation on day 5 (Harris & 
Johnson 1978; Harris et al. 1975). The bulk of these processes occurred to the later 
end of the time ranges given by Harris and Johnson (1978) for each event (ie days 2-3 
for MPC proliferation, days 3-5 for myotube formation). Regarding the timepoints 
chosen in the present study (days 1,2,3,5,10 and 15), two changes were decided upon: 
a) to bring the day 10 timepoint up to 9 days so as to lessen the sampling gap after day 
5, and b) to bring the day 15 timepoint up to day 13, so as to be able to more readily 
distinguish regenerating from survivor fibres. 
Because of the consistent results achieved in this trial, the notexin-induced model of 
muscle damage and regeneration was chosen for further use in this thesis. 
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3.2 Muscle-grafting regeneration model 
3.2.1 Introduction 
For the purposes of the final experiment, the ideal model of regeneration would 
exhibit widespread damage to all fibres, synchronous damage and regeneration 
processes, consistency between and within animals, and have an early onset and peak 
of MPC proliferation and fusion processes. The reasons for establishing these criteria 
are that they would a) allow for some non-histological quantitation of results, b) 
increase the probability of detecting an effect of administered IGF-II on regeneration, 
and c) not necessitate too lengthy a period of peptide administration. To achieve these 
aims two models of muscle regeneration were considered: a) notexin-induced muscle 
regeneration, and b) the muscle grafting-induced regeneration model. 
The muscle-grafting induced model of muscle regeneration is very well characterised 
(Carlson 1986), and has been used extensively for muscle regeneration studies 
(Smythe et al. 2001; White et al. 2000). In the muscle-grafting model, the muscle is 
removed from its natural bed and all vascular and nervous supplies severed. The 
muscle is then placed in either the same, or an alternate position, in the same animal 
( auto grafting) or in a host animal ( allografting). In the field of muscle regeneration 
research, the most prevalent model of muscle-grafting involves the transplantation of 
the M. extensor digitorum longus onto the anterior side of the M. tibia/is anterior. In 
this case, the proximal and distal tendons of the M. extensor digitorum longus are 
attached by means of sutures to the tendon of the M. quadriceps femoris and M. 
tibia/is anterior, respectively. 
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The grafted M. extensor digitorum longus undergoes complete regeneration of all 
muscle fibres, bar a small number of surviving fibres at the periphery of the muscle, 
which survive due to the availability of growth factors and nutrients in the 
surrounding environment (Grounds & McGeachie 1999). As shown in Figure 3-2, 
regeneration proceeds in a gradient from the exterior to the interior of the M. extensor 
digitorum longus (Carlson 1986), again as a result of greater nutrient and growth 
factor supply from the surrounding environment (Grounds & McGeachie 1999), and 
the re-establishment of a vascular supply from the outside which works its way inward 
with time (Bodine-Fowler 1994). This gradient results in a heterogenous population 
of cells and events within the M. extensor digitorum longus, for at certain timepoints 
regenerated myotubes are present in the periphery of the muscle while necrotic 
material is still present in the centre of the muscle. Innervation begins to take place in 
the second week following grafting of rat M. extensor digitorum longus (Carlson 
1986), and as such is delayed relative to the reinnervation of muscle damaged by 
notexin. 
The aim of this study is to determine whether the muscle grafting model is suitable for 
use in CHAPTER 6 by assessing: a) the variability in regeneration using this model, 
and b) the approximate peak of myotube fusion. 
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Figure 3-2. Diagram of muscle regeneration following grafting. 
Diagrammatic representation of a cross-sectional view of a M. extensor digitorum longus 
following grafting, with the times for each stage in the rat indicated. Letter codes are as follows: 
(A) surviving muscle fibres; (B) original muscle fibres that are in a state of ischaemic necrosis; 
(C) muscle fibres that have been infiltrated by phagocytic cells; (D) MPC and new myotubes; (E) 
enlarged muscle fibres containing contractile elements; (F) enlarged and maturing regenerating 
muscle fibres; (G) mature regenerated muscle fibres; (H) normal control muscle fibres. 
Reprinted ( with minor modifications) from Carlson (1986). 
3.2.2 Materials and Methods 
Thirty-three male Sprague-Dawley rats (aged 6 weeks) were used for this experiment, 
three of which were unoperated controls (t=O), and the remainder sacrificed at 
timepoints up to 14 days post-muscle grafting (n=3 per timepoint). Rats were 
balanced for weight at the outset of the trial. On the day of muscle grafting surgery 
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(day 0), rats were anaesthetised with a solution of 5 mg/ml Rompun® (xylazine 
hydrochloride), 37.5 mg/ml ketamine hydrochloride in sterile water (0.2 ml per 100g 
bodyweight), then an incision made in the skin over the M. extensor digitorum longus. 
After the M. extensor digitorum longus was located, a length of 7-0 braided silk suture 
(Ethicon) was slipped under the proximal myotendinous junction of the M. extensor 
digitorum longus, and firmly tied onto it with 3 double reef knots. This procedure was 
followed for the distal end of the M. extensor digitorum longus. The proximal end of 
the M. extensor digitorum longus tendon was subsequently severed with fine scissors, 
and the M. extensor digitorum longus laid over the M. tibia/is anterior. The uncut 
ends of the suture threads on the proximal M. extensor digitorum longus were pulled 
through underneath the distal tendon of the M. quadriceps femoris, and firmly 
knotted. The distal tendon of the M. extensor digitorum longus was next cut with fine 
scissors, and the full length of the M. extensor digitorum longus laid flat upon the 
superficial side of the M. tibia/is anterior. The uncut ends of the suture thread on the 
M. extensor digitorum longus were then tied around the distal tendons of the M. 
tibia/is anterior, taking care to attach the M. extensor digitorum longus at its normal 
length. 
3.2.3 Results 
The grafted muscles showed profound histological changes with time, as shown in 
Figure 3-3. A larger degree of variation in the regeneration process was noted in these 
muscles, relative to the notexin model just described in Section 3.1, however the 
following provides a summary of the key events. By day 1 after grafting, numerous 
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phagocytic and inflammatory cells were interspersed throughout the grafted muscles 
(Figure 3-3B), and this pattern was present in day 2 muscles as well. Oedema, as 
indicated by enlarged pericellular and interstitial spaces, was apparent at early 
timepoints (Figure 3-3B). By days 2 and 3 a band of cells approximately 2-3 cells 
wide near the periphery of the M. extensor digitorum longus had been invaded by 
phagocytic cells, while the remainder of the cells in the more central portion of the M. 
extensor digitorum longus were non-infiltrated. By day 4 the band of phagocytosis 
had enlarged to approximately 4-6 fibres deep in some animals, and the density of 
mononucleate cells in that band had increased relative to day 3. A number of 
surviving muscle fibres around the very outside of the M. extensor digitorum longus 
were easily discernable from day 4 onwards. Myotube fusion was noted as early as 
day 5, but was not observed consistently until days 6 and 7. In day 6 and 7 muscles, 
the regenerated myotubes were generally restricted to a band approximately 8 cells 
wide near the periphery of the muscle, with the centre of the muscle still present as 
non-infiltrated/non-phagocytosed muscle fibres. By day 8, the regenerating myotubes 
were slightly larger in size, as shown in Figure 3-3D. Necrotic fibres were observed 
in the centre of the grafted muscles up through day 11, but were not seen in day 14 
muscle. Day 14 muscle contained numerous enlarged myotubes (Figure 3-3E), some 
of which were similar in diameter to survivor fibres. 
The sequence of regeneration events given in Figure 3-3 summarises the general 
regeneration pattern observed in these grafted muscles, however considerable 
variation relative to that seen in the previously described notexin-induced model (as 
described in Section 3 .1) was observed. This variation appeared to have been due, at 
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least in part, to the deposition of substantial amounts of fibrotic tissue in many of the 
grafted muscles. Accumulations of fibrotic (connective) tissue within and to the 
exterior of the grafted muscle were noted from day 3 onward. These accumulations 
were not consistently deposited within and around the regenerating muscles, so that 
within the same timepoint, grafted muscles often contained vastly different amounts of 
connective tissue/fibrotic material. This is shown for two grafted muscles from day 8 
animals in Figure 3-4. 
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Figure 3-3. Regeneration of grafted muscle. 
Histology of rat M. extensor digitorum longus following grafting on day 0. (A) shows undamaged, 
unoperated muscle at time 0. (B) M. extensor digitorum longus on day 1 following grafting shows 
scattered phagocytic and inflammatory cells throughout the muscle and the presence of oedema. 
(C) Grafted muscle on day 5 contains some survivor fibres (s) along the periphery of the muscle, 
necrotic fibres (n) in the core, and between these are mononucleate cells (mn) prior to the onset of 
fusion. (D) Grafted muscle at day 8 contains myotubes (arrowheads) between areas of 
mononucleate cells and survivor fibres. (E) Grafted M. extensor digitorum longus at 14 days 
contains enlarged myotubes (arrowheads) which are approaching the size of survivor fibres. 
Images are of haematoxylin and eosin stained cross-sections of M. extensor digitorum longus 
taken at 25x magnification (bar =200 microns). 
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Figure 3-4. Fibrotic tissue deposition in grafted muscles. 
(A) and (B) are photomicrographs of grafted M. extensor digitorum longus from two separate 
animals, on day 8 following surgery. (A) shows an area of damaged muscle that contains low 
amounts of fibrotic tissue, while (B) shows muscle at a similar stage of regeneration (early 
myotube stage; arrowheads indicate myotubes) but in the presence of high amounts of fibrotic 
tissue ( f ). Images are of haematoxylin and eosin stained formalin-fixed, paraffin-embedded 
tissue sections taken at 25x magnification (bar=200 microns). 
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3.2.4 Discussion 
In the present study, the sequence of regeneration events normally seen after muscle 
grafting occurred, including the persistence of survivor fibres along the periphery of 
the regenerating muscle (Carlson 1986; Grounds & McGeachie 1999), and the 
gradient of regeneration from the exterior to the interior of the muscle (Carlson 1986). 
The timing of regeneration events such as the onset of muscle fibre phagocytosis on 
days 2-3, and the beginning of new myotube formation on days 6-7, were similar to 
the times reported for rat M. extensor digitorum longus (Carlson 1986). However, in 
contrast to the events indicated in Figure 3-2, whereby necrotic fibres were absent 
from the centre of the graft beyond day 7 post-grafting, the persistence of necrotic 
fibres in the centre of grafted muscles was observed up through day 11 in the present 
trial. 
Although the grafting-induced model resulted in adequate damage and regeneration, 
two factors preclude its use for CHAPTER 6, namely the variability in fibrotic tissue 
deposition between animals and the late onset and peak of myotube formation. 
Fibrotic/connective tissue deposition can hamper muscle regeneration by forming a 
dense barrier to new fibres (McMinn 1967), therefore the presence of fibrous 
accumulations can alter not only the quality, but also the timing, of regeneration. 
Secondly, although the timing of the onset of myotube formation was similar to that 
reported by others for grafted rat M. extensor digitorum longus (Carlson 1986), the 
peak of myotube formation was obviously much later than days 6-7. This was 
3-117 
deduced by the fact that on days 6-7 there was still considerable necrotic tissue present 
in the centre of the grafted muscle. For the purposes of CHAPTER 6, the peak of 
myotube formation needed to occur prior to days 6-7, and over a relatively brief period 
in order to reduce inter-animal variation. The reason for the time requirement was that 
the pump being used to administer the peptide had a maximum administration period 
of 7 days, and because the effect of the administered peptide on MPC fusion was 
being tested, the bulk of MPC fusion had to occur within that time. For these reasons, 
the muscle-grafting induced model of regeneration was not used, and the notexin-
induced model chosen for use instead for CHAPTER 6. 
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CHAPTER4 
THE EFFECT OF GH ON THE IGF 
AXIS DURING SKELETAL MUSCLE 
REGENERATION 
4.1 Introduction 
Skeletal muscle growth is affected by its hormonal environment. Growth hormone 
(GH) and the insulin-like growth factors (IGFs) have been shown to have a role in 
muscle growth and development (Dodson et al. 1985; Etherton & Kensinger 1984; 
Merrill et al. 1977), as described in Section 1. 7 .1. Growth hormone enhances normal 
postnatal muscle growth, at least in part, by augmenting skeletal muscle protein 
synthesis (Fryburg & Barrett 1993 ). The means by which GH exerts its effect on 
skeletal muscle is not fully understood, although much attention has been focussed on 
endocrine, as well as autocrine/paracrine, production of IGF-1 (Isgaard et al. 1988; 
Isgaard et al. 1989; Sara & Hall 1990; Vikman et al. 1991 ). Previous animal studies 
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have suggested that GH may improve wound healing (Jorgensen & Andreassen 1987; 
Pessa et al. 1985). GH has been used in several regeneration studies, and similar to 
the case for normal postnatal muscle, has been found to enhance the weight of 
regenerated muscle (Ullman et al. 1989). Additionally, the GH receptor is expressed 
in regenerating skeletal muscle of rats (Jennische & Andersson 1991), further 
supporting a possible role for GH in regeneration. 
Hypophysectomised rats have been used previously to examine the effect of GH on 
muscle growth and regeneration (Sommerland et al. 1989; Ullman & Oldfors 1991). 
In this study, the dw/dw rat was used to examine the effects of GH. The dwldw rat has 
a selective autosomal recessive defect that results in greatly reduced (6-10% of 
normal) levels of pituitary GH, and reduced bodyweight (approximately 40% less at 3 
months) relative to its normal counterpart, the Lewis rat (Charlton et al. 1988). Male 
and female dwldw rats have barely detectable levels of circulating GH, but maintain 
the sexually dimorphic pattern of GH release typical of normal rats, only reduced in 
amplitude (Legraverend et al. 1992). Administration of GH to dw/dw rats results in a 
dramatic growth response, with approximately 2.5- to 4.0-fold greater daily weight 
gain following GH treatment, relative to untreated dw/dw rats (Charlton et al. 1988). 
Dwldw rats have normal concentrations of the other anterior pituitary trophic 
hormones (LH, TSH, prolactin and ACTH), unlike hypophysectomised rats, which 
lack all anterior pituitary hormones (Charlton et al. 1988). This feature of a selective 
GH-deficiency, made the dwldw rat a preferable model to the hypophysectomised rat 
for the study of a GH effect on muscle regeneration. The dw/dw rat is fertile, and thus 
can be maintained as a self-sustaining breeding colony (Crawford et al. 1994). Male 
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dwldw rats achieve sexual maturity, based on plasma testosterone, and testis and 
seminal vesicle growth, on days 42-63 (Crawford et al. 1994). 
In this study, a histological approach rather than one examining the overall changes in 
muscle, has been used. The reasons for this are: a) muscle tissues respond 
differentially to stimuli, as exemplified by a study of normal ovine muscle showing an 
effect of nutrition on IGF-1 binding to connective tissue but not muscle fibres 
(Oldham et al. 1996); and b) the response of muscle fibres may be different depending 
on the proximity to damage. Therefore in this study IGF expression and binding will 
be examined in connective tissue ("connective tissue"), and in muscle fibres that are 
regenerating ("regenerating fibres"), interspersed with regenerating muscle fibres 
("survivor fibres"), and in fibres that are within the notexin-injected muscle but are 
removed from the damage and not interspersed with regenerating fibres ("undamaged 
fibres"). 
4.1.1 Aim of this chapter 
The aim of this chapter is to test the hypotheses that the IGFs and their receptors are 
regulated during muscle regeneration, and that the level of IGF expression and binding 
in regenerating muscle is regulated by GH. 
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4.2 Materials and Methods 
4.2.1 Animals 
The dw/dw GR-deficient rats used for this study were a gift of Dr. LC.AF. Robinson, 
National Institute of Medical Research (Mill Hill, London, UK). Fifty male dw/dw 
rats were grown to 28 days of age, then castrated under general anaesthetic. 
Prepubertal castration of these dw/dw rats was performed in order to remove 
endogenous testosterone. The reason for removing testosterone relates to the 
administration of GH. As discussed in Section 1. 7 .1. 7 .1, testosterone induces a 
masculine pattern of GH secretion (Painson et al. 2000), a pattern associated with 
greater somatic growth relative to the feminine pattern (Jansson et al. 1985). 
Castration was therefore performed in this trial in order to decrease the somatic 
growth response to endogenous GH. The reason that male rats were used was that this 
trial was part of a larger study in which the effects of testosterone on regeneration of a 
testosterone-responsive muscle (M. levator ani) was examined. 
At 60 days of age, and weighing approximately 120 g, the rats were anaesthetised and 
a small incision made over the right M. biceps femoris. The rats then received one 
intramuscular notexin injection (2.0 µg) in the right M. biceps femoris ("injected 
muscle"; as described in Section 3 .1 ). Contralateral muscles, which were not injected 
with notexin ("non-injected") were used as regeneration controls. Rats were divided 
into a GH-treated group which received a single daily subcutaneous injection of 
human N-methionyl GH (kindly provided by Genentech, So. San Francisco, CA; 200 
µg in 0.1 ml/100 g body weight daily), while the control group received an equal 
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volume of saline vehicle (0.1 ml/100 g body weight daily). Animals were weighed 
and sacrificed at days 1, 2, 3, 5, 9 and 13 post-notexin injection (n=4 or 5 per 
treatment group per day). 
In order to separate out the effects of notexin and GH, a second trial was carried out in 
which dwldw rats received identical GH and saline volumes to those used in the first 
trial, but no notexin. Body weights were recorded on a daily basis up to day 1 O (n=5/6 
per group). 
4.2.2 Tissue Sampling 
Muscle samples for autoradiographic receptor studies were frozen (see Section 
2. 7 .2.1 ), then stored at -70°C. Muscles for in situ hybridisation experiments were 
formalin-fixed and paraffin-embedded according to the method given in Section 
2.7.2.2. Formalin-fixed, paraffin-embedded sections were stained with haematoxylin 
and eosin, by the method described in Section 2.8, for examination of morphological 
changes during regeneration. 
4.2.3 Incubations and receptor autoradiography 
In vitro incubations to determine IGF-I and -II binding capacity were carried out 
according to the methods given in Section 2.10. Notexin-injected muscle from all 
animals (n=4), and non-injected muscles from half (n=2) of each treatment group on 
days 3, 5 and 13 were examined. Days 1 and 2 were omitted as the tissues were at a 
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predominantly necrotic/phagocytic stage, in order to focus more specifically on the 
effects of GH and regeneration during the stages of MPC proliferation and 
differentiation. Pairs of sections were incubated with either 1251-(rh)IGF-I or 1251-
(o )IGF-II for a determination of total binding, and the binding competed with excess 
unlabelled homologous IGF for a determination of non-specific binding. Des (l-
3)IGF-I was utilised as a competing hormone for 1251-IGF-I in order to determine 
whether, and at what times, binding proteins were a significant component of the 
specific 1251-IGF-I binding observed. Other competing hormones for IGF-1 were 1 
µg/ml (rh)IGF-11 and 10 ng/ml bovine insulin. For IGF-11, competing hormones 
included 1 µg/ml rh-N-met-IGF-1, 1 µg/ml des (1-3)1GF-I, 1 µg/ml des (1-6)IGF-Il, 
and 10 ng/ml bovine insulin. 
The binding of radiolabelled IGF-1 and -II to notexin-injected muscle sections was 
uniform, except for the following two exceptions, as described here for 1251-IGF-I, in 
which exceedingly high, isolated binding was noted. Firstly, a small subset of 
regenerating fibres ( estimated to be less than 0.5% of all regenerating fibres) had high 
level binding which was effectively displaced by cold IGF-1 and by des(l-3)1GF-I 
(Figure 4-1 ). This binding was not due to chemographic effects (interaction of tissue 
with emulsion, resulting in grain deposition) (Rogers & John 1969), as determined by 
the presence of visibly elevated signal in macroautoradiographs, corresponding to the 
location of these individual fibres. Because of the very low frequency and the 
distorting effect of the exceedingly high signal on the data obtained, these fibres were 
omitted from the quantitation of IGF-1 binding. There was no association of these 
high signal fibres with GH-treatment, although there was some association with 
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regeneration time in that the fibres were occasionally present in day 3 and 5 muscle, 
but were never observed in day 13 muscle. A second case of aberrant signal was 
observed in cells with the appearance of polymorphonuclear leucocytes (also known 
as neutrophils), which have the morphological characteristics of a lobular, horseshoe-
shaped nucleus and an abundant cytoplasm (Alberts et al. 1994), and are phagocytic. 
The presumed polymorphonuclear leucocytes were observed in regenerating fibres, 
and less frequently in connective tissue/interstitial spaces, and had high total binding 
of 125I-IGF-I which was not displaced by unlabelled IGF-I or des(l-3)IGF-I (Figure 
4-1 ), indicating that the binding was non-specific. These cells were thus also omitted 
from the quantitative analysis of 125I-IGF-I to tissue sections. 
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Figure 4-1. Unusual binding of 125I-IGF-I within damaged muscle. 
The binding of 125I-IGF-I in notexin-injected muscle was unusually high in some regenerating 
muscle fibres (A-C), and presumed polymorphonuclear leucocytes (D-F). In the small subset of 
muscle fibres showing extraordinarily high total binding (A), the 125I-IGF-I is effectively 
displaced by both competition with unlabelled des(l-3)1GF-I (8), and unlabelled IGF-I (C; NSB), 
and is therefore specific. In contrast however, high total binding (D) to presumed 
polymorphonuclear leucocytes (arrows) is not effectively displaced by competition with either 





4.2.4 In situ hybridisation 
In situ hybridisation was utilised in the present study to determine the localisation and 
level of IGF mRNA in regenerating muscle. The procedure employed was based on 
the method of Molenaar et al. ( 1992). 
4.2.4.1 IGF RNA probes 
IGF-1 probes for use in in situ hybridisation experiments were transcribed from a 203-
base pair (bp) Sau3A/Sau3A fragment of human IGF-1 cDNA inserted into pUC 13 
(Jansen et al. 1983). The cDNA, containing the D- and E-domains of the coding 
region plus 40 bp of the 3' non-coding sequence, was cloned into the pGemini-3 
vector (Promega, Madison, WI). IGF-11 RNA probes were transcribed from a 534-bp 
Pstl/Hinfl fragment of a human IGF-11 cDNA (Bell et al. 1984) that codes for the 
signal peptide, mature IGF-11 and part of the E-domain (Rall et al. 1987), cloned into 
the pGemini-3 vector. A. Molenaar and R. Wilkins kindly provided the IGF-1 and -II 
cDNA constructs, respectively. Sense transcripts were used as negative control probes 
for in situ hybridisation, to indicate the level of non-specific binding of the probe. 
Nuclease free MQ water 
Transcription buffer 
DTT 
rATP, rCTP, rGTP 
rUTP 
RNasin 
Purified DNA template 
35S-UTP 



















Probe synthesis was performed according to the Promega Riboprobe protocol with 
minor modifications. All reagents as listed above, were supplied in a Promega 
transcription kit, except for uridine-5'-(a-35S)thiotriphosphate ( 35S-UTP; Amersham 
International, Amersham, UK) which was used to radioactively label the probes. All 
water used for probe synthesis and in situ hybridisation procedures was treated with 
0.1 % DEPC, then autoclaved, in order to avoid RNase contamination. Similarly, 
glassware was treated with DEPC-water, and then autoclaved. The probe synthesis 
reaction was performed at 37°C for 1 hour, with a further 0.5 ul of SP6 RNA 
polymerase added to applicable tubes halfway through the reaction. After this 
reaction, 1.5 µl of RNase-free DNase (Promega) was added to degrade the DNA 
template, followed by a 20 minute incubation at 37°C. At this time, the reaction tube 
was placed on ice, and the probe precipitated by the addition of: 10 µl 7.5 M 
ammonium acetate (BDH), 2 ul of 1 Omg/ml tRNA (from Escherichia coli strain 
HB101; Boehringer Mannheim, Auckland, NZ), and 2.2 volumes of 100% ethanol. 
The reaction tube was placed in a -20°C freezer for at least 30 minutes, then spun at 
13,000 revolutions per minute in a benchtop centrifuge (Jouan S.A., St. Herblain, 
France) for 20 minutes. The supernatant was discarded, and the remaining pellet 
washed three times with 75% EtOH containing DEPC-water. All visible ethanol 
solution was removed, then the remainder left to evaporate off for up to 20 minutes. 
The probe was resuspended in 20 µl of 1 OmM 1,4-dithiothreitol (Boehringer 
Mannheim), with one 5-minute incubation in a 65°C water bath to aid in resuspension. 
Counts were taken from 1 µl of probe placed in liquid scintillation fluor (Beckman, 
Alphatec Systems Ltd, NZ), and the cpm/µl of probe determined (normally greater 
than lx 106 cpm/µl). 
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4.2.4.2 Tissue sections 
Paraffin-embedded tissues from all animals in the 3, 5, 9 and 13 day groups were 
sectioned to a thickness of 7 µm, floated out on DEPC-treated water, and placed on 
slides coated with 3-aminopropyltriethoxysilane (Sigma). Two serial sections were 
placed on each slide, one for antisense probe, and the other for sense probe. Duplicate 
sections were assayed for each animal. 
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4.2.4.3 Solutions 
Proteinase K solution DEPC-water 80 mls 
1 M calcium chloride 200 µl 
1 M Tris, pH 7.2 20 ml 
20 mg/ml Proteinase K (add last) 10 µl 
Acetylation solution triethanolamine 1.32 mls 
pH 8.0 DEPC-water 100 mls 
Acetic anhydride (add just before 1 ml 
use) 
20 x SSC Sodium chloride 175.32 g 
Sodium citrate 88.23 g 
Milli Q water To 1 litre 
DEPC (only for pre-hyb steps) 0.2 ml 
Premix hybridisation 5 M sodium chloride 0.3 ml 
buffer Deionised formamide 5.0ml 
20x SSC 1.0 ml 
10 mg/ml yeast tRNA 0.2 ml 
10 mg/ml degraded herring DNA 1.0 ml 
Hybridisation buffer Premix hybridisation buffer 780 µl 
BSA (20 mg/ml) 20 µl 
50% dextran sulphate 200 µl 
DTT Heaped spatula tip 
Wash solution 1 2XSSC 
50% formamide 
1 OmM P-mercaptoethanol (BME) 760 µI/litre 
Wash solution 2 0.2 X SSC 
lOmMBME 760 µI/litre 
Wash solution 3 70% ethanol 
BME 760 µI/litre 
RNase treatment RNase A (35 mg/ml) 14.3 ul 
*enzymes added after RNase Tl (3.5 mg/ml) 3.4 ul 
heating 2 x SSC 100ml 
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4.2.4.4 Section pre-treatment 
Slides were incubated at 60°C for 10 minutes in order to soften the paraffin, then 
deparaffinised by two successive 10 minute incubations in xylene. Sections were 
rehydrated by passage through a graded series of alcohols (100%, 100%, 95%, 70%) 
for 5 minutes each, then placed in DEPC-water for 3 minutes. The muscle sections 
were treated with 0.2N HCl for 10 minutes at room temperature to remove basic 
proteins, then washed in 2xSSC for 15 minutes. A 15 minute incubation in proteinase 
K solution at 37°C was performed to enhance section permeability to the probe, 
followed by acetylation of amino groups, via two 5 minute incubations at room 
temperature in acetylation solution (solution used immediately after the addition of 
acetic anhydride), to reduce non-specific binding of the probe to the tissue sections. 
Sections were incubated in 2 x SSC for 5 minutes, then placed in 100% ethanol baths 
for 5 minutes each, until the ethanol solution was clear, not cloudy. Sections were 
then air dried at room temperature. 
4.2.4.5 Hybridisation 
Sections were encircled with ADOS™ rubber cement (Para Rubber, Hamilton, NZ), to 
contain the radioactive probe during the hybridisation step. Probes were boiled for 3 
minutes to reduce non-specific interactions, briefly spun, then diluted to 30,000 
cpm/µl in hybridisation buffer. The hybridisation mixture was spread evenly across 
the tissue sections using the long edge of the pipette tip, and any remaining bubbles in 
the solution removed by quickly passing a gas flame over the surface. Slides were 
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placed on racks in air-tight chambers equilibrated with 50% formamide, 2 x SSC and 
hybridised overnight at 55°C. 
4.2.4.6 Post-hybridisation washes 
Slides were removed from the chambers in a ventilated hood, and placed in wash 
solution 1, for 15 minutes at 55°C, then rinsed in Wash Solution 2 for 15 minutes at 
room temperature. Sections were then incubated in RNase solution for 45 minutes at 
3 7°C to destroy non-specifically bound probe, and any residual rubber cement 
removed from the slides at this point. Sections were rinsed in Wash Solution 2 three 
times for 5 minutes each, then transferred to Wash Solution 3 for 5 minutes, followed 
by 95% ethanol for 5 minutes. The slides were then air-dried. 
4.2.4. 7 Autoradiography and Emulsion 
Macroautoradiographs were generated by apposing the slides against XAR film 
(Eastman Kodak) for 3 days. Slides were then coated with NTB-2 (Eastman Kodak) 
photographic emulsion, exposed for 10.5 weeks, developed and counterstained with 
haematoxylin and eosin as per Section 2.8. 
4.2.5 Grain counting 
Radiographic grains in hybridised and incubated sections were quantitated in the 
following fibre/tissue types within the notexin-injected muscle: a) regenerating fibres, 
b) survivor fibres, c) undamaged fibres, and d) connective tissue (excluded from IGF-
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II mRNA grain counting due to low levels in connective tissue). The latter three 
tissue types, which were defined earlier in Section 3 .1.3, were chosen in addition to 
regenerating fibres for the following reasons: a) it was considered that undamaged 
fibres from notexin-injected muscle may have different growth factor activities from 
survivor fibres as the latter are intermixed with the regenerating fibres; and b) 
previous studies have shown high levels of IGF-II receptor in skeletal muscle 
connective tissue (Oldham et al. 1993). Day 1 and 2 tissues were excluded from 
binding and mRNA grain counting as the damaged fibres were predominantly at a 
necrotic, not regenerative, stage. Also, survivor and regenerating fibres could not be 
definitively identified in incubated day 13 sections, so they were not counted. IGF 
binding and mRNA were quantitated in undamaged fibres and connective tissue of 
non-injected muscle (n=2 per treatment group per day for incubated sections; n=4 per 
treatment group per day for in situ hybridised sections). 
For hybridised sections, grain densities were determined using the Visilog system (see 
Section 2.11.1 ). Grain densities were determined for six sites per slide each, and in 
three sites per slide for undamaged fibres as the latter group had less variable levels 
than did connective tissue, survivor and regenerating fibres. Specific IGF-I and -II 
mRNA was determined by subtracting the values from areas in sense-probed sections 
from the values in matched areas of antisense-probed sections. 
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4.2. 6 Statistical analysis 
Values are presented as means ± S.E.M. 1251-IGF-I and -II binding was analysed to 
determine the effects of treatment and the relative tissue levels by the method of 
restricted (residual) maximum likelihood (REML). Tukey ("Honest") Significant 
Difference was used for significance comparisons between individual time x tissue 
values for 1251-IGF binding. Statistical analyses of IGF-1 and -II mRNA levels to 
determine the effects of treatment, time, and fibre or tissue type were carried out on 
log-transformed values using ANOV A. Muscle and body weights, following 
adjustment for initial liveweight, were analysed using ANOV A. Comparisons of the 
IGF mRNA levels of different tissues at individual timepoints were performed using a 
paired t-test, to determine whether the difference in values was significantly different 
from zero. 
For the analysis of the IGFBP component of 1251-IGF-I binding, des(l-3)1GF-I 
competed binding was compared with unlabelled IGF-1 competed binding by using 
Student's t-test to determine if the difference of the two values was significantly 
different from zero. If the difference between the two resultant binding levels was 
significantly different to zero, the presence of IGFBPs was indicated. 
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4.3 Results 
4.3.1 Body and muscle weights 
Body weights changed significantly (p<0.001) after notexin injection (Figure 4-2), 
with a decrease in weights up to day 5 followed by a steady weight gain after this 
time. The initial decrease in body weights suggested a systemic effect of notexin in 
addition to the local effect. To test this, additional rats (n=5/6 per group) of the same 
line and mean weight on day O were administered equal amounts of GH or saline 
vehicle to the amounts used in this trial. Body weights were recorded and are also 
shown in Figure 4-2, and indicate a steady weight gain from day O in the absence of 
notexin, thereby confirming the existence of a systemic effect of notexin in addition to 
its local effect. Growth hormone treatment was not sufficient to overcome the 
systemic effect of notexin on body weights as there was no significant difference in 
weights with and without GH up to day 5 in the present trial. Growth hormone 
administration to notexin-injected rats eventually resulted in 14% higher body weight 
(p<0.001 overall), with increases in the GH-treated group relative to the saline group 
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Figure 4-2. Effect of GU on body weight of dw!dw rats. 
Effects of daily GU (200 µg/lOOg body weight) and notexin (NOT; one i.m. injection, day 0) on 
body weights of dwldw rats. Values represent the mean weights ± S.E.M., n= 4/5 per group. 
Significance is shown for the saline-treated (SAL NOT) versus GU-treated (GU NOT) notexin-
injected rats (*p<0.05, ***p<0.001; ANOVA). 
Weights of notexin-injected and non-injected M. biceps femoris changed significantly 
over days 1-13 (p<0.001; Figure 4-3). Similar to changes in bodyweight, non-injected 
muscle weights declined from days 1-5, while notexin-injected muscle weights 
declined from days 1-9, then increased. Weights of notexin-injected and non-injected 
M. biceps femoris were increased in GH-treated animals by 15% and 18%, 
respectively, relative to saline group animals (p=0.007 and p=0.002, respectively). 
Specific increases in muscle weight due to GH were seen on day 1 (p<0.05, notexin-
injected and non-injected), day 9 (p<0.05, non-injected) and day 13 (p<0.05, notexin-
injected; p<0.001, non-injected). 
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Figure 4-3. Effect of GH on muscle weight of dwldw rats. 
Effect of daily GH (200 µg/lOOg body weight) on the weights of notexin-injected (blue) and non-
injected (orange) M. biceps femoris. Values are the means± S.E.M., n=415 per group. Asterisks 
indicate the significance of the saline ( • ) versus GU-treated<•) muscle weight comparison for 
either notexin-injected or non-injected muscle(* p<0.005, ***p<0.001; ANOVA). 
4.3.2 Morphological changes during muscle regeneration 
Histological examination of haematoxylin and eosin stained sections showed that the 
occurrence of regeneration events in this trial was similar to that reported for dw!dw 
rats in Section 3.1.3. In brief, mononucleate cells presumed to be MPC were most 
abundant in day 3 tissues, while considerable MPC fusion was observed on day 5. 
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Additional myotube formation, and myotube enlargement occurred after day 5. GH-
treatment did not affect the quality or timing of muscle regeneration as determined by 
histological assessment of haematoxylin and eosin stained muscle sections. 
4.3.3 IGF-1 specific binding 
The relative levels of IGF-1 binding to histological zones ofnotexin-injected and non-
injected muscle from saline-treated animals are shown in Table 4-1. Results show 
that there were highly significant differences in binding between the different tissue 
types (p<0.001), and that the pattern of binding to the different tissue types examined 
changed significantly over time (p=0.018). IGF-1 binding to undamaged muscle fibres 
of the non-injected muscle was low at all timepoints, as was binding to the undamaged 
muscle fibres in the notexin-injected muscle on days 3 and 5. In contrast, regenerating 
fibres had high level binding on day 3, which rose further to peak at day 5. 1251-IGF-I 
binding to day 5 regenerating muscle fibres was significantly greater than the binding 
to all other tissue types on day 5 (p<0.001). 1251-IGF-I binding to survivor fibres was 
not significantly different from the binding to undamaged muscle fibres of notexin-
injected and non-injected muscles on days 3 and 5. The binding of 1251-IGF-I to 
connective tissue was similar to the binding to regenerating fibres on day 3, then 
declined to day 5 values. The pattern and level of 1251-IGF-I binding to connective 
tissue of notexin-injected muscle was similar to the 1251-IGF-I binding to connective 
tissue of non-injected muscle. 1251-IGF-I binding at day 13 following notexin-
injection was high in undamaged muscle fibres and connective tissue of notexin-
injected muscle, and in connective tissue from the non-injected muscle. The binding 
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of 1251-IGF-I to connective tissue of non-injected muscle was significantly greater than 
the binding of 1251-IGF-I to muscle fibres of non-injected muscle (p<0.05) on day 13. 
GH did not have a significant effect on 1251-IGF-I binding, as shown in Figure 4-4. 
Table 4-1. 1251-IGF-I binding to muscle from saline-treated rats. 
The values shown for 1251-IGF-I specific binding in notexin-injected and non-injected muscles 
from saline-treated rats were determined by receptor autoradiography. Grain densities 
(grains/µm2) were determined by subtracting non-specific from total binding values for each 
section. Means as determined by the REML method are shown for survivor fibres (S), 
regenerating fibres (R), undamaged fibres (U), and connective tissue (C). Means were 
determined from three animals unless otherwise indicated (§ n=l and 'I n=4). Regenerating and 
survivor fibres were not distinguishable in day 13 sections, and so were not quantitated (N/A; not 
available). Significance is shown for comparisons within time-points (different letters indicate 
significance at the p<0.05 level; all other comparisons were not significant). 
NOTEXIN-INJECTED NON-I JECTED 
Ave 
s R u C u C S.E.M. 
Day 
3 0.0070a 0.0262 a 0.0036 a 0.0230a 0.0102§a 0.0264§a 0.0065 
5 0.0126b 0.0430a 0.00521b 0.01291b 0.0051 §b 0.0022§b 0.0042 
13 NIA NIA 0.0267ab 0.0277ab 0.0078§b 0.0370§a 0.0091 
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Figure 4-4. Effect of GH on 1251-IGF-I specific binding. 
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1251-IGF-I specific binding values were determined by receptor autoradiography for tissues 
within notexin-injected muscle. Grain densities (grains/µm2) were determined by subtracting 
non-specific from total binding values for each section. Means ± S.E.M. as determined by the 
REML method are shown for survivor fibres (S), regenerating fibres (R), undamaged fibres (U), 
and connective tissue (C). There was no significant effect of GH treatment on 1251-IGF-I binding. 
Three animals were analysed per group except for the following groups, in which 4 animals were 
analysed: day 3 CT (GH), day 5 CT (GH and saline), and day 5 U (saline). 
4.3.4 IGF-11 specific binding 
Table 4-2 shows the relative distribution of 1251-IGF-II binding in the histological 
zones of notexin-injected and non-injected muscles from saline-treated animals. 1251-
IGF-II binding in regenerating fibres changed significantly with time (p<0.05), with 
peak levels on day 5. No other tissue types, from either notexin-injected or non-
injected muscles, showed change over time. The 1251-IGF-II binding in regenerating 
fibres was significantly higher than in connective tissue, undamaged fibres or survivor 
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fibres of notexin-injected muscle (p<0.001), and was higher than in undamaged 
muscle fibre and connective tissue (p<0.01) on day 5. There was no significant 
difference in 1251-IGF-II binding at any timepoint between the other tissue types, from 
either notexin-injected or non-injected muscles. 
Table 4-2. 1251-IGF-11 binding to muscle from saline-treated rats. 
The values shown for 1251-IGF-II specific binding in notexin-injected and non-injected M. biceps 
femoris from saline-treated rats were determined by receptor autoradiography. Grain densities 
(grains/µm2) were determined by subtracting non-specific from total binding values for each 
section. Means as determined by the REML method are shown for survivor fibres (S), 
regenerating fibres (R), undamaged fibres (U), and connective tissue (C). Means were 
determined from four animals unless otherwise indicated (' n=2 and 1 n=3). Regenerating and 
survivor fibre values were not determined for day 13 (NIA). Significance is shown for 
comparisons within time-points (different letters indicate significance at the p<0.001 level; all 
other comparisons were not significant). 
NOTEXIN-INJECTED 
Ave 
s R u C u C S.E.M. 
Day 
3 0.03421 0.12421 0.0731 0.0381 0.0250§ 0.0363§ 0.0440 
5 0.0650b 0.2256 a 0.0350b 0.0375 b 0.0388§b 0.0363§b 0.0267 
13 NIA NIA 0.0206 0.0275 0.0125§ 0.0300§ 0.0069 
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The effect of GH on IGF-II binding in notexin-injected muscle is shown in Figure 4-5. 
A significant effect of GH on IGF-II binding was observed on day 5 (p<0.01 overall), 
whereby levels in all notexin-injected muscle tissues were elevated with GH (p<0.001, 
regenerating fibres; p<0.05, connective tissue, survivor and undamaged fibres). 
Notexin-injected muscle tissues responded to GH, whereas non-injected muscle 
tissues did not (p<0.05 for the GH x tissue interaction). No difference in IGF-II 
binding due to GH was noted on either day 3 or 13. 
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Figure 4-5. Effect of GH on 1251-IGF-II specific binding. 
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1251-IGF-II specific binding values were determined by receptor autoradiography for tissues 
within notexin-injected muscle. Grain densities (grains/pm2) were determined by subtracting 
non-specific from total binding values for each section. Means ± S.E.M. as determined by the 
REML method are shown for survivor fibres (S), regenerating fibres (R), undamaged fibres (U), 
and connective tissue (C). The number of animals analysed per tissue type is 3-4, except for all 
day 3 GU-treated values, where n=2. Significance is shown for the GH versus saline comparison 
(*, p<0.005, ***, p<0.001). 
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4.3.5 IGFBPs 
A qualitative assessment of total binding, and competition by unlabelled-IGF-1 and 
des(l-3)IGF-I, indicated that binding proteins may be present within certain tissues at 
distinct times during the regeneration process in notexin-injected muscle. Since the 
presence of significant levels of IGFBPs could affect the assessment of Type I IGF 
receptor levels in these regenerating tissues, an initial analysis was carried out to 
determine at what time, and in which tissues, significant levels of IGFBPs were 
present. One animal per treatment per timepoint was analysed, the results of which 
showed that there was no significant difference between the des(l-3)IGF-I and 
unlabelled IGF-1 competed binding of 1251-IGF-I in the different tissue types of day 3 
and 13 notexin-injected muscles. This indicated that the binding of 1251-IGF-I was to 
receptor and not IGFBPs in these tissues on days 3 and 13. A similar analysis of day 5 
tissues from the two treatment groups indicated, however, that IGFBPs were a 
significant component of the total binding of 1251-IGF-I at this timepoint. Quantitation 
of 1251-IGF-I binding competed with unlabelled des(l-3)1GF-I was thus carried out for 
a larger number of the day 5 animals, in all of the histological tissue types of notexin-
inj ected muscle that showed a significant level of specific binding, namely connective 
tissue, regenerating and survivor muscle fibres, in order to separate out the effect of 
IGFBP from receptor. Figure 4-6 shows the results of this analysis, whereby specific 
binding of 1251-IGF-I (which indicates binding to both BP and receptor) is compared 
with binding following competition with des(l-3)IGF-I (which indicates binding to 
receptor). Each day 5 tissue examined, namely connective tissue, regenerating and 
survivor muscle fibres, has a significant component of binding protein present 
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(p<0.001 ). There was no effect of GH on IGFBPs, either overall or on individual 
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Figure 4-6. IGFBPs in damaged muscle tissues. 
Specific binding versus 1251-IGF-I binding competed with des(l-3)1GF-I in day 5 notexin-injected 
muscle from saline- and GB-treated rats. 1251-IGF-I binding density was determined from tissue 
sections following IGF-1 receptor autoradiography, as detailed in Section 2.11. Treatment groups 
were combined as there was no significant effect of GH on 1251-IGF-I binding competed with 
either unlabelled IGF-1 or des(l-3)1GF-I. Values shown represent the means± S.E.M, n=6 for 
regenerating (R) and survivor (S) fibres, n=8 for connective tissue (CT). Significance shown is 
for comparisons within a tissue(***, p<0.001). 
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4.3.6 IGF-1 mRNA 
IGF-1 mRNA levels in tissue types of notexin-injected and non-injected muscles were 
unaffected by the administration of GH, therefore the two treatment groups were 
pooled together for a combined analysis of IGF-1 expression. Figure 4-7(A) shows 
that the level oflGF-1 mRNA as determined by autoradiographic grain density was not 
significantly different, overall or at individual timepoints, in undamaged muscle fibres 
from notexin-injected versus non-injected muscles. In contrast, connective tissue 
IGF-1 mRNA levels were different between notexin-injected and non-injected muscles 
(Figure 4-7B), whereby connective tissue in notexin-injected muscle had significantly 
greater IGF-1 mRNA levels on day 3 relative to that of connective tissue from non-
injected muscle (p=0.013). Connective tissue IGF-1 mRNA levels were not 
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Figure 4-7. IGF-1 mRNA levels in damaged and undamaged muscles. 
IGF-1 mRNA in undamaged muscle fibres (A) and connective tissue (B) of non-injected (open 
symbols) and notexin-injected (solid symbols) muscles following notexin injection at time 0. IGF-
1 mRNA levels are expressed as grain densities following quantitation of in situ hybridised muscle 
sections as described in Section 4.2.4. Values shown are the means ± S.E.M. of the pooled 
treatment groups (ANOV A). Signficance is shown for notexin-injected versus non-injected 
muscle connective tissue on day 3 (*, p=0.013), however all other timepoints for both connective 
tissue and undamaged muscle fibres are not significant (NS). 
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In notexin-injected muscles, a comparison of IGF-1 mRNA expression in connective 
tissue, regenerating, survivor and undamaged muscle fibres identified a distinct 
pattern of temporal regulation (p<0.001 overall; Figure 4-8). Regenerating muscle 
fibres had greatly increased levels oflGF-1 mRNA as early as day 3 (p<0.001 relative 
to undamaged muscle fibres). IGF-I mRNA levels in regenerating fibres peaked on 
day 9 (Figure 4-8 and Figure 4-9), after substantial myotube formation had occurred, 
with peak levels that were 16-times that of undamaged muscle fibres. IGF-1 mRNA 
levels decreased within regenerating fibres after day 9 to day 13 levels, but remained 
greater than undamaged muscle fibres levels (p<0.001). The increase in IGF-1 mRNA 
observed in regenerating muscle fibres did not appear to be related to changes in 
nuclear density, as the peak in nuclear density in regenerating areas occurred on day 3 
(refer to Section 3.1.3), while peak levels of IGF-1 mRNA occurred on day 9, and 
were still substantially elevated on day 13 (Figure 4-8), when the nuclear density was 
greatly decreased relative to day 3. 
Survivor fibres also showed an early increase in the expression of IGF-1 mRNA, with 
a significantly higher mRNA level relative to undamaged fibres on day 3 only 
(p<0.01). Survivor fibres from day 5 onward, and connective tissue throughout the 
regeneration period, did not contain significantly different levels of IGF-1 mRNA 
when compared to undamaged muscle fibres. 
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DAY 3 5 9 13 
RvsU *** *** *- *** 
SvsU ** NS NS NS 
CTvsU NS NS NS NS 
o. o o 6 o ---------·-----···-··-·-···--········-·- -····-·········-----··---···--·- -----·-1 
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Figure 4-8. IGF-1 mRNA levels in damaged muscle tissues. 
Grain densities, as determined by grain counting following in situ hybridisation, are shown for 
connective tissue ( + ), regenerating ( • ), survivor <•), and undamaged ( •) muscle fibres. 
Significance levels for the comparison of regenerating fibres (R), connective tissue (CT), and 
survivor fibres (S) with undamaged (U) muscle fibres are shown above(**, p<0.01; ***, p<0.001; 
NS, not significant). 
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Figure 4-9. Localisation of IGF-1 mRNA in regenerating muscle fibres. 
Photomicrographs of radiographic grains after in situ hybridisation using antisense (A) and sense 
(B) 35S-IGF-I RNA probes. (A) Regenerating muscle fibres of notexin-injected muscle 9 days 
after insult show elevated IGF-1 mRNA in regenerating fibres (R) relative to survivor fibres (S). 
(B) A matched sense-probed section contains very few radiographic grains. Sections have been 
counterstained with haematoxylin and eosin, magnification is 50x, bar =100 µm. 
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4.3. 7 IGF-11 mRNA 
GH had no effect on IGF-11 mRNA levels in this study, so GH and saline treated 
animals IGF-11 mRNA data were combined for the analysis of IGF-11 mRNA in 
different tissue types. As shown in Figure 4-10, there was no significant difference 
overall between undamaged muscle fibres from notexin-injected versus non-injected 
muscles, however there was a significant tissue by time interaction (p<0.05). This 
interaction was due to the slight elevation in undamaged fibre IGF-11 mRNA in 
injected, relative to non-injected muscles on day 9 (p<O. l 0), followed by a reversal of 
this relationship on day 13 (p<0.10). 
IGF-11 mRNA levels in tissues from the notexin-injected muscle changed significantly 
(p<0.001) with time following notexin injection (Figure 4-11). Distinct patterns of 
localisation of IGF-11 mRNA in damaged muscle were immediately apparent (Figure 
4-11 ), with the highest mRNA levels in regenerating fibres (Figure 4-11 and Figure 
4-12). Regenerating muscle fibre IGF-11 mRNA levels were not significantly different 
to that of survivor and undamaged muscle fibres on day 3, but were significantly 
elevated on day 5, 9, and 13, as indicated in Figure 4-11. IGF-11 mRNA in 
undamaged muscle fibres was not significantly different from survivor fibre IGF-11 
mRNA except for on day 13, when survivor fibre levels were elevated relative to 
undamaged muscle fibre levels (p<0.05). 
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As was the case for IGF-1 mRNA (refer to Section 4.3.6), increases in IGF-11 mRNA 
were discordant with increases in nuclear density during regeneration, as peak levels 
of IGF-11 mRNA occurred on day 9, and not on day 3, when the nuclear density is 
greatest (refer to Section 3.1.3). 
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Figure 4-10. IGF-11 mRNA levels in undamaged muscle fibres. 
IGF-11 mRNA levels were determined for non-injected (open symbols; n=8) and notexin-injected 
(solid symbols; n=7/8) muscles following notexin injection at time 0. IGF-11 mRNA levels are 
expressed as grain densities following quantitation of in situ hybridised muscle sections as 
described in Section 4.2.4. Values shown are the means ± S.E.M. of the pooled treatment groups 
(ANOV A). Significance at the p<0.10 level is indicated by ( t ). 
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DAY 3 5 9 13 
Rvs S NS * *** ** 
SvsU NS NS NS * 
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Figure 4-11. IGF-11 mRNA levels in damaged muscle tissues. 
IGF-11 mRNA expression in notexin-injected muscle sections, as determined by in situ 
hybridisation. Grain density was determined as the difference between antisense- and sense-
probe densities for each fibre type in each section. Undamaged fibres ( .A., n=7/8); survivor fibres 
( e, n=7/8); regenerating fibres ( •, n=7/8). Values shown are the means± S.E.M. of the pooled 
treatment groups (ANOV A). Significance is shown for the between tissue type comparisons 
(*p<0.05, **p<0.01, ***p<0.001). 
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Figure 4-12. Localisation of IGF -II mRNA in regenerating muscle fibres. 
Photomicrograph of radiographic grains after in situ hybridisation using 35S-labelled antisense 
(A) and sense (B) IGF-11 RNA probes. (A) Regenerating muscle fibres of notexin-injected 
muscles 9 days after injection show elevated IGF-11 mRNA in regenerating fibres (R) relative to 
survivor fibres (S). (B) A matched sense-probed section contains very few radiographic grains. 
Arrows show a series of MPC that are lined up end-to-end, indicative of myotube formation. 




Notexin administration to M. biceps femoris resulted in a heterogeneous pattern of 
damage, allowing for separate analysis of both non-regenerating and regenerating 
fibres in the notexin-injected muscle. In the present study, components of the IGF 
axis were observed to change differentially depending on the tissue type and proximity 
to the damage. Specifically, regenerating fibres showed the greatest changes in IGF 
mRNA and binding, and survivor fibres and connective tissue showed greater changes 
than did undamaged fibres. Interestingly, although elevated IGF-1 was noted in non-
regenerating fibres, the same was not observed for IGF-11, suggesting that at least 
some of the functions ofIGF-II are distinct to those ofIGF-1 in these tissues. 
IGF-1 and -II are believed to be key regulators of MPC proliferation and 
differentiation (Duclos et al. 1991; Ewton et al. 1994; Fiorini et al. 1991 a). The 
expression patterns of IGF-1 and -II in regenerating fibres as observed in the present 
study are fully consistent with such a regulatory role for the IGFs, because IGF levels 
were elevated during the phases of MPC proliferation and differentiation. While IGF-
1 and -II expression patterns were generally similar in that they were massively up-
regulated during regeneration and had peak levels during late differentiation ( day 9), 
there were also key differences between the two IGFs. Specifically, IGF-1 was up-
regulated at the time of MPC proliferation, whereas up-regulation of IGF-11 mRNA 
was not apparent until the onset of myotube formation. A similar pattern ofIGF-1 and 
-II mRNA regulation, whereby IGF-1 levels increase prior to IGF-II levels, has been 
reported for regenerating rat M. soleus and M. extensor digitorum longus (Levinovitz 
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et al. 1992). Both IGF-1 and -II mRNA levels reached maximal levels during late 
myotube fusion, suggesting an important role for both IGFs in the stimulation of 
differentiation, as has been shown for cultured muscle cells (Florini et al. 1991 a; 
Florini et al. 1991b). Autocrine induction of IGF-11 is essential for the induction of 
differentiation, as shown by studies using an IGF-11 antisense construct to block 
autocrine IGF-11 production (Florini et al. 1991b). Both IGFs elevate myogenin 
mRNA as a part of the stimulation of myogenesis (Florini et al. 1991 a; Florini et al. 
1991 b ), thereby promoting the expression of muscle-specific gene expression via 
MRFs (Kaushal et al. 1994). In addition to the effects of IGFs on muscle specific 
gene expression via the MRFs (Kaushal et al. 1994), IGFs also function to protect 
cultured muscle cells from apoptosis as they exit the cell cycle and undergo terminal 
differentiation (Stewart & Rotwein 1996). A similar function has recently been 
shown in vivo, whereby skeletal muscle programmed cell death in dystrophic mdx 
mice was prevented by IGF-11 overexpression (Smith et al. 2000). These studies 
would suggest that the elevated IGFs observed in regenerating muscle during 
differentiation could be serving more than one function, and that the consequences of 
a lack of IGF at this point can be quite severe. 
In the present study, 1251-IGF-I binding was highest in regenerating muscle fibres. 
1251-IGF-I binding, which constitutes the cumulative binding to both the Type I IGF 
receptor and IGFBPs, was elevated on day 3 but then rose further to day 5 levels, 
concomitant with the onset of differentiation. Elevated Type I IGF receptor binding in 
regenerating muscle has been similarly reported for the M. extensor digitorum longus 
ofhypophysectomised rats (Jennische & Matejka 1992). What is of interest is that the 
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levels on day 5 were higher than the day 3 levels, which is contrary to the reported 
down-regulation of the Type I IGF receptor during muscle cell differentiation 
(Rosenthal et al. 1991 ). This discrepancy can be reconciled, however, by taking into 
account the presence of IGFBPs, as indicated by the in vitro incubations utilising 
des(l-3)IGF-I as the competing hormone (Ross et al. 1989). Competition with des(l-
3)IGF-I showed that a very significant component (approximately 50%) of the day 5 
1251-IGF-I specific binding is comprised of binding to IGFBPs. Binding proteins were 
not observed in the in vitro incubated sections from day 3, thereby suggesting that the 
day 3 specific binding values are comprised solely of binding to the Type I IGF 
receptor. Thus, in terms of the Type I IGF receptor alone, there may be a decrease in 
specific binding from day 3 to day 5, in the present trial. These findings are thus in 
agreement with the reported decrease in Type I IGF receptor levels during muscle cell 
differentiation in vitro (Rosenthal et al. 1991). Studies of cultured muscle cells have 
shown that the amount of Type I IGF receptor affects the speed with which 
myogenesis occurs, whereby increased receptor levels lead to an increased rate of 
myogenesis (Quinn & Haugk 1996; Quinn et al. 1994), while functional inactivation 
of the receptor results in delayed differentiation (Cheng et al. 2000). Thus, the down-
regulation of receptor levels at differentiation may be a mechanism by which the rate 
of differentiation is controlled in vivo. 
In the current study, binding of 1251-IGF-II to regenerating muscle fibres was increased 
during the myotube stage, concomitant with the up-regulation of IGF-11 mRNA. A 
positive association of IGF-11 mRNA and Type II IGF receptor up-regulation during 
myogenesis has also been shown in culture for C2 muscle cells (Szebenyi & Rotwein 
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1991; Tollefsen et al. 1989b). Whether the simultaneous up-regulation of IGF-11 
mRNA and receptor are functionally related is unknown. Evidence for IGF-11 action 
through the Type II IGF receptor comes from studies in which an IGF-11 analogue with 
high affinity for the Type II IGF receptor was found to stimulate differentiation 
(Rosenthal et al. 1994 ), however additional evidence of such an action is lacking. 
Based primarily on results from knockout studies, the Type II IGF receptor is 
proposed to act as a "sink" for IGF-II by binding and internalisation of the growth 
factor (Haig & Graham 1991 ), however such a function would seem unlikely as it 
would directly counteract the up-regulation ofIGF-II during differentiation. The Type 
II IGF receptor has numerous activities other than growth factor binding and 
internalisation, including activation of TGF-P (Ghahary et al. 1999a; Ghahary et al. 
2000), and the trafficking and targeting of lysosomal enzymes (Kornfeld 1992). It has 
been proposed that in the adult the primary function of the Type II IGF receptor is the 
maintenance oflysosomal activity (Wang et al. 1994). Lysosomal activation has been 
reported to occur in developing primary rat muscle culture, denervated muscle and in 
muscular dystrophy (Libelius & Tagerud 1989). During muscle cell differentiation in 
culture, the increase in Type II IGF receptor number occurs alongside an increased 
proportion of lysosomal enzyme (P-hexosaminidase) in the intracellular versus 
extracellular compartments (Szebenyi & Rotwein 1991 ), suggesting that the Type II 
IGF receptor may function during differentiation to increase the efficiency of 
lysosomal enzyme targeting (Szebenyi & Rotwein 1991). 
In the present study, IGFBPs, as determined by the in vitro binding of 1251-IGF-I 
competed with unlabelled IGF-1 and des(l-3)1GF-I, were observed only in day 5 
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connective tissue, regenerating and survivor fibres. In day 5 connective tissue and 
survivor fibres, IGFBPs appear to account for the majority of the observed 1251-IGF-I 
binding, as competition of 1251-IGF-I binding with des(l-3)1GF-I, failed to displace 
1251-IGF-I binding. This finding of a significant contribution of IGFBPs to 
regenerating muscle tissues is supported by a recent study of IGFBP expression and 
localisation in post-ischaemic muscle, which showed that IGFBPs-4, -5, and -6 are 
up-regulated relative to control muscle on day 4 of regeneration (Jennische & Hall 
2000). The IGFBP expression reported by Jennische and Hall (2000) was found to be 
cell-type specific, with IGFBP-4 expressed predominantly in connective tissue, 
IGFBP-5 in regenerating cells, and IGFBP-6 in muscle cells and connective tissue, 
thus indicating IGFBP up-regulation in the same tissues that IGFBPs were reported in 
in the present study. The actions of IGFBPs can be either inhibitory or stimulatory, 
with inhibition of IGF action by IGFBPs primarily through reduced interaction with 
the Type I IGF receptor (reviewed by Hossner et al. 1997). Stimulation of IGF action 
by IGFBPs is thought to be due to formation of IGF-IGFBP complexes that associate 
with cell surfaces, often with a concomitant reduction in the affinity of IGFBP for IGF 
(Hossner et al. 1997). IGFBP-4 acts predominantly as an inhibitor oflGF-stimulated 
proliferation (Bayes-Genis et al. 2001; Duan & Clemmons 1998), IGFBP-5 as a 
potentiator of IGF-induced proliferation and an inhibitor of IGF-stimulation of 
differentiation (James et al. 1996), and IGFBP-6 as an inhibitor oflGF-11 induction of 
muscle cell differentiation (Bach et al. 1994). IGFBPs thus constitute additional 
mechanisms for fine-tuning the actions of IGFs during skeletal muscle regeneration. 
The differential localisation of IGFBPs in regenerating muscle may allow for 
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inhibitory effects on some tissues, such as connective tissue, alongside stimulatory 
actions on other tissues such as muscle. 
In the present trial an effect of GH on IGFBP levels, as determined by the in vitro 
binding of 1251-IGF-I competed with unlabelled IGF-1 and des(l-3)IGF-I, was not 
observed in M. biceps femoris. Similarly, skeletal muscle IGFBP-3 mRNA in pigs is 
unaffected by GH administration (Dunaiski et al. 1999), as is the case for an IGFBP 
(presumed to be IGFBP-4) in the same strain of dwarfrats as used in the present study 
(Lemmey et al. 1997). These findings are in contrast, however, to the observation of 
increased IGFBP-3 protein ( 42-48 kDa band), and presumably IGFBP-1 and/or -2 
protein (28-32 kDa band), in response to GH in dwldw rats (Lemmey et al. 1997), as 
well as the up-regulation of IGFBP-5 mRNA in hypophysectomised rats in response to 
GH administration (Gosteli-Peter et al. 1994). It is possible that the differences 
between the latter studies and the present study relate to sampling time, which in the 
present study was approximately 24-hours post GH injection. IGFBP mRNA levels 
have been shown to vary with time following GH administration, as exemplied by the 
increased 28-32kDa band (presumed to be IGFBP-1 and/or -2) by Western blot at 4 
hours, but not at 8 or 24 hours, following GH treatment (Lemmey et al. 1997). 
In the present study a low level oflGF-II mRNA over connective tissue was observed. 
Human foetal connective tissue expresses high levels of IGF-II mRNA, suggesting 
that it may provide a source of paracrine IGF-II for developing tissues (Han et al. 
1987). However, in adult sheep, IGF-II mRNA is undetectable in connective tissue 
(Hodges et al. 1992), a finding that supports our current observation. Low levels of 
IGF-II mRNA in connective tissue were noted at all stages of the regeneration process, 
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and were in contrast to the increased levels of IGF-1 mRNA observed during early 
regeneration (day 3). IGF-1 mRNA is transiently expressed in the healing wound 
(Steenfos & Jansson 1990), and is produced by fibroblasts in wound chambers 
(Steenfos et al. 1990) and in vitro (Clemmons 1984). IGF-1 protein in connective 
tissue during regeneration could serve as a local source of IGF-1 for regenerating 
muscle fibres, or as a source of IGF-1 protein for fibroblasts. During regeneration, 
IGF-1 may stimulate the proliferation of fibroblasts, as occurs in vitro in response to 
IGF-1 (Cook et al. 1988), and/or stimulate the synthesis of collagen, the major 
structural component of connective tissue (Kelley et al. 1990). IGF-1 stimulates 
collagen synthesis by lung-derived fibroblasts in vitro (Goldstein et al. 1989), a 
process that likely occurs in regenerating muscle as a part of the repair of 
intramuscular connective tissue and/or the synthesis of scar tissue. 
The rats used in this trial responded to exogenous GH with increased body weight, 
notexin-injected and non-injected muscle weights, an observation which is in accord 
with the growth enhancing effect of GH on body and skeletal muscle weights 
previously reported for normal and regenerating muscle (Clark et al. 1985; Ullman et 
al. 1989). However, despite these effects of GH, analysis of in situ hybridised 
notexin-injected and non-injected M. biceps femoris failed to reveal an effect of GH 
on IGF-1 or -II mRNA levels in any of the fibre types examined. In contrast to our 
findings, porcine muscle has increased IGF-1 mRNA in response to GH administration 
(Brameld et al. 1996), and skeletal muscle IGF-1 and -II mRNA is increased in 
response to GR-stimulated hypertrophy in GH3-tumour implanted rats (Turner et al. 
1988). It is possible that the discrepancy between this report and the present one is 
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that the sampling times used in this study may have missed an induction of IGF 
mRNA, for peak levels of tissue IGF-1 occur 12 hours after GH injection in 
hypophysectomized rats (D'Ercole et al. 1984). It would be interesting to examine 
IGF mRNA in regenerating muscle at earlier timepoints relative to the daily GH 
administration, ie. within 6-8 hours of GH treatment. 
Just as an effect of GH was not observed for IGF-1 and -II mRNA, an effect of GH on 
1251-IGF-I binding was not observed. The lack of an effect of GH on 1251-IGF-I 
binding is supported by the demonstration that in hypophysectomised and normal rats, 
identical patterns of 1251-IGF-I binding relative to regeneration stage are seen in both 
animals (Jennische & Matejka 1992). This indicates that the GH status does not 
significantly affect 1251-IGF-I binding during regeneration. 
In contrast to the above-mentioned lack of effect of GH on IGF mRNA and 1251-IGF-I 
binding, this study showed that binding of 1251-IGF-II to damaged muscle tissues is 
sensitive to GH. The fact that the growth promoting effect of GH was observed in 
both notexin-injected and non-injected muscles, but that the effect of GH on 1251-IGF-
II binding was observed in only the notexin-injected muscle, suggests that the GH 
effect on 1251-IGF-II binding was related to the regeneration process. Additionally, the 
effect of GH on 1251-IGF-II binding within the notexin-injected muscle tissues showed 
temporal variation, with a significant effect observed on day 5, but not on days 3 and 
13. The presence of antibodies to human GH following 9 days of GH administration 
to hypophysectomised rats has been reported, and it has been suggested that this could 
result in a decreased growth response (Groesbeck & Parlow 1987). This could explain 
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the lack of effect of GH on 1251-IGF-II binding after 13 days of GH treatment in the 
present trial, although this is considered unlikely as no such effect on growth rates 
following long term GH treatment was observed in this strain of dwarf rats. The 
difference between the two sets of observations may relate to the animal model used. 
The function of the up-regulated 1251-IGF-II binding in response to GH in notexin-
injected muscle tissues may involve modulation of lysosomal enzyme transport and 
uptake by the Type II IGF receptor (Kornfeld 1992; Roth 1988), as previously 
discussed in this section. Growth hormone administration to both hypopituitary 
dwarfs and normal subjects results m elevated lysosomal activity in 
polymorphonuclear leucocytes (Rovensky et al. 1985), thus suggesting that in the 
present study the increased binding to the Type II IGF receptor in GH-treated notexin-
injected muscle tissues may be related to alterations in lysosomal enzyme trafficking. 
In conclusion, this study has identified specific increases in IGF-1 and -II mRNA, IGF 
receptor binding, and indicated changes in the abundance of IGFBPs, during skeletal 
muscle regeneration. GH administration resulted in increased muscle weight of both 
notexin-injected and non-injected muscles, and elevated binding of IGF-11, but no 
changes in the histology of the notexin-injected muscle. This study suggests 
involvement of the IGF axis in skeletal muscle regeneration, and that GH may 
modulate the regeneration process in part through the IGF axis. 
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CHAPTERS 
LOCALISATION OF MYOSTATIN 
DURING MUSCLE REGENERATION 
5.1 Introduction 
While the focus of the previous chapter was IGFs, the focus of this chapter is 
myostatin. The study of both IGFs and myostatin was chosen because a) the 
coordinated expression of different growth factors is an integral part of muscle 
regeneration (Grounds 1991), and b) the balance of both positive (IGFs) and negative 
(myostatin) regulators, at least in part, determines net muscle growth. 
Myostatin, and the current body of literature concerning its role in muscle growth, was 
reviewed in Section 1.7.2. Key studies discussed therein showed that an absence of 
myostatin leads to a substantial increase in muscle weight in mice (McPherron et al. 
1997), while in vitro, the addition of myostatin results in an inhibition of myoblast 
proliferation (Thomas et al. 2000). 
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These studies strongly indicate a role for myostatin as a negative regulator of muscle 
growth, and raise the question of whether myostatin is differentially regulated in a 
situation of enhanced growth, such as following GH-stimulation; and whether levels 
of myostatin are temporally-regulated during regeneration, thereby suggesting a role 
for this protein during muscle regeneration. 
5.1.1 Aim of this Chapter 
The aim of the present study is to determine whether a negative regulator of growth, 
myostatin, is temporally regulated during muscle regeneration, and whether its levels 
are decreased in muscles undergoing enhanced growth due to the administration of 
GH. 
5.2 Materials and Methods 
5.2.1 Animals 
Twenty-one intact male Sprague-Dawley rats were used to determine regeneration in 
normal animals. Intact (non-castrated) rats were used for these normal rats, and for 
the study contained in CHAPTER 6, because GH was no longer being administered, 
thus testosterone was no longer considered a confounding factor (refer to Section 
4.2.1 ). At 60 days of age and weighing approximately 330g, these animals were 
anaesthetised with a solution of 5 mg/ml Rompun® (xylazine hydrochloride), 37.5 
mg/ml ketamine hydrochloride in sterile water (0.2 ml per 100g bodyweight), and the 
right M. biceps femoris injected with 2 µg notexin, as described in Section 4.2.1. The 
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dwarf (dwldw) rats used for this study were a subset (n=3/timepoint), chosen at 
random, of the animals studied in CHAPTER 4. 
5.2.2 Tissue sampling 
Normal rats were sacrificed, as described in Section 2.7.1, on days 1, 2, 3, 5, 9, and 13 
(n=3/timepoint). Contralateral muscles were used as regeneration controls, and three 
normal rats were sacrificed on day O as additional regeneration controls. Muscle 
samples were formalin-fixed for 18 hours prior to paraffin-embedding. Sections were 
cut to a thickness of 7 microns then placed on slides coated with 3-
aminopropyltriethoxysilane (Sigma-Aldrich, St. Louis, MO, USA). 
5.2.3 Immunohistochemistry 
Antibodies used for this study were the following: rabbit anti-bovine myostatin 
antibody, raised against amino acid sequence 201-370, which recognises the precursor 
and processed forms of myostatin protein (Sharma et al. 1999); the irrelevant 
antibody, rabbit anti-human a- lactalbumin; and non-immune rabbit immunoglobulin 
fraction were used to verify the specificity of myostatin immunohistochemistry; the 
monoclonal antibodies mouse anti-slow muscle myosin (slow MHC), and mouse anti-
fast muscle myosin (fast MHC) which recognises all Type II fibres, were used together 
to determine fast and slow fibre-types in muscle sections. The myostatin antibody 
used in these studies does not cross-react with other TGF-~ superfamily members, as 
determined by Western blot analysis of normal and Belgian Blue skeletal muscle 
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extracts (Sharma et al. 1999). Immunohistochemistry was performed according to 
the method described in Section 2.9. 
5. 2. 4 Statistics 
Muscle and body weights were adjusted for initial liveweight, then analysed using 




5.3.1 Characteristics of the regenerating muscle 
The regeneration of notexin-injected muscle in both normal and dw!dw rat muscle 
was similar, although the regeneration in normal rats tended to occur at an earlier 
time. This reduction in regeneration time was determined by analysis of histological 
sections which showed that a greater proportion of damaged fibres were at the 
myotube stage in normal rat muscle relative to dwldw rat muscle on days 3 and 5, as 
shown for day 3 in Figure 5-1. 
Figure 5-1. Regenerating muscle of dwldw and normal rats. 
Cross-sections of dwldw (A) and normal (8) rat M. biceps femoris on day 3 following notexin-
injection. Notexin-injected muscle from normal rats (8) contains occasional inunature myotubes 
(white arrow), in contrast to notexin-injected muscle from dwldw rats (A), which does not show 
signs of MPC fusion into myotubes. Haematoxylin and eosin stained, magnification=lOOx, bar= 
50 microns. 
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Notexin-injected muscle weights from normal rats are given in Figure 5-2, alongside 
the muscle weights for the subset of saline-treated dwldw rats from CHAPTER 4 that 
were used in this study. Notexin-injected muscle weights from normal rats changed 
significantly over time (p=0.005), with lowest levels on days 2 and 3, followed by an 
increase after that time (Figure 5-2A). In dwldw rats, notexin-injected muscle weights 
increased from day 9 onward (p<0.001, Figure 5-2B). The highly significant 
(p<0.001) changes in weight of both notexin-injected and non-injected muscles of the 
normal rat (Figure 5-2A), and non-injected muscles of the dw/dw rat (Figure 5-2B), 
were similar in pattern to the changes in body weight in the respective animals (Figure 
5-2C, D), although this was not the case for the notexin-injected muscles of dw/dw 
rats (Figure 5-2B). A pronounced systemic effect of notexin was observed in dwldw 
rats, as evidenced by decreased bodyweight up to day 5 (Figure 5-2; see also Section 
4.3.1), in contrast to normal rats which showed little sign of a systemic effect of 
notexin (Figure 5-2) with bodyweights that only decreased marginally between days 1-
2, then increased. 
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Figure 5-2. Muscle and body weights of normal and dwldw rats. 
Muscle (A,B) and body weights (C,D) following injection of notexin on day O in normal (A,C) and 
saline control dwldw rats (B,D). A, B: Weights of notexin-injected and non-injected muscles are 
shown by the open and solid circles, respectively. Values represent the means, the error bar 





§ 25 ..... 
.c 
Oil ·;:; 
~ 2.4 .. .. ., 



















0.6 B dwldw I 
0.5 
































0 2 4 6 8 10 12 14 
Day 
5-171 
5.3.2 Myostatin distribution within muscle tissue 
In non-injected normal and dw/dw rat muscle, myostatin was localised in the muscle 
fibre cytoplasm (Figure 5-3A,B, respectively), and was absent from the connective 
tissue (Figure 5-3A). Sections immunostained with non-immune rabbit IgG showed 
no immunostaining over connective tissue or muscle (Figure 5-3D), as was the case 
for all negative control sections in these studies. A similar distribution of myostatin to 
non-injected muscle was also observed for notexin-injected muscle, with three 
exceptions, all of which occurred during early damage and regeneration. Firstly, 
myostatin was observed in interstitial areas and connective tissue in heavily damaged 
areas at early timepoints following notexin injection (Figure 5-3C; Table 5-1). 
Interstitial and connective tissue myostatin was highest on day 1 and then declined 
until day 3 when it was absent. Secondly, although myostatin was mainly found in the 
cytoplasm of muscle fibres, it was occasionally also observed in the nuclei of fibres up 
to day 5. Lastly, myostatin was observed within some phagocytic cells during early 
damage ( data not shown), which possibly resulted from phagocytosis of necrotic 
tissue containing myostatin (Figure 5-3C,E,F). 
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5.3.3 Myostatin localisation . In necrotic and regenerating 
muscle fibres 
Distinct temporal variation in the intensity of myostatin immunostaining was observed 
in regenerating muscle fibres of both normal and dwldw rats (Table 5-1 ). Necrotic 
fibres contained high levels of myostatin protein on day 1 following damage (Figure 
5-3C). Myostatin protein within necrotic fibres then reached peak levels, and in the 
majority of fibres observed, stayed elevated until the necrotic debris was removed 
(Figure 5-3F; Table 5-1 ). A slight decrease from peak levels of myostatin 
immunostaining in necrotic fibres was noted in some normal rat necrotic fibres that 
were heavily infiltrated by phagocytes, but not in the necrotic fibres in the dwldw rat 
(Table 5-1, day 3). Mononucleate cells located in regenerating areas at the end of 
phagocytosis, when activated satellite cells are most abundant (Koishi et al. 1995), did 
not contain myostatin (Figure 5-3F). Similarly, myotubes initially did not contain 
myostatin protein (Figure 5-3G). There was then a slight but noticable increase in the 
intensity of myostatin immunostaining in regenerating myotubes (Figure 5-3H), an 
increase that occured more rapidly in normal rats than in dw/dw rats (Table 5-1). 
Specifically, some larger regenerating myotubes of the normal rat had increased 
myostatin at day 5, whereas the regenerating myotubes of dwldw rats did not show an 
increase in myostatin until day 9. 
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Figure 5-3. Myostatin localisation in regenerating muscle. 
Myostatin localisation in non-injected (A, B) and notexin-injected (C-H) muscle. Notexin-
injected muscle sections show the progression through necrosis and regeneration as follows: (C) 
and (D) are of early necrosis; (E) from mid to late necrosis; (F) from late necrosis/early 
regeneration; (G) from early to mid regeneration, at the onset of myotube formation; (H) from 
late regeneration. Sections were immunostained with anti-myostatin antibody (A-C, E-H) or 
matched normal rabbit non-immune immunoglobulin (D) then counterstained with nuclear fast 
red. Myostatin was localised in the muscle fibre cytoplasm in non-injected normal (A) and dwldw 
(B) muscle. During muscle necrosis, high intensity myostatin localisation was observed in 
connective tissue (ct, C) and necrotic muscle fibres (black arrowheads; C, E, F), but was absent 
from the mononucleated cells present during late necrosis (mn, F). Newly-formed myotubes 
(white arrowheads, G) also lacked myostatin protein, but showed increased intensity of myostatin 
immunostaining after further development (arrows, H). Negative control sections (D) had no 




Table 5-1. Myostatin immunoreactivity in damaged muscle tissues. 
Shown below are the relative levels of myostatin protein in skeletal muscle tissue types during 


























































The intensity of myostatin immunostaining was detennined on a scale of - to ++++, where ++++ 
represents the highest intensity. 









Myostatin expression has been shown by others (Carlson et al. 1999) to be fibre-type 
specific, as determined by the presence of myostatin mRNA in fast (Type 11b) fibres, 
and absence from slow (Type I) fibres. Therefore the association of myostatin with 
muscle fibre-type in notexin-injected and non-injected muscle was examined. Serial 
sections of non-injected rat muscle were immunostained with anti-myostatin, anti-
slow MHC and anti-fast MHC to reveal the presence of myostatin protein in fast, but 
not slow, fibres (Figure 5-4, A-C). Immunostaining of notexin-injected muscle with 
the same panel of antibodies, however, showed the presence of myostatin within not 
only fast fibres, but also slow fibres (Figure 5-4, D-F). This indicates that during 








Figure 5-4. The association of myostatin with muscle fibre-type. 
Sections (A-C) are from non-injected muscle, while sections (D-F) are from notexin-injected 
muscle. Serial sections of normal rat muscle were immunostained with antibodies to myostatin 
(A, D), fast MHC (B, E), and slow MHC (C, F) as detailed in Section 2.9. Positive 
immunostaining with anti-slow MHC, and negative immunostaining with anti-fast MHC, was 
used to identify slow muscle fibres (arrows). Myostatin immunostaining was absent from slow 
muscle fibres of non-injected (A), but not notexin-injected (D), muscle. Bar=IOO microns. 
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5.3.4 Myostatin localisation in survivor fibres 
Temporal regulation of myostatin levels was observed in the survivor fibres of normal 
and dwldw rats. Specifically, myostatin immunostaining in survivor fibres increased 
immediately after notexin treatment when compared with non-injected muscle in 
normal rats (Table 5-1 ). This was not observed in the survivor fibres of dw/dw 
damaged muscles. Both normal and dw/dw rat survivor fibres showed a decrease in 
the intensity of myostatin immunostaining on days 3-5, and a subsequent increase in 
the intensity of myostatin immunostaining on days 9-13. The changes in the intensity 
of myostatin immunostaining in survivor fibres during regeneration tended to be later 
in normal rats than in dw/dw rats. 
5.3.5 Effect ofGH on myostatin protein 
Although GH had a significant effect on the muscle mass of regenerated muscle 
(Section 4.3.1) no effect of GH-administration on the intensity or distribution of 
myostatin immunostaining was observed in these tissues. 
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5.4 Discussion 
This study describes the localisation of myostatin in the regenerating muscles of 
normal and dwldw rats. High levels of myostatin protein were observed in necrotic 
fibres and connective tissue during the damage phase, followed by a marked decline in 
myostatin concurrent with new fibre synthesis. Survivor fibres showed a notably 
different pattern of myostatin regulation from regenerating fibres. 
Histological analysis showed that the muscle regeneration that occurred in the GH-
deficient dw!dw rats was delayed relative to that of normal rats. Interestingly, the 
pattern of myostatin immunostaining in necrotic fibres/regenerating myotubes was 
similarly altered, as the decrease in the intensity of myostatin immunostaining 
observed in both normal and dw/dw rats took place earlier in the notexin-injected 
muscle of normal rats (day 3) relative to dw/dw rats (day 5). This observation of a 
similar pattern of myostatin localisation and expression in two strains of rats may 
indicate the importance of maintaining this pattern of myostatin expression in order to 
effectively regenerate damaged skeletal muscle. 
High levels of myostatin were associated with the earliest stages of the muscle repair 
process, when necrosis and phagocytosis were the primary activities taking place. 
Similarly, increased myostatin protein has been reported for M. extensor digitorum 
longus and M. soleus on days 1 and 3 following notexin-induced damage (Mendler et 
al. 2000). In the present study, not only was the elevated myostatin protein observed 
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m notexin-injected muscle fibres, it was also observed at high levels within 
connective tissue and interstitial areas. In a separate regeneration study, Yamanouchi 
et al. (2000) reported the presence of myostatin mRNA in presumed fibroblasts, and 
showed that when exposed to crushed muscle extract, cultured fibroblasts from rat 
muscle increased expression of myostatin mRNA. This shows that a cell type that is 
normally associated with connective tissue is responsive to one or more factor(s) in 
damaged muscle, and that this results in the synthesis of myostatin. Whether this is 
the means by which connective tissue-associated myostatin protein is increased, or 
whether it is due to an influx of myostatin from the circulation is not known. 
Myostatin protein has been identified in the circulation, and levels therein found to be 
increased in humans with AIDS-associated muscle wasting (Gonzalez-Cadavid et al. 
1998), however changes, if any, in circulating levels of myostatin, associated with 
regeneration, have not as yet been determined. That connective tissue might function 
as a "reservoir" for myostatin in damaged muscle might be expected, given that other 
TGF-~ family members have been shown to bind to extracellular matrix components 
(Munger et al. 1997). A proposed function for myostatin located within connective 
tissue is the enhancement of connective tissue deposition, as TGF-~ both enhances the 
synthesis, and down-regulates the proteolysis, of extracellular matrix components 
(Gleizes et al. 1997), and double-muscled cattle, which lack functional myostatin 
(Grobet et al. 1997; Kambadur et al. 1997; McPherron & Lee 1997), have decreased 
amounts of connective tissue (Arthur 1995). A second possibility is that high levels of 
myostatin protein within damaged muscle fibres and/or connective tissue may serve as 
a chemoattractant for phagocytes and inflammatory cells, or conversely as an inhibitor 
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of their proliferation, as has been reported for TGF-P (Adams et al. 1991; Ranges et 
al. 1987; Reibman et al. 1991; Wahl et al. 1987; Wahl et al. 1988). 
Of additional interest during this time was the altered association of myostatin 
expression with fibre type. Specifically, myostatin protein in control muscles was 
confined to a subset of fast fibres, however during early regeneration this pattern 
changed so that slow fibres also contained myostatin protein. Notexin affects muscle 
fibre innervation (Harris et al. 2000), and innervation in tum has a potent effect on 
fibre type (Yoshimura et al. 1998). As discussed in Section 1.5.4, this is demonstrated 
by the observation that regenerating muscle fibres lacking innervation become fast in 
fibre type, and that the return to a slow fibre type is not possible until innervation has 
been restored (Yoshimura et al. 1998). It may therefore be postulated that myostatin 
is localised within slow fibres of damaged muscle because of acute sensitivity of the 
myostatin regulatory elements and/or pathways to changes in innervation. Muscle 
denervation has been shown to have varying effects on myostatin protein levels as 
determined by Western blot analysis, with decreased myostatin protein in M. soleus (a 
slow-type muscle), and increased myostatin in M. gastrocnemius and M. plantaris 
(fast-type muscles) (Sakuma et al. 2000). Because the direction of changes in 
myostatin expression ( decreased myostatin in slow muscle) reported by Sakuma et al. 
(2000) for denervated muscle are opposite to those observed in the present study 
(increased myostatin in slow muscle fibres), it appears unlikely that the cause of the 
altered association of myostatin with fibre type in the present study is muscle 
denervation. This would be worthy of subsequent study, however, because the total 
protein levels as assessed by Western blot analysis in the Sakuma et al. (2000) study 
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are the sum total of changes in a number of histological tissue types, and may not 
represent specific changes in slow, damaged fibres alone. 
Myostatin is a key controller of C2C12 muscle cell proliferation in vitro, via 
inhibition of cell cycle progression (Thomas et al. 2000). Consequently, one might 
expect that myostatin levels would be low during a time of high MPC proliferation, 
thus allowing proliferation to proceed unhindered. Indeed, that is the pattern observed 
in this study, wherein myostatin immunostaining levels were low to non-existent in 
regenerating areas during the time of MPC proliferation, and absent from myotubes. 
Although slightly elevated from proliferation- and fusion-associated myostatin levels, 
myostatin protein in post-fusion fibres undergoing enlargement was still very low. 
Satellite cell proliferation, as indicated by the presence of MyoD (Koishi et al. 1995), 
is elevated in notexin-damaged rat muscle during the time of post-fusion fibre 
enlargement (Mendler et al. 1998). Although the period of fibre enlargement during 
regeneration is distinct from muscle hypertrophy, there are certain similarities, 
including increased satellite cell replication in order to maintain a constant nuclear 
domain (Goldberg et al. 1975; Hikida et al. 1997; Snow 1990). Myostatin has been 
reported to have a regulatory role in hypertrophic processes, as indicated by the 
presence of both hypertrophy and hyperplasia in myostatin null mice (McPherron et 
al. 1997), as well as hypertrophy, not hyperplasia, in mice expressing a dominant-
negative form of myostatin (Zhu et al. 2000). The observation of low myostatin 
during the phase of muscle fibre enlargement in the present study thus fits well with a 
role for myostatin in the regulation of hypertrophic processes (McPherron et al. 1997; 
Zhu et al. 2000). 
5-183 
In the survivor fibres of normal but not dwldw notexin-injected muscle there was a 
slight increase in myostatin immunostaining immediately after notexin treatment. 
This was followed by a decrease and then a rise in survivor fibre myostatin in both 
normal and dw/dw survivor fibres, however these changes occured later in the normal 
rats as compared to the dw/dw rats. The earlier changes in the pattern of myostatin 
immunostaining in dwldw survivor fibres did not appear to be associated with their 
lack of GH, as GH treatment failed to delay the pattern seen in dw/dw rats. 
Furthermore, the earlier pattern of changes in myostatin immunostaining in dw/dw rats 
did not appear to be associated with changes in muscle weight, as the dw/dw rats 
showed a delay in muscle growth relative to normal rats. This delay in muscle growth 
may have been because the area of damage was relatively greater in the dwldw rats as 
their muscle weights were less than half those of the normal rat muscle weights, yet 
they had identical doses of notexin. The greater weight of normal rats relative to 
dw/dw rats is also likely to account for the presence of a pronounced systemic effect of 
notexin in dw/dw rats, but not normal rats, due to the greater relative concentration of 
notexin per gram of bodyweight in the dw/dw rats. 
This study did not identify altered myostatin immunostaining associated with GH-
induced muscle growth in dw/dw rats. This is similar to the findings of Ji et al. 
( 1998), where GH administered to growing pigs did not alter the abundance of 
myostatin mRNA. There is no evidence of direct regulation of myostatin expression 
by GH, however a possible inter-relationship between myostatin and the GH/IGF axis 
is suggested by recent research. IGF-1 regulates the expression of myogenin, a 
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myogenic regulatory factor (MRF) involved in the terminal differentiation of skeletal 
muscle cells (Florini et al. 1991a), and the related MRF, MyoD (Lawlor & Rotwein 
2000). MRFs bind to E-boxes, and this binding is enhanced by the muscle-specific 
enhancer factor-2 (MEF-2) (Li & Capetanaki 1994). Sequence analysis has identified 
both an E-box and a MEF-2 binding site in the upstream region of the bovine 
myostatin gene (Jeanplong et al. 1999), thereby suggesting that IGF-1 could indirectly 
affect myostatin expression via MRFs. GH administration can lead to up-regulation 
of locally produced IGF-1 in muscle (lsgaard et al. 1989), however in the dw/dw rats in 
this study, GH administration did not affect the levels oflGF-1 or myostatin in muscle 
(see CHAPTER 4). Therefore, the results of the present study can neither confirm nor 
discount an association oflGF-1 with myostatin expression. 
The results from these studies indicate a role for myostatin in the regeneration of 
skeletal muscle, and suggest that it may serve more than one function during this 
process, including possible functions as a chemotactic agent and/or as a regulator of 
connective tissue deposition. 
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CHAPTER6 
EFFECT OF IGF-11 ON SKELETAL 
MUSCLE REGENERATION 
6.1 Introduction 
Skeletal muscle regeneration 1s a process that figures into many physiological 
situations, including sports injuries (Armstrong et al. 1991), reconstructive surgery 
(Arnold et al. 1994), and severe trauma. In these situations it is important that 
regeneration proceeds in a timely and efficient manner, and that the full complement 
of muscle is regenerated in order to restore full function. For this reason there is 
interest in developing therapeutics capable of enhancing the regeneration of skeletal 
muscle. 
As discussed in detail in Section 1.5, skeletal muscle regeneration consists of a series 
of sequential steps. Therapeutic agents can be developed to target one or more of 
these steps. A number of peptides and growth factors have been used to date in 
regeneration studies. A summary of the relevant studies is given in Table 6-1, 
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showing the administered growth factor(s) and their effects on major regeneration 
processes. It is clear that administration of individual growth factors can, and often 
does, affect more than one step of the regeneration process (Lescaudron et al. 1999; 
Menetrey et al. 2000; Miller et al. 2000). 
Two opposing therapeutic approaches have been taken in the studies listed in Table 
6-1, one of which is to increase growth factor levels by administering the peptide 
directly, and the other is to eliminate the naturally occurring peptide of interest by 
administering an antibody directed against it (Lefaucheur et al. 1996; Lefaucheur & 
Sebille 1995c )). Antibodies have the advantage of an often longer half-life within the 
body, however they carry the disadvantage of causing both enhancing and inhibitory 
effects when administered (Dijiane et al. 1985; Massart et al. 1993), thus potentially 
clouding the assertions made regarding the activity of the peptide of interest in vivo. 
As shown in Table 6-1, significant effects of growth factor administration on the 
regeneration process have been reported for both single injection (Lefaucheur & 
Sebille 1995a) and continuous infusion (Barnard et al. 1994) methods, although 
continuous infusion of growth factor is frequently used due presumably to concerns 
that a single injection of peptide would not provide peptide at later timepoints, when it 
might have a biological effect, due to loss from the regenerating area. 
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Table 6-1. Effect of growth factors on muscle regeneration. 
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Peptide administration 
Mitchell et 
bFGF Mil and CR NR 
al. (1996) 
NR NR NR B 
Menetrey et bFGF t t 
al. (2000) IGF-1 Mil NR NR NR t t 
NGF B B 
Miller et al. 
HGF 
Mil early 
NR t* ,I..* NR torB (2000) Mil late B 
Lescaudron MIP 1-[3 In vitro t t B 
NR 
B 
et al. (1999) VEGF conditioning t t t t 
Barnard et 
LIF CR t# NR NR NR t 
al. (1994) 
Lefaucheur 
& Sebille bFGF Sil NR t NR NR t 
(1995a) 
Antibody administration 
Lefaucheur IGF-1 ,I.. 
& Sebille bFGF Sil NR NR NR NR ,I.. 
(1995c) TGF-[31 t 
Lefaucheur IGF-1 t 
et al. (1996) bFGF Sil ,I.. NR NR NR NR 
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• assayed in vitro. 
# effect indicated but not measured 
Abbreviations: LIF, leukaemia inhibitory factor; HGF, hepatocyte growth factor; bFGF, basic 
fibroblast growth factor; NGF, nerve growth factor; MIP-1[3, macrophage inflammatory protein 1-beta; 
MPC, muscle precursor cell; NR, not reported; Mil, multiple intramuscular injection; Sil, single 
intramuscular injection; CR, continuous release; t, enhancement of regeneration process; ,I.., inhibition 






















In the previous two chapters, temporal and histological regulation of growth factor 
expression during the regeneration of skeletal muscle was reported. Among these 
changes was a dramatic up-regulation of IGF-II mRNA in newly-formed myotubes 
(CHAPTER 4). Further, the increased IGF-II mRNA was in regenerating muscle 
fibres, but not survivor fibres, connective tissue, or undamaged muscle fibres, 
suggesting that the provision of high amounts of IGF-II locally is important for 
skeletal muscle regeneration, and that the IGF-II protein is likely to function in an 
autocrine/paracrine fashion during regeneration. In the elegant study of Stewart et al. 
(1996), the overexpression of autocrine IGF-II by C2 myoblasts resulted in an 
advancement of the onset of differentiation. This study combined with earlier 
findings (CHAPTER 4) raised the possibility that if exogenous IGF-II were 
administered locally during skeletal muscle regeneration, that the timing of myogenic 
differentiation could be advanced. 
In CHAPTER 4, an up-regulation of IGF-II at the time of MPC fusion was observed, 
but not an upregulation of IGF-II concurrent with the period of MPC proliferation. 
Studies by others (Bach et al. 1995; McFarland et al. 1993; Minniti et al. 1995) 
however have clearly shown an effect of IGF-II on myoblast proliferation, via 
interactions with the Type I IGF receptor (Ewton et al. 1987). These in vitro studies 
suggested that if exogenous IGF-II were supplied at the time of MPC proliferation, it 
might positively affect that step. Therefore, in this trial the effect of IGF-II on the 
process of MPC proliferation, as well as fusion, will be examined. 
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The IGF axis, which includes not only the growth factors IGF-1 and IGF-11, but 
receptors and binding proteins as well, is tightly regulated by way of positive and 
negative feedback loops between the various components. For instance, GH down-
regulates its own secretion via negative feedback (Hashimoto et al. 2000), while IGF-
1, IGF-11 and high concentrations of insulin down-regulate IGF-11 at the transcriptional 
level (Magri et al. 1994). Similarly, IGF-11 down-regulates the Type I IGF receptor, 
via transcriptional down-regulation and increased receptor degradation (Rosenthal & 
Brown 1994; Rosenthal et al. 1991). Such an IGF-11-induced down-regulation of the 
Type I IGF receptor could have a significant effect on the timing of differentiation of 
myogenic cells, as suggested by studies showing an advancement of differentiation 
with Type I IGF receptor overexpression (Quinn & Haugk 1996; Quinn et al. 1994), 
or a delay with functional inactivation of the Type I IGF receptor (Cheng et al. 2000). 
As stated in the introduction (Section 1.6.1 ), two members of the MRF family of 
transcriptional regulators, MyoD and myogenin, are frequently used as markers of 
myogenic proliferation and differentiation processes. MyoD is localised within 
proliferating MPC, while myogenin is one of the earliest markers of differentiation. 
These markers have been employed in the ensuing study in order to precisely 
determine the effects of administered IGF-11 on proliferation and early differentiation 
events. Developmental MHC ( dMHC), an embryonic/neonatal form of MHC that is 
not normally expressed in adult muscle, but is expressed during regeneration, is used 
in this study as a later marker of differentiation, for dMHC has been shown to persist 
in damaged rat muscle until at least 7 days after damage (St. Pierre & Tidball 1994). 
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6.1.1 Aim of this chapter 
The aim of this chapter is to test the hypothesis that administration of IGF-II during 
skeletal muscle regeneration advances regeneration. This will be determined by 
exammmg: 
a) MPC proliferation and differentiation 
b) muscle fibre size. 
6.2 Materials and Methods 
6.2.1 Alzet pumps 
Two methods were considered for the administration of IGF-II, namely a single 
intramuscular injection or continuous infusion. Single injections of polypeptide 
during regeneration have been used with success by others (Lefaucheur & Sebille 
1995a), however continuous polypeptide infusion was preferred, as it is unlikely that a 
single dose of polypeptide would remain throughout the 7-day time period under 
examination. A sampling period of up to 7 days was chosen so as to include the 
periods of MPC proliferation, MPC fusion and muscle fibre enlargement during 
notexin-induced regeneration in these Sprague-Dawley rats. 
Localised, as opposed to systemic, peptide administration was chosen because 
previous work (see CHAPTER 4) showed high levels of IGF-II within regenerating 
fibres, suggesting that local production of IGF-II is important during muscle 
regeneration. The options available for the local delivery of peptide included 
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impregnated polymers (Langer & Folkman 1976; Mitchell et al. 1996), microspheres 
(Lee et al. 1997), and miniosmotic pumps (Alzet pumps; Alza Corporation, Mountain 
View, CA). Miniosmotic pumps were chosen for use in this study for the following 
reasons: a) they are the best characterised of the three options; b) Alzet miniosmotic 
pumps have been frequently used to administer IGF-II (Conlon et al. 1995; Shaar et 
al. 1989; Spencer et al. 1996), including over periods of 14 days (Conlon et al. 1995), 
and often with a significant treatment effect ofIGF-II (Conlon et al. 1995; Shaar et al. 
1989). A seven-day Alzet miniosmotic pump that was suitable for implantation in rats 
(Model 1007D) was therefore chosen for this study. Pumps were fitted with single 
lumen, vinyl catheters (SV55 tubing, inner diameter 0.80mm, outer diameter 1.20mm; 
Dural Plastics and Engineering, Dural, NSW, Australia) so that they did not lie 
directly over the damaged/regenerating muscle (possibly causing further damage). 
Catheters were cut to length then fitted with a "cuff' to ensure that the catheter stayed 
in place. Cuffs were made by attaching 2 small rings of SV102 (inner diameter 
1.40mm, outer diameter 1.90mm, single lumen vinyl tubing; Dural Plastics) 
approximately 2 mm apart, two-thirds of the way along the length of the catheter. The 
catheter was then autoclaved, allowing for 25% shrinkage. To attach the catheter 
tubing, the plastic portion of the flow moderator was crushed with scissors or pliers 
and disposed of. The catheter tubing was then attached to the end of the metal flow 
moderator tube, and secured with Loctite adhesive (Loctite Australia, Caringboh, 
NSW, Australia). 
On the afternoon prior to surgery, both the pump assembly, and the flow moderator 
with attached catheter, were filled with a 0.29 ug/ul solution of recombinant human 
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IGF-11 (OM-001, lot EJI-001, GroPep Pty Ltd, Adelaide, Australia; reconstituted to 
lmg/ml in lOmM acetic acid) diluted in RPMI 1640 media, or diluent only (controls). 
After filling each component (the pump and the flow moderator/catheter), the two 
parts were fitted together. If the pumps are being used with catheters, or if immediate 
peptide delivery is desired, the manufacturers recommend that the filled Alzet pumps 
be pre-incubated in saline for 4-6 hours at 37°C, or preferably overnight, prior to use 
(Alzet miniosmotic pump instruction and specification sheet). Therefore, for this 
study the filled pump and catheter assemblies were stored at 37°C in sterile 0.9% 
saline overnight, in order to start the pumps flowing. 
The concentration of IGF-11 used in this study was 0.29 ug/ul. The flow rate of the 
Alzet pump model 1007D was 0.5 ul/hr over a period of 7 days, therefore the IGF-11 
filled pumps used in this study delivered 0.145 ug IGF-11/hr, or 3.48 ug IGF-11/day. 
This particular IGF-11 concentration was chosen because earlier work by Conlon et al. 
(1995) showed that administration of 5.87 ug IGF-11/g bodyweight/day (=2.93 ug/0.5 g 
bodyweight/day) from subcutaneously implanted Alzet pumps to young rats resulted 
in significant effects on body weight gain and feed conversion efficiency. The amount 
of tissue affected by injection of 1 Oul of notexin was unlikely to exceed 0.5 g, as 
deduced by the fact that injection of 10 ul of methylene blue dye into non-viable rat 
muscle affects only 0.11 g of tissue. Local administration of IGF-11 would have a 
small amount of peptide loss due to diffusion to tissues other than the regenerating 
muscle, so that with these factors taken into account, the concentration used in this 
study approximates the concentrations used in the study by Conlon et al. (1995). 
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6.2.2 Surgical procedures 
Seventy-five male Sprague-Dawley rats were housed in the Small Animal Colony of 
Ruakura Agricultural Research Centre. At approximately 7 weeks of age, 70 rats were 
anaesthetised with a solution of 5 mg/ml Rompun® (xylazine hydrochloride), 37.5 
mg/ml ketamine hydrochloride in sterile water (0.2 ml per 100g bodyweight) then 
operated on to inject notexin and implant the Alzet pumps. Surgical manipulations 
began with the making of two incisions: one on the dorsal region on the right side of 
the body and slightly anterior to the M. biceps femoris, and the second directly over 
the M. biceps femoris. These two incisions were referred to as "DI" ("dorsal 
incision") and "BFI" ("biceps femoris incision"), respectively. The catheter portion of 
the pump/catheter assembly was fed through the DI out through the BFI as shown in 
Figure 6-1 A and B. The pump was sited just to the side of the DI (Figure 6-18), and 
the DI closed with 9mm autoclips (Clay Adams, Becton-Dickinson, Franklin Lakes, 
NJ) (Figure 6-1 C). The catheter was secured in place with polypropylene suture 
thread (Prolene blue monofilament with attached RB-1 taper needle, Johnson and 
Johnson, Janssen-Cilag Pty. Ltd., Newmarket, Auckland, New Zealand) within the 
cuff (see above) and approximately 1 cm above that, then the end of the catheter cut at 
an angle so that the angled end sat directly over the muscle (Figure 6-1 D and E). A 
loop was placed in the catheter, to allow the rat freedom of movement without 
dislodging the pump/catheter assembly (Figure 6-1 E). Figure 6-1 F shows the 
microsyringe (50 µl gastight microsyringe, 005229, SGE, Melbourne, Australia) with 
attached Luer-Lok microlance needle (26 gauge x 13mm, Becton-Dickinson) and 
11.5mm long vinyl tubing sleeve (0.028mm inner diameter, 0.046mm outer diameter, 
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VX028, No 6129; Becton-Dickinson) that was used to administer the notexin. The 
sleeve was fitted onto the needle to prevent the notexin from being delivered too deep 
in the muscle, as it was critical in this trial to have the regeneration occurring as close 
as possible to the site of IGF-II/diluent administration. The lOul volume of notexin 
was injected into the right M. biceps femoris directly under the angled end of the 
catheter tubing (Figure 6-1 G). Finally, the BFI was closed with wound clips (Figure 
6-1 H). Rats were kept in a warm room until actively moving (approximately 45 
minutes). Rats were walking normally and bearing weight on both legs without 
favouritism, as well as eating and drinking, within 2.5 hours of surgery. 
6-195 
Figure 6-1. Alzet pump implantation and notexin injection. 
(A) The catheter attached to the Alzet pump ("pump") was fed through from the dorsal incision 
(DI) and out through the incision over the M. biceps femoris (BFI). (B) The pump was sited just 
to the side of the (DI), then (C) the DI closed with wound clips. (D, E) The pump and catheter 
assembly was secured in place, and the notexin injected (F, G) using a modified 







6.2.3 Sampling and tissue processing 
Animals were sacrificed by CO2 gas followed by cervical dislocation on days 0-7, 5 
rats per treatment per timepoint. Prior to dissection of the leg muscles, the Alzet 
pumps were carefully removed from the flow moderator plus catheter assembly. 
Using a marker pen (Stephen's Vivid permanent waterproof marker, Bic NZ Ltd, 
Auckland, New Zealand), the site of peptide delivery/notexin injection was marked on 
the right M. biceps femoris. The catheter assembly and associated sutures were then 
cut away, and both right and left biceps femoris muscles dissected away from the 
hindlimb. Muscle tissue was both frozen for immunohistochemistry, and formalin-
fixed, paraffin-embedded for routine histological staining, as described in Section 2. 7. 
6.2.4 Immunohistochemistry 
Immunohistochemistry was utilised to identify the presence of myogenic proteins 
(MyoD, myogenin and dMHC), as markers of proliferation and differentiation, in 
regenerating muscle sections. The reason for choosing a microscopic approach over 
methods such as Northern or Western analysis, where tissues are ground up prior to 
analysis, is that the former method allows for the study of areas of similar damage. 
The core of damage (refer to Section 3.1.3) was chosen for examination in all facets of 
this trial because of its proximity to the site of peptide administration. The core of 
damage represents the site where notexin is most abundant, ie. the site of injection. 
This site was purposefully located just below the site of peptide infusion, in order to 
optimise for peptide effects on regenerating muscle tissue. 
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Cross-sections of regenerating muscle tissue were carefully sectioned in order to 
obtain an optimal core of damage. These tissue sections were then incubated with 
MyoD, myogenin and dMHC antibodies according to the protocol listed in Section 
2.9. Nuclei that were positive or negative for a given marker were quantitated, using 
the Scionlmage system (refer to Section 2.11.3). Five areas, generated by random 
coordinates, were counted for each animal. These values were then used to yield the 
percent positive nuclei per total nuclei. 
6.2.5 Fibre area 
The purpose of this analysis was to determine the size of regenerated fibres at the last 
timepoint ( day 7). Images of regenerating muscle were captured from the core of 
damage in sections that had been immunostained with dMHC antibody. The captured 
images (one per animal) were obtained using the Olympus BX-50 microscope fitted 
with a 5.0x photo eyepiece and lOx objective, which was attached to the Scionlmage 
system (as described in Section 2.11.3). To determine regenerating fibre size in the 
Scionlmage programme, individual fibres were outlined using the freeform selection 
tool, then the "measure" command used to generate the fibre area (in pixels). The 
counted fibres were numbered and the data recorded for each individual fibre. The 
number of regenerating fibres analysed per animal ranged from 31 to 89. A 
conversion factor of 2.46 x 10-7mm2 /pixel was used to convert the data to actual 
numbers. 
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6.2.6 Type 1 receptor autoradiography 
Receptor autoradiography was performed, as detailed m Section 2.10, on frozen 
muscle sections taken one day after notexin-injection. Muscle sections were 
incubated with 1251- rh IGF-1 alone or in the presence of unlabelled competing peptides 
including the following: 1 µg/ml (rh) N-Met IGF-1, 1 µg/ml des(l-3) IGF-1, 1 µg/ml 
rh IGF-11, or 10 ng/ml bovine insulin. Macroautoradiographic analysis of the 
incubated section images on XAR film showed no difference in the displacement of 
1251-IGF-I binding by unlabelled des(l-3)-IGF-I versus unlabelled IGF-1, indicating 
that the binding observed was to receptor and not binding protein. Grain counting to 
determine Type I IGF receptor levels was performed as detailed in Section 2.11.3. 
6.2. 7 Statistics 
Body and muscle weights were adjusted for initial liveweight, then analysed by 
ANOVA for the overall effect of time and treatment. Values shown are means ± 
SEM. 
MyoD, myogenin, and dMHC data were log-transformed then analysed by Student's t-
test for differences at individual timepoints, or by ANOV A to determine overall 
effects. Day 1 values were omitted from myogenin and dMHC overall analyses due to 
high "zero" components in the data sets. Values shown for MyoD, myogenin and 
dMHC are least squares means, and the errors shown are SEMs. 
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Fibre area and receptor autoradiography data were analysed by Student's t-test, and 
the values given are means ± SEM. 
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6.3 Results 
6.3.1 Body and muscle weights 
The body weights of notexin-injected rats changed significantly (p<0.001) over time, 
with a decline to day 2 values, then a steady increase in weight over the remaining 
days (Figure 6-2). By days 6/7, bodyweights were similar to day O (pre-treatment) 
values. There was no significant effect of IGF-II on body weight, and no interaction 
of IGF-II treatment with time. 
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Figure 6-2. Effect of IGF-11 on body weight. 
Body weights of IGF-11 treated and control rats following administration of notexin at time Oare 
shown. Control<•> and IGF-11 treated (•)values are means (n=4-5), bars indicate one SEM. 
6-205 
8 
Non-injected muscle weights changed significantly (p=0.004; Figure 6-3) over time 
following notexin administration. Non-injected muscle weights decreased between 
days O and 1, remained low until day 4, and then gradually increased through to day 7. 
There was no significant difference in non-injected muscle weights between IGF-Il 
and control groups at any timepoint, or overall, nor any interaction of treatment with 
time. 
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Figure 6-3. Effect of IGF-11 on non-injected muscle weights. 
Non-injected M. biceps femoris weights following administration of notexin at time 0. Control 
<•> and IGF-11 treated (•)values are means (n=4-5), and the bar indicates one SEM. 
Notexin-injected muscle weights changed significantly (p<0.001; Figure 6-4) over 
time after damage on day 0. Notexin-injected muscle weights showed an initial 
increase on day 1, a sharp decline to day 2 values, then little change through to day 7. 
As was the case for non-injected muscle weights, there were no differences in notexin-
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injected muscle weights between IGF-II and control groups at any timepoint, or 
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Figure 6-4. Effect of IGF-11 on notexin-injected muscle weights. 
Notexin-injected M. biceps femoris weights following administration of notexin at time 0. Control 
(•)and IGF-11 treated (•)values are means (n=4-5), and the bar indicates one SEM. 
6.3.2 Muscle histology 
The timecourse of muscle regeneration, within the core of damage in animals that 
were not treated with IGF-II, is depicted in Figure 6-5. In undamaged (day 0) animals 
fibres are whole, and contain low numbers of mononucleate cells (Figure 6-5A), 
however by day 1 in notexin-injected control muscle, substantial numbers of 
infiltrating phagocytic and inflammatory cells are observed both within and outside of 
muscle fibres (Figure 6-5B). Approximately 50% of damaged muscle fibres in control 
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animals showed signs of phagocytic infiltration, and considerable necrotic fibre 
cytoplasm fragmentation was observed. Day 2 control muscles (Figure 6-5C) 
contained large accumulations of mononucleate cells, with low to moderate amounts 
of necrotic debris. Fusion was first observed on day 3 following notexin-injection 
(Figure 6-5D), with high levels of myotube formation occurring on both days 3 and 4, 
such that the bulk of the regenerated myofibres had been formed by day 4. Myotube 
enlargement occurred between days 5-7, with the myotube diameter at day 7 still less 
than that of survivor fibres (Figure 6-5E). 
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Figure 6-5. Muscle regeneration in control animals. 
(A) shows undamaged (day 0) muscle fibres prior to notexin injection. On day 1 following 
notexin-injection (B), muscle fibres are both infiltrated (white arrow) or non-infiltrated (black 
arrow) by phagocytic cells. By day 2 of damage (C), mononucleate cells, often in the absence of 
necrotic debris, are seen in the heavily damaged areas, and by days 3 and 4 (D; day 3 shown) 
immature myotubes are evident (black arrows). (E) By day 7 after notexin-injection, 
regenerating myotubes (black arrows) have enlarged, but are still smaller in diameter than the 
survivor fibres (white arrow). Haematoxylin and eosin stain; magnification = 50x, bar = 100 
microns. 
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Regeneration of the two treatment groups was compared histologically by examining 
haematoxylin and eosin stained sections of regenerating muscle. There was no 
histological difference in the rate of muscle regeneration between IGF-II and control 
groups on day 1 after damage, as both groups contained approximately 50% infiltrated 
fibres. However by day 2 there were obvious differences in the regenerating muscle, 
as shown in Figure 6-6. Day 2 control tissues had considerably higher numbers of 
mononucleate cells with the morphological appearance of MPC (refer to Section 
3.1.3) present in the regenerating areas. Conversely, the IGF-II treatment group 
contained considerably fewer mononucleate cells, and of these mononucleate cells, 
many appeared to be phagocytic, as assessed by their cellular morphology (multi~ 
lobed nuclei with extensive cytoplasm (polymorphonuclear leucocytes), or cells with a 
much greater cytoplasm to nuclear ratio than is found in MPC (macrophages)). 
Furthermore, the IGF-II treated regenerating muscle contained higher amounts of 
necrotic debris relative to the control group (Figure 6-6), consistent with the greater 
proportion of phagocytic cells present in the IGF-II treated muscle. 
6-210 
Figure 6-6. Histology of control and IGF-11-treated regenerating muscle. 
Sections of control (A) and IGF-11 treated (B) muscles on day 2 of regeneration are shown. 
Regenerating muscle sections of control rats (A) have high numbers of mononucleate cells with 
the morphological appearance of MPC, and sparse necrotic debris, while IGF-11 treated (B) 
muscles have a high proportion of cells with the morphological appearance of phagocytes, and 
greater amounts of necrotic debris. Haematoxylin and eosin stain, magnification 50x, bar= 100 
microns. 
6.3.3 MyoD 
MyoD was used as a marker of proliferating MPC in this study. Immunocytochemical 
staining of muscle sections showed changes in the number of nuclei positive for 
MyoD during the process of muscle regeneration. Specifically, MyoD positive nuclei 
were observed infrequently in undamaged (day 0) muscle sections. In regenerating 
muscle from day 1 onwards, MyoD protein was observed in mononucleate cells 
(Figure 6-7) either in the presence or absence of necrotic debris. The proportion of 
nuclei that were positive for MyoD protein was less than that observed for either 
myogenin or dMHC. MyoD protein was never observed in myotube nuclei, however 
after substantial myotube formation, MyoD( +) mononucleate cells were often 
observed closely aligned to myotubes, presumably m satellite cells. 
6-211 
Immunohistochemistry usmg this particular protocol did result in low level 
background staining, staining that was also observed in negative control sections 
(Figure 6-7), and so considered to be non-specific. This light background staining 
was easily distinguished from the specific nuclear staining of MyoD, and never 
interfered with the detection of MyoD positive nuclei. 
Figure 6-8 shows the frequency of MyoD protein m the core of damage of 
regenerating muscle in treated and control rats over the period of days 1-4. This time 
period was chosen for an examination of MyoD, myogenin and dMHC levels because 
it included virtually all proliferation and differentiation events in these tissues. MyoD 
positive nuclei were counted, then expressed as a percentage of total nuclei, in order to 
determine the effect of IGF-II on the proliferation of MPC. The results of this 
quantitation show that there was a significant change over time (p<0.001), with an 
increase up to day 2 in the percentage of nuclei that contain MyoD protein, after which 
time levels decreased. On day 1 there is less MyoD protein in the IGF-II treated group 
relative to the control group (p= 0.057; Figure 6-7 and Figure 6-8). 
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Figure 6-7. Localisation ofMyoD protein. 
MyoD immunohistochemistry in day 1 regenerating muscle of control (A) and IGF-11 (B) treated 
animals. MyoD protein (arrows) was localised within nuclei in regenerating areas. Negative 
control sections (C,D) were devoid of nuclear staining. The proportion of nuclei that contained 
MyoD protein was greater (p=0.057) in control versus IGF-11-treated muscles. Sections were 
counterstained with haematoxylin. Magnification lOOx, bar=40 microns. 
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Figure 6-8. Proportion of MyoD positive nuclei. 
MyoD protein expression in regenerating muscle of control ( •> and IGF-11 ( •) treated rats. 
Values are means (n=3-5) ± SEM. + indicates significance (p=0.057) between control and IGF-11 
treatment groups for the timepoint shown. 
6.3.4 Myogenin 
Myogenin protein was present only occasionally (approximately 1 per 250 nuclei) in 
undamaged ( day 0) muscle. These myogenin positive nuclei were near the periphery 
of muscle fibres, suggestive of localisation within satellite cells. In damaged muscle, 
virtually all myogenin was contained within the nuclei of mononucleate MPCs (Figure 
6-9). After fusion, myogenin protein was sometimes observed in very immature 
myotubes, within the cytoplasm and less often within the myotube nuclei. Larger, 
more mature myotubes did not contain myogenin protein. 
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Myogenin positive nuclei in mononucleate MPC in day 1-4 regenerating muscle were 
counted within the core of damage, and expressed relative to total nuclei, the results of 
which are shown in Figure 6-10. The percentage of nuclei that were positive for 
myogenin changed significantly over time (p<0.001) with an increase up to day 3, 
followed by a decrease to day 4 values. Minimal numbers of myogenin positive 
nuclei were observed in day 1 tissues, as only one of the five control muscles had non-
zero values, while all IGF-II treated rat muscles yielded zero values when counted. 
Because of the low numbers of myogenin positive nuclei observed on day 1, these 
values were omitted from the overall statistical analysis of myogenin data. On day 2, 
prior to the peak in myogenin values, IGF-II treated muscle had significantly less 
(p=0.034) myogenin protein than control muscle (Figure 6-9 and Figure 6-10). No 
significant effect oflGF-II treatment on myogenin protein was observed on days 3 or 
4. 
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Figure 6-9. Localisation of myogenin protein. 
Myogenin immunohistochemistry in muscle sections of control (A) and IGF-11- (B) treated 
animals 2 days after notexin treatment. Myogenin protein was localised almost exclusively within 
nuclei of mononucleate MPC (arrows indicate examples of myogenin positive nuclei) within 
regenerating areas in the first 4 days following damage. Negative control sections are shown in 
(C) and (D) for control and IGF-11 animals, respectively. Sections were counterstained with 
haematoxylin. Magnification lOOx, bar=40 microns. 
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Figure 6-10. Proportion of myogenin positive nuclei. 
Myogenin protein expression in regenerating muscle of control <•) and IGF-11 ( & ) treated rats 
on days 1-4 after notexin-injection. Values are means (n=3-5) ± SEM. * indicates significance 
(p=0.034) between control and IGF-11 treatment groups for the timepoint shown. 
6.3.5DMHC 
No dMHC protein was observed in undamaged fibres, or in day 1 damaged muscles. 
By days 2 and 3 however, dMHC was observed in individual nuclei in regenerating 
areas (day 3, Figure 6-1 lB). As regeneration proceeded, dMHC became localised 
within the cytoplasm, but not in the nuclei, of regenerating myotubes (Figure 6-11 A). 
hnmunostaining with dMHC antibody identified a very flattened morphology within 
the early regenerated myotubes. These early myotubes stained particularly intensely 
for dMHC protein. Immunostaining with the dMHC antibody within the core of 
damage clearly showed the presence of newly regenerated myotubes that appeared to 
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be using earlier, larger regenerated myotubes as a scaffold. For quantitation purposes, 
nuclei were considered dMHC positive if they fitted either of the following criteria: a) 
they were dMHC(+) mononucleate cells, orb) they were myonuclei contained within 
newly regenerated dMHC positive myotubes. 
The results of the quantitation of dMHC protein in regenerating muscle sections are 
shown in Figure 6-12. This figure shows that the percentage of dMHC positive nuclei 
changed significantly over time (p<0.001), with a sharp rise in dMHC positivity up to 
day 3, followed by a more gradual increase to day 4. Analysis of day 3 dMHC values 
revealed a significant (p=0.047; Figure 6-11, Figure 6-12) decrease in the percentage 
of dMHC positive nuclei in IGF-II treated muscles relative to control muscles, while 
days 2 and 4 showed no significant difference between the two treatment groups. 
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Figure 6-11. Localisation of dMHC protein. 
Immunolocalisation of dMHC protein in regenerating muscle sections of control (A) and IGF-11-
(B) treated animals 3 days after notexin injection. DMHC protein was detected in the nuclei of 
mononucleate cells during early regeneration (white arrow), and almost exclusively in the 
cytoplasm of myotubes (black arrows) in tissues that were further along in the regeneration 
timecourse. Negative control sections are shown in (C) and (D) for control and IGF-11 animals, 
respectively. Sections were counterstained with haematoxylin. Magnification lOOx, bar=40 
microns. 
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Figure 6-12. Proportion of dMHC positive nuclei. 
DMHC protein expression in regenerating muscle of control <•) and IGF-11 (•)treated rats on 
days 1-4 after notexin-injection. Values are means (n=3-5) ± SEM. * indicates significance 
(p=0.047) between control and IGF-11 treatment groups for the timepoint shown. 
6.3.6 Muscle fibre size 
Muscle fibre size was measured at the final sampling point to determine a) whether 
the treatment effect of IGF-II, as previously noted on days 1 (MyoD), 2 (myogenin), 
and 3 ( dMHC), was still apparent at day 7, and b) whether the two groups had 
different rates of fibre enlargement in the newly-regenerated muscle fibres. Figure 
6-13 shows the microscopic appearance of regenerated fibres in day 7 IGF-II treated 
and control groups. The results of the fibre size analysis (Figure 6-14) show that the 
IGF-II treated muscle contains significantly larger regenerated muscle fibres than did 
the control muscles on day 7 (p=0.0092). 
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Figure 6-13. Effect of IGF-11 treatment on the area of regenerating fibres. 
Cross-sectional fibre area in control (A) and IGF-11-treated (B) regenerating muscle 7 days after 
injury. Fibre areas of IGF-11-treated muscles were significantly greater than those of control 
muscles. These sections have been immunostained with anti-dMHC antibody, then 
counterstained with haematoxylin. Magnification 50x, bar= 100 microns. 
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Figure 6-14. Quantification of fibre area. 
Cross-sectional fibre area at day 7 in the regenerated muscle of control and IGF-11 treatment 
groups. Fibre size was determined as described in Section 6.2.5. Values shown are the means 
(n=3/4), and the error bars show 1 SEM. ** indicates a significant difference (p=0.0092) between 
treatment groups. 
6.3. 7 Type 1 IGF receptor autoradiography 
Receptor autoradiography was chosen to determine levels of Type I IGF receptor in 
regenerating muscle from control and IGF-11 treatment groups on day 1. This 
timepoint was chosen because the earliest differences in the expression of myogenic 
markers in response to IGF-11 were noted on day 1, suggesting a possible difference in 
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receptor levels on, or prior to, this time. The results of this analysis show that the 
Type I IGF receptor levels were greater in the control (0.247 ± 0.073 grains/ µm2) than 
in the IGF-11-treatment (0.137 ± 0.063 grains/ µm2) group however this difference was 
not significant (p=0.311; Figure 6-15). 
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Figure 6-15. Specific binding of 1251- IGF-1 to day 1 damaged muscle. 
Type I IGF receptor levels in regenerating muscles from control and IGF-11 treatment groups on 
day 1 following notexin injection. Tissue sections were incubated with 1251-labelled IGF-1, then 
the bound peptide visualised as silver grains in an overlying emulsion layer, as described in 
Section 2.10. Grains were counted as per Section 2.11.3 and used to generate the density of 
radiolabelled IGF-1 in treated and control tissues. The Type 1 IGF receptor levels in treated and 
control tissues was not significantly different (p=0.311). Values shown are the means± SEM. 
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6.4 Discussion 
The aim of this study was to determine whether the processes of MPC proliferation 
and differentiation during skeletal muscle regeneration are altered by the continuous 
administration of IGF-11 to the damaged muscle. The MRFs, MyoD and myogenin, 
were used as markers of proliferation and early differentiation, respectively, while 
dMHC was employed as a later marker of differentiation. This study clearly shows 
that the administration of IGF-11 to regenerating muscle delayed both proliferation and 
differentiation. Furthermore, fibre size analysis showed that although proliferation 
and differentiation processes were delayed in the IGF-11-treatment group, by day 7 the 
IGF-11 treatment group had larger regenerated muscle fibres relative to the control 
group. These results show that IGF-11 had varying actions throughout the course of 
regeneration. 
The present study identified induction times of less than 1 day for MyoD, 1-2 days for 
myogenin, and 2 days for dMHC protein expression in regenerating rat M. biceps 
femoris. Similarly, it is well established in the literature that MyoD expression 
precedes that of myogenin (Cornelison et al. 2000; Smith et al. 1994) and that 
myogenin expression precedes the expression of sarcomeric myosin heavy chain 
isoforms (Andres & Walsh 1996). Peak values for the number of nuclei positive for 
MyoD, myogenin, and dMHC were observed on days 2, 3, and 4, respectively. These 
observed patterns of MyoD, myogenin and dMHC protein induction and peak values 
are virtually identical to those reported by Yablonka-Reuveni and Rivera (1994) for 
activated satellite cells undergoing myogenesis on cultured rat muscle fibres. Our 
6-224 
results combined with those of Yablonka-Reuveni and Rivera (1994), support the 
existence of an approximate 24-hour lag between MyoD(+), myogenin(+), and 
dMHC(+) compartments for rat MPC and muscle fibres. 
IGF-II has been firmly established as a proliferation and differentiation-enhancing 
peptide, with the evidence for this coming from a number of in vitro studies (Minniti 
et al. 1995; Prelle et al. 2000; Stewart et al. 1996). Given the body of evidence for 
positive effects of IGF-II on proliferation and differentiation in culture, the 
observation of an opposite effect in this regeneration experiment was surprising. 
Furthermore, the effects were of a highly consistent, sequential nature, with significant 
differences observed on day 1 for MyoD, day 2 for myogenin, and day 3 for dMHC, 
and the significant treatment effects always occurred prior to peak marker expression. 
This pattern, taken together with the fact that the effect ofIGF-II treatment occurred as 
early as day 1, suggests that IGF-II may have affected a process up to, or on, day 1 
following damage, and that this initial set-back of the regeneration process by IGF-II 
was simply carried on through until at least the stage of myotube fusion. One key 
possibility that was considered for these initial effects of IGF-II was down-regulation 
of the Type 1 IGF receptor. 
IGF-II can down-regulate the Type 1 IGF receptor in muscle cells via transcriptional 
down-regulation and/or increased receptor degradation (Rosenthal & Brown 1994; 
Rosenthal et al. 1991 ). IGFs bind to, and exert effects through, the Type I IGF 
receptor during the stimulation of MPC proliferation and differentiation (Ewton et al. 
1987; Rosenthal et al. 1994). Functional inactivation of the Type I IGF receptor 
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results in delayed differentiation in mouse C2C12 cells (Cheng et al. 2000). In the 
present trial, the level of Type I IGF receptor in day 1 regenerating muscle was 
measured in order to determine whether administration of IGF-11 effected down-
regulation of the Type 1 IGF receptor which may have in turn caused the delays in 
proliferation and differentiation. Results show that while the density of Type I IGF 
receptors is lower in the IGF-11 treatment group relative to the control group, the 
difference is non-significant. These results suggest that rather than affecting Type 1 
IGF receptor levels, IGF-11 treatment may have affected another early process, such as 
phagocytosis. 
The rate of phagocytosis that occurs within damaged muscle can affect subsequent 
phases of regeneration (Grounds 1991), for phagocytosis is a necessary event in the 
regeneration of skeletal muscle. A role for the IGF system in the modulation of 
inflammatory and phagocytic responses is supported by studies in which immune 
neutralisation of endogenous IGF-1 during muscle repair resulted in enhanced 
macrophage infiltration (Lefaucheur et al. 1996). The means by which macrophages 
contribute to the regeneration process is not limited to just the removal of necrotic 
tissue, but rather includes the production of growth factors that are capable of 
affecting MPC (Grounds 1991; Layne & Farmer 1999). One such growth factor is 
tumour necrosis factor-alpha (TNF-a) (Renier et al. 1996), a growth factor that is 
believed to be responsible for muscle wasting in a number of pathological conditions, 
including cancer (Meadows et al. 2000). Monocytes and macrophages up-regulate 
TNF-a in response to exogenous IGF-1 in vitro (Renier et al. 1996), and TNF-a 
inhibits IGF-1-induced stimulation of myogenesis in cultured C2C12 cells (Layne & 
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Farmer 1999). These findings thus lend support to the interaction of IGFs with 
phagocytic processes, and indeed a detailed examination of the different phagocytic 
cell populations within the 0-24 hour timeperiod following notexin injection and IGF-
11 administration in a future study would be of great interest. 
This study was designed to address the hypothesis that administration oflGF-11 results 
in a change in the onset of proliferation and/or differentiation processes within 
regenerating skeletal muscle. The pattern of control versus IGF-11 treatment values 
observed in this study would seem to suggest that instead of a change in the onset of 
proliferation and differentiation events, an overall decrease in MPC proliferation and 
differentiation was observed. Two factors which cloud the interpretation of an overall 
decrease, however, are that: a) there is a lack of sampling points between days which 
would unequivocally establish when the absolute peaks of MyoD and myogenin 
expression occurred, as otherwise it cannot be ruled out that the peak values obtained 
were taken from different parts of their respective curves, and b) the dMHC values on 
day 4 are virtually identical, indicating that by day 4 the same total number of nuclei 
in control and IGF-11 treatment groups had gone through the differentiation process. 
For this reason, it is reasonable to assert that there was a delay in the onset of 
proliferation and differentiation processes, but it cannot be stated whether there were 
changes in the overall numbers of MPC undergoing proliferation and differentiation 
processes. 
This study identified an effect of IGF-11 on both proliferation and differentiation 
events, thus raising the question of whether the delayed proliferation results in the 
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delayed differentiation, or m fact whether these two observations are completely 
independent of each other. This question could be addressed in an interesting series of 
experiments where IGF-II is pulsed at different times and durations, in order to see if 
effects are observed on single or multiple regeneration events. 
This study showed a delay in MPC proliferation and fusion in muscles that received 
exogenous IGF-II, as well as a late effect whereby the regenerated fibres that received 
IGF-11 were larger than the control fibres. The fact that the IGF-II treated fibres were 
larger at day 7 than the control group fibres was precisely the opposite result to what 
might have been anticipated given that the early regeneration was hindered. This 
suggests that the administered IGF-II had a pronounced effect on the regenerated 
muscle between days 4-7, when the primary process occurring was fibre enlargement. 
Likewise, an increase in muscle fibre diameter has been reported for laceration-
damaged muscle treated with IGF-1 peptide (Menetrey et al. 2000), and a decrease in 
fibre diameter observed following treatment of damaged muscle with anti-IGF-1 
antibodies (Lefaucheur & Sebille 1995b ). 
Strictly speaking, the period of fibre enlargement in regenerating muscle fibres is 
distinct from muscle hypertrophy, however both processes lead to increased muscle 
fibre size, thus warranting an examination of the role of IGFs in hypertrophy in 
relation to the present findings. It should be noted that the term "hypertrophy", which 
is classically defined as an increase in the protein to DNA ratio in the mature fibre, is 
also frequently used in the literature to refer to instances of increased protein with 
concomitantly increased DNA (Adams & McCue 1998; Barton-Davis et al. 1999). 
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Markers of hypertrophy as reported in the literature include increased muscle weight 
(Barton-Davis et al. 1998), fibre size (Coleman et al. 1995), and biochemical 
determinations of protein and DNA (Adams & McCue 1998). 
A role for IGF-1 in the induction of hypertrophy has been very clearly established by 
studies in vitro (Semsarian et al. 1999) and in vivo (Adams & McCue 1998; Barton-
Davis et al. 1998; Coleman et al. 1995), with as much as a 66% increase in fibre area 
reported for IGF-1-transfected myotubes in culture (Semsarian et al. 1999). In this 
study there was a fairly similar increase ( 42%) in fibre area in response to exogenous 
IGF-11. Hypertrophy in response to IGF-1 occurs via binding to the Type 1 IGF 
receptor (Semsarian et al. 1999), induction of calcineurin and the transcription factor, 
GATA-2, which then cooperate with selected NF-ATcl transcription factor isoforms 
in order to activate genes responsible for the hypertrophic response (Musaro et al. 
1999). Despite the fact that Type 1 IGF receptor levels increase after differentiation 
(Tollefsen et al. 1989a), hypertrophy occurs only if the exogenous IGF-1 is 
administered prior to, but not after, the induction of differentiation (Semsarian et al. 
1999). In the present trial IGF-II was administered continuously throughout 
proliferation, differentiation and enlargement, and was therefore present in high levels 
during the critical period for a hypertrophic response. 
IGF-11 has also been associated with hypertrophy, although certainly to a lesser degree 
than IGF-1, for at present there have been no studies looking directly at the effects of 
administered IGF-11 on skeletal muscle hypertrophy. Levels of both IGF-1 and IGF-II 
mRNA are elevated in rat M. plantaris and M. soleus subjected to compensatory 
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hypertrophy (DeVol et al. 1990), suggesting that both IGFs have a role in the 
induction of hypertrophy. Hypertrophy of cardiac tissue, which occurs by a similar 
mechanism to muscle hypertrophy in response to IGF-1 (Musaro et al. 1999), has also 
been shown to occur in response to IGF-11 (Adachi et al. 1994; Liu et al. 1996). 
Taken together, there is a strong body of evidence supporting a role for IGF-11 in the 
enhancement of muscle fibre enlargement as seen in this study. 
An additional factor that must be considered within the scope of the current study is 
re-innervation, and possible effects of IGF-11 upon that process. Notexin injection 
results in denervation of 70% of the muscle fibres in rat M. soleus (Harris et al. 2000), 
and the ensuing functional innervation is complete by 7 days (Whalen et al. 1990). 
Sesodia and Cullen ( 1991) report that the regeneration of denervated and non-
denervated rat M. soleus is identical up to 3-4 days following notexin injection, 
however after that time non-denervated muscles grow more rapidly than denervated 
muscles. IGF-11 has positive effects on nervous tissue, as illustrated by studies in 
which IGF-11 administration to damaged nerves results in increased motoneuron 
survival and enhanced nerve regeneration (Near et al. 1992; Pu et al. 1999a). This 
opens up the possibility that in the current study, IGF-11 administration may have 
speeded up and/or enhanced the functional innervation of the regenerating muscle, 
thus allowing for more rapid growth of the regenerating muscle fibres. 
In summary, this study clearly shows that local administration of IGF-11 to 
regenerating skeletal muscle results in delayed MPC proliferation and differentiation 
events, however by late regeneration the muscle fibres formed in the presence oflGF-
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II attain a larger size than control fibres. These findings indicate that IGF-11 has 
pleiotropic effects within regenerating skeletal muscle, likely as a function of the 
unique environment present during the sequential steps that make up the whole of 
muscle regeneration. The use of IGF-11 as a therapeutic agent for skeletal muscle 
regeneration may have potential, pending further investigation into the individual 




Regeneration of skeletal muscle is a fascinating process involving a number of 
coordinate steps, each of them regulated, at least in part, by the presence of growth 
factors. Recent studies suggest a critical role for locally produced growth factors in 
the regulation of normal postnatal growth and development (Sjogren et al. 1999; Ueki 
et al. 2000; Yakar et al. 1999). Accordingly, in the present studies, the tissue levels of 
IGF mRNA and myostatin protein have been associated with the processes occurring 
concomitantly within the regenerating muscle. A histological approach was used 
throughout this thesis in order to assess the individual growth factor activities in 
damaged muscle tissues; the identified growth factor activities can then be related to 
the histological changes taking place at that particular time. Finally, in the last 
experimental chapter, the effect of IGF-II administration on muscle regeneration was 
examined, and the effects on key regeneration steps examined in detail. 
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7.1 Summary of Results 
7.1.1 Muscle regeneration 
7.1.1.1 Necrosis 
Two of the earliest processes m the repair of muscle following damage are 
inflammation and phagocytosis of necrotic debris. The IGF axis was not examined 
during the stage of muscle necrosis, as the focus of work contained in this thesis is on 
MPC proliferation and fusion events, however, when myostatin was examined, it was 
apparent myostatin regulation was considerably altered during these early timepoints. 
The results presented here showed that during the stage of inflammation and 
phagocytosis, high levels of myostatin protein were present in connective tissue and 
necrotic fibres. Similarly, M. extensor digitorum longus and M. soleus have increased 
levels of myostatin protein, as determined by immunoblot analysis, on days 1 and 3 
following notexin-induced damage (Mendler et al. 2000). Skeletal muscle-derived 
fibroblasts up-regulate myostatin expression in a dose-dependent fashion in response 
to crushed muscle extract (Y amanouchi et al. 2000), suggesting that the myostatin 
protein within interstitial areas, as observed in the present study, may be produced by 
connective tissue-associated fibroblasts. Other likely candidate sources for the 
increased myostatin protein within interstitial areas include necrotic fibres, which 
show markedly increased protein levels at this time; or the bloodstream, as increased 
circulating myostatin is associated with muscle wasting (Gonzalez-Cadavid et al. 
1998). Regeneration is a process associated with significant changes in the connective 
tissue compartment (McMinn 1967; Phillips et al. 1990; Stauber et al. 1990), thus a 
7-233 
proposed role for the increased myostatin protein within connective tissue during 
necrosis is in the enhancement of connective tissue deposition. A role in connective 
tissue deposition is inferred by the presence of decreased connective tissue (Arthur 
1995) in double-muscled cattle, which lack functional myostatin (Grobet et al. 1997; 
Kambadur et al. 1997; McPherron & Lee 1997). Alternatively, during the necrotic 
stage, the high myostatin protein present in muscle fibres and connective tissue may 
modulate phagocytic and inflammatory cell processes, as has been shown for the 
related factor TGF-P (Adams et al. 1991; Ranges et al. 1987; Reibman et al. 1991; 
Wahl et al. 1987; Wahl et al. 1988). 
7.1.1.2 MPC proliferation 
In the present growth factor localisation studies (CHAPTER 4 and CHAPTER 5), day 
3 tissues of the dwldw rat contained the greatest proportion (relative to other 
timepoints) of mononucleate cells with the histological appearance of MPC. This 
timepoint (day 3) therefore will be the focus of this section regarding MPC 
pro Ii ferati on. 
Survivor, regenerating and undamaged muscle fibres from notexin-injected muscles 
on day 3 were not significantly different from undamaged muscle fibres of non-
injected muscles in terms of IGF-1 and IGF-11 binding, and IGF-11 mRNA production, 
as was the case for connective tissue comparisons (CHAPTER 4). These results are in 
agreement with the virtually unchanged levels of IGF-11, and Type I and II IGF 
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receptor mRNA, relative to time zero controls, in M. soleus following notexin 
injection, as determined by solution hybridisation (Levinovitz et al. 1992). 
These studies showed that, in contrast to the lack of change in other components of 
the IGF axis, differences were observed in IGF-1 mRNA levels in regenerating fibres 
relative to undamaged muscle fibres (CHAPTER 4). Similarly, elevated IGF-1 
mRNA, as determined by solution hybridisation, has been reported for rat M. soleus 
on day 3 following notexin injection (Levinovitz et al. 1992). In histological studies, 
IGF-1 immunoreactivity was found in satellite cells of normal and hypophysectomised 
rat M. extensor digitorum longus following ischaemia (Jennische et al. 1987) and 
taipoxin-induced (Jennische & Hansson 1987) injury. Given the role of IGF-1 in the 
stimulation of cell proliferation, as discussed in Section 1.7.1.5.2, and the presence of 
the Type I IGF receptor on regenerating muscle fibres (CHAPTER 4), it is possible 
that IGF-1 produced by regenerating muscle fibres acts in an autocrine manner to 
stimulate the proliferation of MPC during muscle regeneration. 
The present studies showed that during the stage of MPC proliferation, IGF-1 mRNA 
was also elevated in survivor fibres of notexin-injected muscle (CHAPTER 4). In 
regenerating rat M. extensor digitorum longus, IGF-1 immunoreactivity was present in 
regenerating muscle fibres, but not in "surviving, undamaged" muscle cells (Jennische 
et al. 1987). The apparent discrepancy between the Jennische (1987) study and the 
present one is possibly due to the proximity of the "surviving, undamaged" fibres of 
the Jennische (1987) study to the damaged area. Following notexin injection, there is 
a decreasing gradient in activated satellite cell number from the damaged area of 
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notexin-injected muscle (Klein-Ogus & Harris 1983), so that "survivor" fibres (that 
are interspersed with the regenerating fibres) would be expected to have a greater 
satellite cell activity than "undamaged" fibres (which are located further away from 
the damage) (see Section 3.1.3). In the present study (CHAPTER 4), IGF-1 mRNA 
was elevated in survivor, but not undamaged, muscle fibres, a pattern that suggests the 
IGF-1 production in survivor fibres may be linked to satellite cell replication. 
Previous studies have treated all uninjured fibres as a single population (Jennische et 
al. 1987), however the results of the present study shows that the uninjured muscle 
fibre population is not homogenous. 
The results of the present study showed that like regenerating and survivor fibres, 
connective tissue of notexin-injected muscles contained greater IGF-1 mRNA than did 
non-injected muscles (CHAPTER 4). IGF-1 may act in connective tissue to stimulate 
fibroblast proliferation and/or collagen synthesis by fibroblasts, as occurs in vitro in 
response to IGF-1 (Cook et al. 1988; Goldstein et al. 1989), or it may be a source of 
locally-acting growth factor for damaged muscle tissues. 
Myostatin protein was not observed in proliferating MPC in this study (CHAPTER 5). 
This finding is in contrast to that of Y amanouchi (2000), who reported occasional 
localisation of myostatin mRNA in mononucleated myogenic cells of regenerating rat 
femoral muscle two days after bupivacaine-induced damage, but is similar to the 
virtually undetectable levels of myostatin protein, by Western blot analysis, in rat 
muscle 1-14 days after bupivacaine-induced damage (Sakuma et al. 2000). The report 
that myostatin mRNA was only occasionally observed in mononucleated myogenic 
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cells of regenerating muscle (Y amanouchi et al. 2000), combined with the apparently 
undetectable levels for M. tibia/is anterior (Sakuma et al. 2000), and the present 
report of no myostatin localisation in MPC (CHAPTER 5), suggest that myostatin 
does not play a critical role in the proliferation of MPC during skeletal muscle 
regeneration. 
7.1.1.3 Myotube formation 
In the present study, the period of myotube formation, the peak of which occurred on 
day 5 in regenerating muscle tissues of the dw/dw rat, was typified by dramatic 
increases in components of the IGF axis (CHAPTER 4). Specifically, IGF-1 and -II 
binding capacity, and IGF-1 and -II mRNAs, were significantly up-regulated in 
regenerating muscle fibres on day 5, and it was at this time that the presence of 
IGFBPs in regenerating muscle tissues was indicated by the in vitro binding of 1251-
IGF-I (CHAPTER 4). A similar elevation of IGF-1 and -II mRNA, in homogenised 
tissue, during myotube formation has been shown for notexin-injected rat M. soleus 
(Levinovitz et al. 1992). Similarly, specific binding of IGF-1 and Type I IGF receptor 
mRNA are both elevated in damaged rat muscles on day 5 following 
ischaemia/glycogen depletion and bupivacaine injection, respectively (Jennische & 
Matejka 1992; Marsh et al. 1997), and the Type II IGF receptor is co-ordinately up-
regulated with IGF-II during muscle cell differentiation in vitro (Tollefsen et al. 
1989b ). However, such an elevation of Type -I and -II IGF receptors was not reported 
for regenerating rat M. soleus analysed by solution hybridisation (Levinovitz et al. 
1992). The lack of change in the Levinovitz ( 1992) study is possibly due to dilution 
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of receptor levels in the homogenised muscle. IGFBPs, as mentioned above, were 
determined by the in vitro binding of 1251-IGF-I to be present in day 5 tissues only, and 
to be localised within connective tissue, and regenerating and survivor fibres 
(CHAPTER 4). In the present study, competition of 125IGF-I with unlabelled des(l-
3)IGF-I and IGF-1 suggested that IGFBPs account for virtually all of the IGF-1 specific 
binding to connective tissue and survivor fibres, and approximately half of the IGF-1 
specific binding to regenerating muscle fibres, at day 5 (CHAPTER 4). In a detailed 
study of IGFBP mRNAs in regenerating rat skeletal muscle, the presence of IGFBPs-4 
and -6 in connective tissue, IGFBP-5 in regenerating muscle fibres, and IGFBP-6 in 
uninjured muscle fibres was reported (Jennische & Hall 2000). IGFBPs may serve 
important modulatory functions within damaged muscle tissues, as they can either 
potentiate or inhibit IGF action (Bach et al. 1994; Wood 1995). 
In the present study, myostatin protein was not observed in newly regenerating muscle 
fibres (CHAPTER 5). Similarly, in cultured C2C12 muscle cells, increased myostatin 
mRNA was not observed until day 4 following the switch to differentiation medium, 
when fusion was already well-established (Mendler et al. 2000). In rat M. tibialis 
anterior regenerating after bupivacaine-induced damage, myostatin protein is virtually 
undetectable by Western blot analysis during the stage of myotube formation (Sakuma 
et al. 2000). Results from another regeneration study, where both low and high 
intensity immunostaining were observed in newly formed myotubes of notexin-
damaged M. soleus (a slow-type muscle) and M. extensor digitorum longus ( a fast-
type muscle) (Mendler et al. 2000), respectively, suggests that muscles vary 
considerably in the expression of myostatin at the time of myotube formation, leading 
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to the proposal by Mendler et al. (2000) that this variation may be modulated by the 
re-innervation status of the muscle. 
7.1.1.4 Muscle fibre enlargement 
Late regeneration, when the major event taking place was muscle fibre enlargement, 
persistent increases in IGF-1 and -II message were observed in regenerating muscle 
fibres, and elevated IGF-11 in survivor fibres relative to undamaged muscle fibres 
(CHAPTER 4). Similarly, IGF-1 mRNA levels are elevated in homogenised M. 
tibia/is anterior on day 15 following bupivacaine-induced damage (Marsh et al. 
1997). 
In this study, myostatin was observed in generally increasing amounts in regenerating 
and survivor muscle fibres undergoing enlargement and maturation (CHAPTER 5). 
Similarly, the stage of muscle fibre enlargement is associated with increased 
myostatin protein in homogenised rat M. tibia/is anterior (Sakuma et al. 2000), and 
with increased myostatin mRNA in homogenised rat M. extensor digitorum longus 
(Mendler et al. 2000). The increased myostatin levels in these fibres may be related to 
the slowing down of cellular proliferation, relative to earlier timepoints. 
7.1.2 Modulation of muscle regeneration 
7.1.2.1 GH 
The GH-deficient, dwarf dw/dw rat was used in these studies to examine the effect of 
GH on skeletal muscle regeneration. In order to eliminate the confounding effects of 
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endogenous GH on somatic growth in the trial, the dwldw rats were castrated in order 
to remove testosterone. Exposure to testosterone alters the pattern of GH pulsatility 
from a feminine to a masculine pattern of GH secretion (Painson et al. 2000), and the 
masculine pattern is associated with a greater somatic growth response relative to the 
feminine pattern (Jansson et al. 1985). This strategy has been similarly undertaken by 
others (Gevers et al. 1995). It is possible that castration of the dw/dw rats in these 
experiments slightly altered the resultant regeneration processes, for exogenous 
testosterone has a stimulatory effect on satellite cell proliferation in castrated neonatal 
pigs (Mulvaney et al. 1988), and research suggests that during regeneration, elevated 
testosterone may impair phagocytic processes (Grounds 1987). However, the 
regeneration processes observed in castrated dw/dw rats in the present study were 
qualitatively similar to those reported in the literature for notexin-induced damage 
(Harris & Johnson 1978; Harris et al. 1975), with the only observed difference being a 
slightly extended timeframe for the regeneration process, which may be due to the 
dwldw GB-deficient phenotype, and/or castration. 
In this set of experiments, an effect of GH was observed on body and muscle weights, 
and on IGF-11 binding. Similarly, a 25% increase in body weight, and significantly 
greater damaged and undamaged M. extensor digitorum longus weights were reported 
for GB-treated Sprague-Dawley rats following ischaemic necrosis (Ullman et al. 
1989). The effect of GH on muscle weights was observed in both notexin-injected 
and non-injected control muscles, thus indicating that the enhancement of muscle 
weight was not related to regeneration. The effect of GH on IGF-II binding levels in 
all tissues of the notexin-injected muscle on day 5 only was unexpected. The Type II 
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IGF receptor has been postulated to be a negative regulator of IGF-II action, based 
primarily on developmental studies (Haig & Graham 1991). A few studies have 
indicated a signalling pathway for the Type II IGF receptor, via G-proteins (McKinnon 
et al. 2001; Okamoto & Nishimoto 1991), and a role for the Type II IGF receptor in 
muscle has been suggested by the report that an IGF-II analog with high selective 
affinity for the Type II IGF receptor, stimulates differentiation (Rosenthal et al. 1994). 
However, the Type II IGF receptor up-regulation in response to GH that occurred in 
this study was observed in all tissues, including connective tissue, making it unlikely 
to be a muscle differentiation-associated up-regulation. The primary role of the Type 
II IGF receptor in adults has been proposed to be the maintenance of lysosomal 
activity (Wang et al. 1994 ), and GH administration elevates lysosomal activity in 
polymorphonuclear leucocytes (Rovensky et al. 1985). This suggests that GH may 
modulate lysosomal activity in regenerating muscle tissues. 
These studies did not identify changes in myostatin or other components of the IGF 
axis, including IGF-1 mRNA, in response to GH. This was in contrast to other studies 
showing GH regulation of IGF-1 mRNA in muscle cells in vivo and in vitro (Brameld 
et al. 1996; Butler et al. 1994; Sadowski et al. 2001), but was in keeping with 
previous studies using the same strain of rats where GH treatment did not affect levels 
of the Type I IGF receptor (Butler et al. 1994), and an earlier immunohistochemical 
study that showed IGF-1 levels are unaffected by the GH status of the animal during 
regeneration (Sommerland et al. 1989). A number of studies now have implicated GH 
in having direct effects, ie. not mediated by IGF-1, on skeletal muscle by showing 
immediate up-regulation (within 5 minutes) of many GH-signalling proteins (Chow et 
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al. 1996; Sadowski et al. 2001). Furthermore, treatment of GR-responsive pro-B 
Ba/F3 cells with an anti-IGF-1 antibody that blocks IGF-1 action does not block the 
proliferative effects of GH (Baixeras et al. 2001). These reports combined with the 
present study thus provide evidence of GH effects that are distinct from those of IGF-
1. The findings of the present study and that of Sommerland et al. ( 1989) may suggest 
that for regenerating muscle, the IGF-1 mediated pathway (for GH action) is utilised to 
a lesser degree relative to normal, uninjured muscle and cultured muscle cells. 
7.1.2.2 IGF-11 
In the present study, the administration oflGF-11 to regenerating skeletal muscle led to 
interesting, and unanticipated results, with a delay in the expression of MyoD (a 
marker of proliferating MPC), myogenin and dMHC (sequential markers of MPC 
differentiation) (CHAPTER 6). The effects on these markers of the regeneration 
process were consistent, with each step showing the same directional change, that is, a 
delay due to IGF-11 administration. The fact that a delay in regeneration was apparent 
by day 1 following notexin-injection indicated that an early regeneration process was 
affected, or that perhaps there had been a down-regulation of the Type I IGF receptor 
in response to the administered IGF-II, as has been shown in vitro for BC3H-1 muscle 
cells (Rosenthal & Brown 1994; Rosenthal et al. 1991 ), which could account for the 
lack of a positive effect on regeneration by IGF-11. The latter hypothesis, of a down-
regulation of Type I IGF receptor, was examined in day 1 tissues, however the 
receptor levels were found to be unchanged by the administration of IGF-11. Because 
the Type I IGF receptor levels were not down-regulated on day 1, it is postulated that 
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the administration of IGF-II to regenerating muscle impeded phagocytic and/or 
inflammatory processes, as those were the other major events occurring at that early 
time, and the rate of phagocytosis can affect ensuing phases of regeneration (Grounds 
1991). A proposed inhibitory effect of IGF-II on phagocytic processes corresponds 
with the reported enhancement macrophage infiltration following immune 
neutralisaton of endogenous IGF-1 (Lefaucheur et al. 1996). Certainly, an interesting 
experiment would be to determine if there are changes in the phagocytic population, 
with administered IGF-11, in the first 0-24 hours following notexin injection. 
The most promising result from the trial examining the effect of IGF-II on skeletal 
muscle regeneration is the significant enhancement of muscle fibre size observed on 
day 7. This finding is particularly exciting given the inhibition of regeneration 
processes observed as late as day 4, implying that the effects of IGF-11 between days 
4-7 were potent. The enhancement of regeneration between days 4-7 may have been 
the result of stimulation of hypertrophic-like events as has been observed for cultured 
C2C12 cells stably transfected with IGF-1 (Semsarian et al. 1999), and cultured rat 
cardiomyocytes administered IGF-11 (Adachi et al. 1994). A second possibility is that 
the enhancement of muscle fibre size of day 7 was due to an augmentation of 
innervation by IGF-11. Administration of IGF-II to crushed sciatic nerve results in 
increased distance of motor axon regeneration (Near et al. 1992), and conversely, 
spontaneous nerve regeneration is inhibited by the presence of antiserum directed 
against IGF-II (Near et al. 1992). From 3-4 days following notexin injection, 
regeneration is more rapid in non-denervated muscles than in denervated muscles 
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(Sesodia & Cullen 1991), therefore an effect of IGF-II on nerve regeneration could 
lead to enhanced muscle fibre size by day 7. 
An important feature of the trial testing the effects of IGF-II is that it has identified a 
"window" of time (days 4-7) during which IGF-II appears to be beneficial to the 
regeneration process in these trial animals (CHAPTER 6). This "window" of time is 
coincident with the natural pattern of IGF-II expression during regeneration, as 
determined in earlier studies (CHAPTER 4). The finding of an enhancement of 
regeneration processes with additional IGF-11 suggests that a greater endogenous 
expression of IGF-11 during regeneration is associated with improved muscle 
regeneration. 
7.1.3 Achievement of the aims of the thesis 
The aims of the thesis, as outlined in Section 1.9, were to test the following 
hypotheses: 
1. The IGFs and their receptors are regulated during muscle regeneration, and the 
level of IGF expression and binding in regenerating muscle is regulated by 
GH. 
2. A negative regulator of growth, myostatin, is temporally regulated during 
muscle regeneration, and its levels are decreased m muscles undergoing 
enhanced growth due to the administration GH. 
3. Administration of IGF-II during skeletal muscle regeneration enhances the rate 
of regeneration. 
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As a result of the studies contained in this thesis, these hypotheses were tested. IGF-I 
and -II mRNAs, Type I and II IGF receptors, and myostatin protein were regulated 
during muscle regeneration, as reported in CHAPTER 4 and CHAPTER 5. GH 
administration regulated IGF-II binding to regenerating muscle, but did not affect 
other components of the IGF axis (CHAPTER 4) or myostatin protein levels 
(CHAPTER 5). Lastly, administration of IGF-II during skeletal muscle regeneration 
inhibited the early stages of muscle regeneration (up to myotube formation), but then 
enhanced the later stages of regeneration (CHAPTER 6). 
7.2 Future Work 
This work has highlighted a number of avenues worthy of pursuit, as described below. 
7.2.1 IGF-11 
In the present study, administered IGF-II inhibited MPC proliferation on day 1, 
inhibited MPC differentiation on days 2 and 3, but enhanced regenerating fibre size on 
day 7. These results leave the following questions unanswered: 
a) Was there an early inhibitory effect on phagocytosis and/or MPC 
migration? 
b) Was the inhibition of differentiation simply a follow on from the 
inhibition of proliferation, or did IGF-II have separate effects on both 
of these stages? 
c) What is the optimal administration protocol for IGF-II? 
d) Does the quantity ofIGF-II delivered alter the effect ofIGF-II? 
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To address (a) above, a similar trial to the one reported in CHAPTER 6, with a 
number of sampling times in the first 24 hours after injury, could be carried out, then a 
histological assessment of phagocytic processes and/or MPC migration performed. 
Such an investigation in an IGF-II knockout mouse would also be useful in 
determining the effects of IGF-II on these processes. If the histological assessment of 
IGF-II effects on phagocytosis and/or MPC migration showed an effect of IGF-II, the 
effects on migration could be further studied in vitro using a Boyden chamber {Takano 
& Nakagawa 2001). 
To address (b) and ( c) above, IGF-II would be administered at varying times, such as 
from day 2.5 onwards to determine whether IGF-II has a negative effect on MPC 
differentiation that is separate to its negative on MPC proliferation ((b) above). To 
determine the optimal administration time for IGF-11 ((c) above), peptide would be 
administered on days 4-7, 5-7, and 6-7, histological sections taken, and fibre area 
determined to decide the optimal time to begin IGF-11 administration. Similarly, the 
optimal duration of IGF-11 administration would be determined in studies going 
beyond 7 days. 
A much earlier in vitro study of the effects of IGF-II on L6 muscle cells showed that 
IGF-11 stimulates myogenesis at low concentrations, and inhibits myogenesis at 
supraphysiological levels (Fiorini et al. 1986). A logical extension then, which would 
test (d) above, would be to administer different concentrations of IGF-11 to 
regenerating muscle, to see if the amount ofIGF-11 delivered alters the effect ofIGF-II 
on MPC proliferation and differentiation. 
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7.2.2 GH 
In the present studies, GH treatment resulted in effects on Type II IGF receptor levels, 
but not on any other component of the IGF axis or myostatin. The effects of GH vary 
considerably depending on the administration regime used (Gevers et al. 1995; 
Jansson et al. 1985), therefore it would be of interest to test other dose and treatment 
regimes for GH, to see if these alterations result in additional changes in the IGF axis 
or myostatin. 
As discussed, in the present study GH treatment resulted in up-regulation of IGF-II 
binding to all tissues, including connective tissue, of the notexin-damaged muscle. 
The Type II IGF receptor has a number of different functions, but in the adult, the 
primary function of this receptor is believed to be the maintenance of lysosomal 
activity (Wang et al. 1994). A logical set of experiments would thus be aimed at 
determining whether GH administration results in changes in lysosomal activity in 
regenerating muscle tissues. If GH is found to alter lysosomal activity during 
regeneration, GH could then be administered to an animal with a conditional gene 
knockout of the Type II IGF receptor in skeletal muscle, such as that generated using 
Crellox technology (Le & Sauer 2001). If an altered pattern of lysosomal enzyme 
processing resulting from GH treatment is present in regenerating muscles with a 
disrupted Type II IGF receptor, relative to muscles with a functional Type II IGF 
receptor, then the Type II IGF receptor would be implicated in having a role m 
lysosomal enzyme processing in GB-treated regenerating muscle tissues. 
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7. 2. 3 Myostatin 
The present study identified high levels of myostatin within connective tissue of 
regenerating muscle in the first few days after muscle damage (CHAPTER 5). This 
localisation, in a tissue that it is normally absent from, suggests that myostatin has a 
specialised function that is specific to early regeneration processes, such as 
phagocyosis, MPC recruitment/chemotaxis and/or granulation tissue formation. To 
determine the functional significance of the myostatin in connective tissue, the 
myostatin knockout mouse (McPherron et al. 1997) would be an extremely useful 
model. Muscle damage could be induced in the knockout mice and their background 
strain (as a control), histological samples taken, and the following parameters 
examined: infiltration of phagocytes; rate of removal of necrotic debris; MPC 
migration into damaged areas; and connective tissue deposition. lfresults of knockout 
experiments indicate an effect of myostatin on MPC and phagocyte chemotaxis, these 
effects could then be examined in vitro using a Boyden chamber (Takano & 
Nakagawa 2001). 
7.2.4 Other factors 
In the present study, a histological approach was taken, with the presumption that 
different tissues within a notexin-damaged muscle may not be identical in their growth 
factor and receptor levels. This was supported, for instance, by the findings of 
elevated IGF-11 mRNA in regenerating muscle fibres, relative to undamaged and 
survivor fibres (CHAPTER 4). An extension of the present study, in which the 
localisation of IGFs and myostatin was examined, is to use laser microdissection to 
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separate out the tissue types (regenerating, surviving, and undamaged muscle fibres, 
and connective tissue) of damaged muscle, isolate the RNA from each, and then to 
carry out a microarray analysis (Schena et al. 1995) of each sample. Such an approach 
could identify other candidate genes that may play a role in the damage and repair 
process in specific tissues. The use of microarray technology means that only a small 
sample quantity is required (Schena et al. 1995). The localisation and expression 
patterns of candidate genes during muscle regeneration would then be determined 
using an approach like that used for the studies in CHAPTER 4 and CHAPTER 5. If 
the candidate genes are temporally regulated during regeneration, suggesting a role in 
the process, the effect of the particular candidate gene product could be tested by 
either administration of the factor (such as carried out in CHAPTER 6), or elimination 
of the factor by antibody administration or by use of a gene knockout model. 
7 .3 Conclusion 
In summary, the results presented in this thesis show that local growth factor 
expression is tightly regulated during skeletal muscle regeneration, and indicates roles 
for IGF-1, IGF-11, IGFBPs, the Type 1 and II IGF receptors, and myostatin in this 
process. The results of these studies suggest that IGFs may carry promise of 
improving muscle regeneration after injury. 
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